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Cancer-associated inflammation, both in the systemic circulation and in the tumour 
microenvironment, is widely recognised to influence disease progression and survival.  
Surgical resection is fundamental in achieving cure in patients with colorectal cancer.  The 
generation and maintenance of a systemic inflammatory response, with subsequent 
compromise of the anti-tumour immune response, has been associated with poor outcome.  
Neutrophils may facilitate metastatic progression in the context of systemic inflammation 
and therefore implementing a therapeutic strategy in the peri-operative period to reduce 
the systemic inflammation associated with surgery may be beneficial, particularly 
therapeutic strategies aimed at modifying tumour-neutrophil interactions. 
HMG-CoA Reductase Inhibitors (statins) were developed as lipid-lowering agents.  In 
addition, they have been implicated in the modulation of the immune system and have 
demonstrable anti-inflammatory effects.  It has been proposed that they could be utilised in 
the peri-operative period to modulate the systemic inflammatory response and to preserve 
the anti-tumour immune competency of the host.   
This study was conducted to serially characterise neutrophil function in patients undergoing 
colorectal cancer resection over the peri-operative period and to explore the impact of 
HMG-CoA Reductase Inhibitors on neutrophil function. 
The experiments conducted in this thesis demonstrate a distinct change in neutrophil 
phenotype in response to surgery which exhibits reduced NET formation, reduced apoptosis 
and increased phagocytotic activity.  The immune-modulatory capacity of HMG-CoA 




attenuated with in-vitro treatment with simvastatin in patients with colorectal cancer.  Post-
operatively, a reduction in NET production was identified with in-vitro treatment with 
simvastatin which is considered advantageous as NETs have been strongly implicated in 
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Glossary of Terms 
Abdomino-Perineal Excision of the Rectum (APER) - An operation to remove the entire rectum and 
anal canal. 
Anastomotic Leak – A breakdown of an anastomosis (the join between two ends of bowel) allowing 
bowel fluid to leak out into the abdominal cavity. 
Anterior Resection – An operation to remove part of or the entire rectum.  
Adjuvant Treatment – An additional therapy (e.g. chemotherapy or radiotherapy) provided to 
improve the effectiveness of the primary treatment (e.g. surgery).  
Bowel Cancer Screening – The NHS Bowel Cancer Screening Programme offers screening every two 
years to all men and women aged 60 to 74. Those over 74 can request a screening kit from the 
Programme. 
Chemotherapy – Drug therapy used to treat cancer. It may be used alone, or in conjunction with 
other types of treatment (e.g. surgery or radiotherapy). 
Colostomy – A stoma (surgical opening) constructed by bringing the large bowel (colon) out onto the  
surface of the skin.  
Enhanced Recovery Programme – An evidence-based perioperative care approach that facilitates 
recovery after major surgery.  
Hartmann’s Procedure – An operation to remove the left colon and part of the rectum and involves 
the formation of a colostomy. 
Ileostomy – A stoma (surgical opening) constructed by bringing the end or loop of small intestine 
(ileum) out onto the surface of the skin.  
Laparoscopic – Also called minimally invasive surgery or keyhole surgery, is a type of surgical 
procedure performed through small incisions in the skin instead of the larger incisions used in open 
surgery. 
Lymph Nodes – Also referred to as lymph ‘glands’, which form part of the immune system. They are 




Multi-disciplinary Team (MDT) – A group of professionals, from diverse specialties that work to 
optimise the diagnosis and treatment throughout the patient pathway.  
Metastases – Deposits of cancer that occur when the cancer has spread from the place in which it 
started to other parts of the body.  These are commonly called secondary cancers.  Disease in which 
this has occurred is known as metastatic disease.  
Neo-adjuvant Therapy – Therapy (radiotherapy, chemotherapy or chemo-radiotherapy) given before 
another treatment, usually surgery.  This is usually given to reduce the size, grade or stage of the 
cancer and therefore improve the effectiveness of the surgery performed.  














List of Abbreviations 
7-AAD   7-Amino-Actinomycin 
AFU   Arbitrary Fluorescent Units 
APC   Adenomatous Polyposis Coli (tumour suppressor gene) 
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1.1 The Origins of Immunotherapy 
Immunotherapy is centred on the concept that a patient’s immune system can be 
stimulated, or augmented, to attack a malignant tumour.  The first systematic study of 
immunotherapy was conducted in 1891 by William B. Coley, an American Bone Sarcoma 
Surgeon, from New York Cancer Hospital (which later became Memorial Sloan-Kettering 
Cancer Centre).  Coley injected streptococcal organisms into patients with inoperable 
cancers.  He hypothesised that the infection would stimulate the patient’s immune system 
and this would initiate tumour regression.  He successfully demonstrated his hypothesis and 
this highlighted the potential of immunotherapy in the treatment of cancer [1]. 
Because of the dangers associated with the transfer of live micro-organisms, Coley utilised 
heat-killed streptococcal and serratia organisms, which he named Coley’s Toxin, to initiate 
an immune response against malignant tumours.  Throughout his career, over 1,000 
patients received the Coley’s Toxin and a near complete response was observed in 
approximately half [2]. 
The field of immunology has developed into a sophisticated speciality and there is increasing 
interest in the development of vaccines and in the therapeutic modulation of the immune 
system for the treatment of numerous cancer types to improve patient outcomes in the 
continued fight against cancer. 
William Colley was the first to document that the stimulation of the immune system may be 







1.2 Colorectal Cancer 
Colorectal cancer constitutes a major health problem.  It is the third most common cancer 
type in both men and women and the second most common cause of cancer death in the 
UK.  Approximately 41,500 patients were diagnosed with and 16,000 died of colorectal 
cancer in the UK in 2012 [3].   
The 5 year survival rate is currently in the region of 50% and has improved significantly since 
the 1970’s when the 5 year survival was reported at approximately 20% [3].  This reflects 
improved diagnostic strategies, surgical techniques and neo-adjuvant and adjuvant 
therapies implemented in the management of colorectal cancer. 
Colonic tumours are tumours of the large bowel.  It is important to differentiate them from 
tumours of the rectum which are tumours arising within 15cm of the anal verge or from 
where the two anti-mesenteric taenia converge into an amorphous area [4].   
These distinctions are important in planning treatment as rectal cancers should be 
considered for neo-adjuvant long-course chemo-radiotherapy or short-course radiotherapy 
in an attempt to downstage the disease and allow complete resection (and enable sphincter 
preserving surgery) in selected cases [5-7].  The differentiation also assists clinicians in 
predicting short-term and longer-term oncological outcomes as these differ between 
patients undergoing colonic (segmental excision) and rectal (including total meso-rectal 
excision) resections [5-7].  This results from different pre-operative treatments, intra-
operative techniques, post-operative complications and recovery following surgery.  
It is accepted that most colorectal cancers (adenocarcinomas) are sporadic and arise from 




[8].  This is a multi-step process and it implicates mutations in K-ras and p-53 genes [8].  It 
has been suggested that different pathways to carcinogenesis exist as rarely do the 
mutations occur simultaneously [9].  Tumours with a K-ras mutation are associated with an 
advanced stage at presentation and a poor prognosis in node negative disease [10].  
Therefore precise knowledge of the genetic abnormality that initiates carcinogenesis may 
have implications in diagnosis, treatment and prognosis. 
The main environmental factors that predispose patients to colorectal cancer are obesity, 
lack of exercise, a low-fibre diet, consumption of red and processed meat, alcohol and 
tobacco smoking, long-standing inflammatory bowel disease and previous gastric surgery 
which induces altered bile acid metabolism [11]. 
Colorectal cancers can present in a symptomatic patient population with well recognised 
chronic symptoms or as an emergency.  They can also present in an asymptomatic 
population through the NHS Bowel Cancer Screening Programme (BCSP).  This is a screening 
programme gradually introduced nationally from 2006-2010,  where men and women from 
60-74 years are invited to conduct a faecal occult blood test every two years [12].  If the test 
is positive then individuals are invited to attend screening colonic investigation (usually 
colonoscopy).  The purpose of the BCSP is to detect colorectal cancer at an early stage 
where treatment is more likely to be effective or to detect and remove adenomatous polyps 
and prevent their development into colorectal cancers [12].  Despite advances in the BCSP, 
in the UK, approximately 20% of patients present as an emergency to acute surgical care.  
The usual presentation is obstruction (16%) and less commonly bleeding or perforation [13]. 
Staging describes the severity of an individual’s cancer with regard to the magnitude of the 




TNM Classification.  This is a staging system based on the extent of the tumour (T), the 
extent of the spread to the lymph nodes (N) and the presence of distant metastases (M).  
The TNM Classification reflects the American Joint Commission on Cancer Classification and 
Dukes’ staging system as outlined below [14].  The systems are often used concomitantly. 
 
Table 1.1 Tumour, Nodal, Metastatic (TNM) Staging System for Colorectal Cancer 5th 
Edition 
T0 No evidence of primary tumour 
T1 Tumour is confined to the submucosa 
T2 Tumour has grown into (but not through) the muscularis propria 
T3 Tumour has grown into (but not through) the serosa 
T4 Tumour has penetrated through the serosa and the peritoneal surface 
T4a Tumour extends directly into other nearby structures 
T4b Tumour perforates the bowel 
N0 No regional lymph node metastases 
N1 1-3 regional lymph node metastases 
N2 ≥ 4 regional lymph node metastases 
M0 No distant metastases 
M1 Distant metastases 
 
Colorectal cancers are staged utilising the TNM Classification.  This is a staging system based on the extent of 
the tumour (T), the extent of the spread to the lymph nodes (N) and the presence of distant metastases (M).  
Table adapted from:  The diagnosis and management of colorectal cancer, National Institute for Health and 









Table 1.2 Comparisons between the Tumour, Nodal, Metastatic (TNM) Staging 
System for Colorectal Cancer, the American Joint Commission on Cancer 
(AJCC) Classification and Dukes’ Stage for Colorectal Cancer 
T N M AJCC  Dukes’ 
T1 
N0 M0 I A 
T2 
T3 




M0 III C 
N2 
Any T Any N M1 IV D 
 
Table adapted from:  The diagnosis and management of colorectal cancer, National Institute for Health and 
Clinical Excellence, Clinical Guideline Number 131 [14]. 
 
An accurate histopathological stage of the disease allows clinicians to accurately 
prognosticate and determine potential adjuvant treatment strategies that may be employed 
to improve patients overall survival.  After curative resection the age-adjusted 5 year 
survival for Dukes’ A, B and C cancer is 85%, 67% and 37% respectively [14].  Adjuvant 
therapy with 5-fluorouracil (5-FU) is offered to patients with Stage III or Dukes’ C cancer 
where it confers a 5-10% improvement in absolute survival.  5-FU has more recently been 
combined with oxaplatinin and may be offered to patients with high-risk Stage II or Dukes’ B 
cancer.  This combination therapy is not employed routinely and is reserved for those 







1.3 Patient Outcomes following Colorectal Cancer Resection 
The National Bowel Cancer Audit is an annual, national clinical audit commissioned by the 
Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit 
and Patient Outcomes Programme (NCAPOP) delivered by the Health and Social Care 
Information Centre (HSCIC) [13].  The primary aim of the audit is to improve the quality of 
care and survival of patients with a diagnosis of Colorectal Cancer.  All patients over the age 
of 18 with a diagnosis of Colorectal Cancer who are managed in the NHS are included in the 
audit.  Data is collected about each patient, their cancer, treatment and outcomes.  The 
performance of Strategic Clinical Networks and individual hospitals are compared.  This 
enables identification of the most effective treatments which benefit patients most. 
A description of the patients undergoing major resection for colorectal cancer from 1st April 












Table 1.3 A description of the patients undergoing major resection for colorectal 
cancer from 1st April 2013 to 31st March 2014 in the United Kingdom  
 
 
 Number % 
Total Number of Patients  19,445 - 
Gender Male 11,087 57.1 
Female 8,340 42.9 
Age ≤ 65 years 6,099 31.4 
65-74 years 6,218 32.0 
75-84 years 5,702 29.3 
≥85 years 1,426 7.3 
Performance Status Normally Active 6,417 47.5 
Walk and Light Work 4,684 34.7 
Walk and Self-care >50% 1,869 13.8 
Limited Self-care <50% 487 3.6 
Completely Disabled 59 0.4 
Cancer Site Caecum / Ascending Colon 5,477 28.2 
Hepatic Flexure 830 4.3 
Transverse Colon 1,266 6.5 
Splenic Flexure / Descending Colon 1,269 6.5 
Sigmoid Colon 4,573 23.5 
Recto-sigmoid 1,052 5.4 
Rectum 4,978 25.6 
T-stage T0 338 1.8 
T1 1,204 6.4 
T2 2,982 15.8 
T3 9,455 50.1 
T4 4,678 24.8 
N-stage N0 11,026 58.4 
N1 4,615 24.4 
N2 2,973 15.7 
M-Stage 
M0 14,708 77.9 
M1 1,672 8.9 
Neo-Adjuvant Therapy 
Chemotherapy 895 4.6 
Chemoradiotherapy 1,736 8.9 
Adjuvant Therapy 
Chemotherapy 4,951 25.5 
Chemoradiotherapy 455 2.3 
 








The use of laparoscopic surgery has increased from 30% in 2009-2010 to 48% in 2013-2014.  
The utilisation of this technique varies considerably between NHS Trusts.  Less than 40% of 
patients underwent laparoscopic resections in 36 NHS Trusts compared with over 80% of 
patients in 23 NHS Trusts [13]. 
The surgery-associated mortality, length of stay and emergency readmissions from 1st April 
2013 to 31st March 2014 in the United Kingdom are outlined below. 
 
Table 1.4 Total number of patients with Colorectal Cancer and surgery-associated 
mortality from 1st April 2013 to 31st March 2014 in the United Kingdom  
 Number % 
Total Patients 30,663 - 
Patients Undergoing Major  Surgical Resection 19,445 63.5 
Mortality within 90-days 746 3.8 
Mortality within 24-months 3,448 18.0 
 











Table 1.5 Length of stay in days, percentage of patients with a length of stay greater 
than 5 days and percentage of patients with an unplanned emergency 
readmission for patients with Colorectal Cancer undergoing major surgical 
resection from 1st April 2013 to 31st March 2014 in the United Kingdom 
 Colon Recto-sigmoid Rectum 
Length of Stay in days (Median / IQR) 7 5-12 7 5-13 8 6-14 
Length of Stay > 5 days (%) 65.0 67.8 79.0 
Emergency Readmission (%) 18.4 19.8 24.0 
 
Table adapted from:  The National Bowel Cancer Audit, 2015 [13]. 
 
The 90 day mortality for patients undergoing surgical resection for Colorectal Cancer has 
fallen since 2008 and is currently at the lowest recorded rate with less than 4 patients out of 
every 100 dying.  Interestingly there is a great variation in 90 day mortality depending upon 
presentation type.  Patients presenting as an emergency have a 90 day mortality of 13.3% 
compared to only 2.2% of patients presenting electively. The 24 month mortality for 
patients undergoing surgical resection for Colorectal Cancer currently stands at 18%.  In 
those patients with a diagnosis of Colorectal Cancer who do not undergo major resection 
the 24 month mortality is approximately 60%.  This group comprises those patients who are 
too unwell or have cancer too advanced for surgical resection.  Interestingly, and perhaps as 
a direct result of the Bowel Cancer Screening Programme and an earlier stage of disease at 
presentation, 744 patients underwent a local excisional procedure (Endoscopic polyp 
excision or Trans-anal Endoscopic Microsurgery) with a resultant 24 month mortality of less 




Discharge from hospital in 5 days or less is endorsed as a measure of ‘good care’.  Enhanced 
Recovery Programmes in Colorectal Surgery have been implemented in the UK since 2002.  
The Enhanced Recovery Programme is an evidence-based peri-operative care approach that 
promotes recovery after major surgery.  It is used with laparoscopic or open surgery to 
optimise rehabilitation after surgery.  The programme aims to modify many aspects of the 
surgical and anaesthetic intervention and recovery to facilitate optimal recovery [15].   
Despite the compliance with multimodal rehabilitation, over two thirds of patients had a 
hospital length of stay greater than 5 days and this approached 80% in patients undergoing 
rectal cancer resection [13].   
There are many reasons why patients have a prolonged hospital recovery and the length of 
hospital stay not only accounts for post-operative complications and a prolonged functional 
recovery but represents an additional patient need for assistance with stoma therapy, 
occupational therapy and physiotherapy in this specific patient group.  As expected, 
increasing age has been shown to increase the length of hospital stay.  Those patients over 
85 years of age had a median length of stay of 10 days (IQR 7-18 days) compared to those 
less than 65 years of age who had a median length of stay of 7 days (IQR 4-10 days) [13].  Of 
the 10,919 patients undergoing surgery for rectal cancer (Anterior Resection, APER, 
Hartmann’s Resection) over 80% of patients underwent stoma formation of which the 
majority were temporary ileostomies used to ‘cover’ the colorectal anastomosis of an 






1.4 Cancer and Inflammation 
It is increasingly appreciated that outcomes in patients with colorectal cancer are not 
determined by tumour characteristics alone [16].  Cancer-associated inflammation, both in 
the systemic circulation and in the tumour microenvironment, is now widely recognised to 
be a key determinant of disease progression and survival in colorectal cancer. 
1.4.1 Systemic Inflammation and Cancer  
The patients’ Systemic Inflammatory Response (SIR) is recognised to influence patient 
outcomes.  The patients’ SIR can be assessed by examining changes in concentrations of 
circulating acute phase proteins, such as C-reactive protein (CRP), serum cytokines (TNF-α, 
IL-6, IL-8, IL-10) and low levels of circulating albumin [17-18].  Pre-operatively, these factors 
have been demonstrated to be stage-independent prognostic factors in many cancer types 
including colorectal cancer [19-24].   
It has been demonstrated that a simple pre-operative objective scoring system, the 
modified Glasgow Prognostic Score (mGPS), which measures CRP and albumin, is effective in 
predicting overall and cancer-specific survival in a variety of solid organ malignancies 
including colorectal cancer [25]. A significant correlation exists between the mGPS and 




















CRP > 10 mg/L 
 
1 
CRP > 10 mg/L 
AND 
Albumin < 35 g/L 
2 
 
The Modified Glasgow Prognostic Score (mGPS) is a pre-operatively determined inflammation-based score.  It 
is suggested that a significant correlation exists between the mGPS and prognosis in several cancer types.  
Higher scores indicate a poorer prognosis.  Table adapted from [20]. 
 
Acute phase proteins are just one aspect of the SIR.  The cellular components of the SIR, 
such a neutrophils, lymphocytes, monocytes and platelets have all been reported to have 
prognostic value in patients with colorectal cancer [26-30].  The SIR results in changes in 
circulating white blood cells and the neutrophil-lymphocyte ratio (NLR) has been used to 
predict overall and cancer specific survival in solid organ malignancies including colorectal 
cancer [31]. 
The systemic inflammation prognostic scores (mGPS and NLR) were compared in a large 
cross-sectional cohort study which revealed a reduced cancer specific survival independent 
of age, gender, deprivation and tumour site for both prognostic scores (p<0.001) [32].  The 
mGPS and NLR have also been compared longitudinally (not just pre-operatively) and it was 
demonstrated that post-operative assessment of the mGPS and NLR also had prognostic 




pre-operatively and post-operatively, is associated with poorer prognosis and there is 
undoubtedly a role for monitoring the SIR in patients who are undergoing colorectal cancer 
resection. 
The mechanism of a persistently elevated SIR in patients with colorectal cancer who have 
undergone surgical resection is undetermined.  It has been proposed that the pro-
inflammatory cytokine interleukin-6 (IL-6), which is upregulated by tissue injury and 
inflammatory cells, has the ability to activate and maintain the SIR via trans-signalling 
pathways involving the soluble IL-6 receptor [34].  A chronic dysregulation of the immune 
system may also account for the persistently elevated SIR, either as a consequence of its 
activation by micro-metastases or as a result of disease which induces tissue injury [35,36], 
for example in the presence of septic complications.   
It has been revealed that a post-operative anastomotic leak is associated with up to three 
times the risk of disease recurrence [37] and the development of any post-operative septic 
complication (surgical site infection, respiratory tract infection, urinary tract infection) 
further augments this risk [38].  Interestingly it has been found that pre-operative SIR is 
independently associated with the risk of developing infective post-operative complications 
in patients undergoing curative colorectal cancer resection [39]. 
1.4.2 Peri-tumoural Inflammation and The Tumour Microenvironment 
The prognostic value of a patient’s SIR to a tumour is well established as a negative 
prognostic factor in primary operable [40] and metastatic colorectal cancer [16, 41-44].  The 
peri-tumoural, or local, inflammatory response has also provoked considerable interest.  An 




response to the tumour by the host [45].  In contrast to the SIR, local infiltration of 
inflammatory cells in the tumour microenvironment is associated with improved survival in 
patients with cancer [45, 46].  There is great interest in establishing the cellular composition 
of immune cells infiltrating colorectal cancers and determining their prognostic value. 
Whilst the prognostic value of a generalised peri-tumoural response is associated with 
improved survival it is apparent that specific immune cell types relate more closely to 
survival, particularly cytotoxic T-cells (CD8+), memory T-cells (CD45RO+) and regulatory T-
cells (FOXP3+) [47].  This indicates that the adaptive anti-tumour immune response plays a 
key role in determining cancer progression.    
The type, density and location of the tumour inflammatory cell infiltrate appear especially 
relevant to patient outcomes, but as yet, there is uncertainty regarding which parameters of 
tumour inflammatory cell infiltrate are most closely related to survival.  In patients with 
primary, operable colorectal cancer a strong infiltration of inflammatory cells in the invasive 
margin conferred a marked survival advantage [46].  Particular survival benefit has been 
attributed to high numbers of lymphocytes and plasma cells [46] and it has been suggested 
that a co-ordinated inflammatory response at a local level, in the tumour 
microenvironment, mediated primarily through cells of the adaptive immune system are 
responsible [46].  Interestingly, the presence of peri-tumoural lymphocytes has been 
associated with favourable tumour characteristics such as an expanding, rather than 
infiltrative, growth pattern [48] and lower levels of venous invasion [46, 49]. 
Evidence regarding the prognostic significance of the innate immune response in the 
tumour microenvironment is contradictory.  Inflammatory cell types associated with the 




have a role in predicting outcomes.  Increased neutrophil infiltration has been associated 
with improved survival [50-52] and with reduced local recurrence without a survival 
advantage [53] along with other immune cells (lymphocytes, eosinophils, mast cells).  It has 
been reported that increased neutrophils at the invasive margin of the tumour is an 
important prognostic factor,  but the positive prognostic value of multiple other cell types 
was also concurrently described [51].  This suggests that the generalised, non-specific 
immune reaction is important [45].   
Although a number of studies have described that a strong infiltration of neutrophils [52] 
and macrophages [54] confer a survival benefit in patients with colorectal cancer, other 
studies have demonstrated no such association [53, 55].  It has been proposed that tumours 
may even exploit the innate immune system to promote tumour proliferation and invasion 
[56]. 
1.4.3 Peri-operative Immune Insult in Cancer Surgery 
High grade peri-tumoural infiltrates are composed of a co-ordinated adaptive and innate 
immune response [57].  The maintenance of such co-ordination in the tumour micro-
environment is associated with improved outcomes [58].  Cancer surgery elicits a high-
grade, non-specific SIR.  This overwhelming, systemic inflammation suppresses systemic 
cell-mediated immunity and consequently compromises the tumour immunity in the host 
[58].  This has been described as the ‘immune-hit’ [58, 59]. 
The immune-hit can be exacerbated by pre-operative SIR, for example, an emergency 
presentation with colonic obstruction, bleeding or perforation, confers a higher risk of 




of post-operative complications and the associated post-operative SIR increases the risk of 
disease recurrence [38].  It is therefore appreciated that major surgical resection for 
colorectal cancer presenting as an emergency or in the presence of a post-operative 
infective complication results in further compromise of the immune response to residual 
disease [40, 58].  This is consistent with the negative prognosis associated with the presence 
of SIR in patients affected by most tumour types at any stage of disease [40]. 
The intricate balance of anti-tumour and pro-tumour responses of tumour and systemic 
immunity during the peri-operative period is outlined below. 
Table 1.7 The balance of anti-tumour and pro-tumour responses of tumour and 
systemic immunity during the peri-operative period 
Tumour Immunity Systemic Immunity 
Anti-tumour 
High Density Adaptive Immune Responses 
CD3+ / CD8+ T-cell infiltrates 
Pre-operative State 
Inflammation Suppression 
Intact Cell-mediated Immunity 
Pro-tumour 
Absent T-cell Responses 




Systemic Inflammatory Response 




High grade peri-tumoural infiltrates are composed of a co-ordinated adaptive and innate immune response.  
The maintenance of such co-ordination in the tumour micro-environment is associated with improved 
outcomes.  Cancer surgery elicits a high-grade, non-specific SIR.  This overwhelming, systemic inflammation 
suppresses systemic cell-mediated immunity and consequently compromises the tumour immunity in the host.  





As a consequence of this theory there has been an increased interest in the development of 
immune-modulatory therapies that might be implemented in the peri-operative period.  The 
goal of such a therapy is to suppress non-specific systemic inflammation and maintain an 
effective anti-tumour, cell-mediated immunity of the host [58].  The implementation of 
effective peri-operative immune-modulatory therapy may assist the clearance of circulating 
tumour cells and the development of occult metastases.  Accumulating evidence suggests 
that simple immune-modulatory strategies (anti-inflammatories or immune-modulatory 
therapies) could be safely implemented in the peri-operative period [60].  These strategies 
may be of particular benefit in those patients presenting as an emergency or those deemed 
high-risk of developing post-operative infective complications.  
The interaction between tumour immunity and systemic immunity is likely to be complex 
and the delivery of appropriate immune-modulatory therapies to modify the peri-operative 












1.5 The Neutrophil 
Neutrophils are the most abundant polymorphonuclear (PMN) cell and contribute up to 
70% of the circulating leucocytes in health [61-63].   Neutrophils undergo six distinct 
morphological stages in their maturation.  They ultimately differentiate into mature 
segmented neutrophils which have a characteristic multi-lobar nucleus.  They are released 
from the bone marrow as terminally differentiated cells and have a short circulating half-life 
of approximately 6-8 hours [61].    
Neutrophils are an essential part of the innate immune system.   They function as the first-
line of defence against infections and are responsible for the containment and elimination 
of pathogens.  They are prevalent at sites of tissue trauma and are the hallmark of acute 
inflammation [61].  Neutrophils are also appreciated to have an important role in cancer 
progression [64].   
Neutrophils have a variety of specific of functions.  In health, circulating neutrophils adhere 
to the endothelium before transmigrating through it in a process termed chemotaxis.  At the 
site of inflammation neutrophils kill invading pathogens by phagocytosis, extracellular ROS 
release and by producing neutrophil extracellular traps (NETs) [65].  
Activated neutrophils produce cytokines which attract other immune cells and they are 
therefore responsible for modulating the inflammatory response.  After they have 
performed their function they subsequently undergo apoptosis (programmed cell death), an 






1.5.1 Neutrophil Functions 
Neutrophils were discovered at the origin of the immunological sciences and therefore the 
elucidation of their role in the immune response has been an ongoing process for over a 
century [67].  Neutrophils are not only ‘professional killers’ of pathogens but are also 
instructors of the immune system in the context of infection and inflammation.  They are of 
vital importance in the innate immune system and are fundamental in immune function.  
Despite their importance in immunity, neutrophil research has been hindered by their 
experimental intractability (short-life span, terminally differentiated) and consequently they 
have been overlooked by breakthroughs in the adaptive immune system [68]. 
Within the bone marrow, under the instruction of growth factors and cytokines, pluripotent 
haemopoietic cells differentiate into myeloblasts which are developmental cells committed 
to becoming granulocytes.  They pass through six distinct morphological stages in their 
maturation into mature segmented neutrophils which are characterised by their multi-lobar 
nucleus; Myeloblast, Promyelocyte, Myelocyte, Metamyelocyte, Immature Band Cell and 
Mature Segmented Neutrophil [67].   
As the precursor cells develop into neutrophils, they synthesise proteins that are sorted into 
different granules [69].  These granules are subdivided into three classes, azurophilic, 
specific and gelatinase granules.  The subdivision is generally artificial as the neutrophil 
alters its transcriptional profile during its maturation and this changes the granule content 
resulting in a continuum of granule species [70]. 
Chemokines control the release of neutrophils into the circulation and cells are stored for 




indications of developing inflammation where they then perform a multitude of cellular 
tasks [67]. 
Recent evidence suggests a wider functional diversity of neutrophils than previously 
appreciated, expanding their role in adaptive immunity.  The concept of neutrophil 
heterogeneity has emerged with accumulating evidence of neutrophil populations with 
distinct functions under both homeostatic and pathological conditions.  Cell surface 
markers, cell maturity and cellular functions have been used to identify neutrophil ‘subsets’.  
Novel neutrophil populations have been identified during infection, autoimmunity, cancer, 
cardiovascular disease and pregnancy [302].  It is not yet understood if distinct neutrophil 
subsets are derived from separate lineages or if they represent different activation or 
polarisation states from a common plastic neutrophil precursor. 
1.5.1.1 Neutrophil Activation 
At sites of inflammation, either bacterial-derived or host-produced, there is an abundance 
of inflammatory signals.  The bacterial derived LPS and fMLP and classical chemoattractants 
and cytokines, such as TNF-α, IL-1β and IL-17 stimulate endothelial cells to produce 
adhesion molecules.  The adhesion molecules include P-selectin, E-selectin and members of 
the integrin superfamily [69].  Circulating neutrophils encounter the stimulated endothelial 
cells and utilising two constitutively expressed proteins (P-selectin glycoprotein ligand-1 and 
L-selectin) they can engage with the adhesion molecules of the endothelial cells resulting in 
selectin-mediated tethering, or ‘capture’, to the vessel wall [71, 72]. 
The neutrophils then perform characteristic, selectin-mediated, ‘rolling’ along the 




kinases, Syk kinases, phosphoinositide 3-kinase and p38 mitogen-activated protein kinase 
[73-75].  The neutrophil can then enter its ‘firm adhesion’ state which is mediated by the β2 
integrin family of proteins (LAF-1 and Mac-1) [75, 76] which engage with endothelial ligands, 
namely the ICAM-1 immunoglobulin superfamily [77].  The neutrophil then ‘transmigrates’ 
through the endothelium utilising a complex interaction between neutrophil integrins, 
neutrophil surface proteins and endothelial junction molecules [75].  It is speculated that 
the protein mesh of the basement membrane is digested by neutrophil granule proteases 
[67]. 
When the neutrophil has traversed the endothelial barrier its behaviour is determined by 
the chemoattractants and inflammatory stimulants from both the pathogen (LPS, fMLP) and 
the host (IL-8).  The neutrophil follows chemotactic gradients towards invading microbes, 
stimulates the oxidative burst and begins to implement its regime of pathogen elimination 
via degranulation, phagocytosis and NETosis (the process of NET formation) [67]. 
Neutrophil activation can occur as a consequence of the recognition of pathogen-associated 
molecular patterns (PAMPs) by pattern-recognition receptors, but also in response to self-
derived molecules that are either altered or relocated from their normal cellular 
compartment.  Self-derived molecules from damaged tissue can therefore initiate 
neutrophil activation and the innate immune response.   Damage-associated molecular 
patterns (DAMPs) are usually hidden from the innate immune system, but they are actively 
or passively released following cell damage which initiates an inflammatory response.  
External cell components can also act as DAMPs following chemical or proteolytic 
modification of their structures allowing detection by inflammatory cells [303, 304].  The 




of DAMPs and PAMPs.  For example, Toll-like Receptor (TLR) 4 binds self-molecules high 
mobility group box-1 (HMGB1) and heat shock proteins, but also binds bacterial derived LPS 
[305].  Irrespective of the source of the ligand the pattern-recognition receptors initiate an 
equal response.   Other DAMPs include; S100 proteins, endogenous nucleic acids (RNA and 
DNA), altered extracellular matrix components (hyaluronan), mitochondrial DNA, 
mitochondrial formylated peptides and extracellular ATP [303, 304].  DAMPs are implicated 
in ‘sterile injury’, either by directly activating neutrophils or by facilitating neutrophil 
recruitment by altering the microenvironment following their detection by resident cells.  
Parallel signalling pathways are stimulated by PAMPs and DAMPs and this explains the 
similarities between microbial sepsis and the SIR associated with traumatic (sterile) injury. 
1.5.1.2 Elimination of Microbes 
The neutrophil is equipped with an array of microbial elimination techniques which reflects 
the neutrophil’s attempt to exploit the weakness of microbes during the course of infection. 
Degranulation 
The neutrophil has developed a specialty storage organelle designed to transport dangerous 
substances and deploy them at the appropriate time.  This is called the neutrophil granule 
and it is active in almost all neutrophil activities.  Granules are subdivided into three classes, 
azurophilic, specific and gelatinase granules.   
1. Azurophilic granules are named for their ability to take-up the dye Azure A and 
contain numerous enzymes and proteins including myeloperoxidase (MPO), an 




2. Specific granules are characterised by the presence of glycoprotein and lactoferrin 
and contain many anti-microbial compounds including, NGAL, hCAP-18 and lysozyme 
[79, 80]. 
3. Gelatinase granules serve as a storage location for metalloproteases, including 
gelatinase and leukolysin [69]. 
Neutrophil secretory vesicles are often thought of as granules, but they are formed by 
endocytosis rather than budding from the Golgi Apparatus as are the granules. 
The granule subdivisions have differing propensities for mobilisation and are associated with 
a particular stage of neutrophil activation.  The gelatinase granules are mobilised as the 
neutrophils move through the endothelium [81, 82].  At the site of inflammation the specific 
and azurophilic granules are mobilised and contribute to the oxidative burst reaction.  
Flavocytochrome b558, which is found in the specific granule, is a key component of the 
NADPH oxidase machinery and subsequently allows reactive oxygen species formation [83]. 
Degranulation of specific and azurophilic granules also contribute to the creation of an 
inhospitable environment to invading pathogens [67]. 
Anti-microbial Proteins 
Neutrophils produce a vast array of anti-microbial proteins which can eliminate microbes 
directly or indirectly.  They can be broadly grouped into cationic peptides, proteolytic 
enzymes and proteins that deprive microbes of essential nutrients. 
The neutrophil cationic peptides include defensins and cathelicidins which are thought to 
have roles in inhibition of bacterial cell wall synthesis [84] and in the DNA activation of 




bacterial permeability, bacterial hydrolysis and cell death [86] and histones which perform 
antimicrobial role by an unknown mechanism.  
The neutrophil proteolytic enzymes contribute to microbial elimination by various 
mechanisms.  Lysozymes degrade bacterial cell walls [87], proteinase-3 and azurocidin bind 
to the bacterial membrane, neutrophil elastase and cathepsin G cleave bacterial virulence 
factors and outer membrane proteins [88]. 
Several proteins produced by neutrophils deprive microbes of essential metals and 
subsequently impact on bacterial growth.  Lactoferrin binds preferentially to iron and 
calprotectin sequesters zinc and results in ‘nutritional immunity’ [89]. 
Reactive Oxygen Species 
Neutrophils kill micro-organisms by ingesting them into phagosomes.  Phagocytosis is 
accompanied by activation of the NADPH oxidase, an enzyme complex that assembles in the 
phagosomal membrane (internalised neutrophil membrane) and converts oxygen into the 
superoxide radical anion (O2°
-) [67, 90].  O2°
- undergoes dismutation, catalysed by 
superoxide dismutase (SOD), inside the phagosome to produce hydrogen peroxide (H2O2).  
Simultaneously, myeloperoxidase (MPO) is released into the phagosome which catalyses the 
formation of hypochlorous acid (HOCl) from chloride and H2O2.  HOCl is considered the 
major oxidative weapon of the neutrophil.  The build-up of high concentrations of H2O2 may 
kill micro-organisms directly or by formation of hydroxyl radicals and singlet oxygen in 







Phagocytosis is an active, receptor-mediated process used to remove pathogens and cell 
debris.  Particles are internalised by the cell membrane into a vacuole called the phagosome 
[67]. 
Phagocytosis can be direct, through the recognition of pathogen-associated molecular 
patterns (PAMPs) by pattern-recognition receptors or opsonin mediated.  Opsonin mediated 
phagocytosis includes FcϒR mediated phagocytosis, which relies on pseudopod extensions 
for engulfment of IgG-opsonised particles and complement receptor mediated 
phagocytosis, which does not require pseudopod extensions [91]. 
Our understanding of neutrophil phagocytosis is principally based upon the study of 
macrophage phagocytosis, however crucial differences between macrophage and 
neutrophil phagocytosis exist.  Macrophage phagocytosis follows an endocytic maturation 
pathway whereas neutrophil phagosome maturation occurs upon fusion of the granules to 
the phagosome when antimicrobial molecules are delivered into the phagosome.  In the 
neutrophil the assembly of the NADPH oxidase on the phagosome membrane allows ROS 
production and this creates an antimicrobial environment within the phagosome.  NADPH 
oxidase activity also maintains an alkaline pH which is essential for the function of the 
proteolytic enzymes, neutrophil elastase and cathepsin G [92]. 
Neutrophil Extracellular Traps 
Activated neutrophils can undergo ‘NETosis’.  This is an active form of cell death that leads 
to the release of decondensed chromatin into the extracellular space [93, 94].  The fibrous 




granule products (MPO) and cytoplasmic proteins (BPI, neutrophil elastase, cathepsin G and 
lactoferrin) [95].  NETs trap many types of microbes and their anti-microbial properties are 
thought to arise from exposing them to high local concentrations of anti-microbials [96].   
The exact mechanism for NET formation is not yet completely understood.  It is thought that 
the ROS pathway is involved as both NADPH oxidase and MPO are required for NET 
formation [94, 97, 98].  In this oxidant dependent pathway the formation of NETs follows 
the sequence of loss of nuclear segregation and the fragmentation of the lobar nucleus, 
disintegration of the nuclear membrane into vesicles and the disappearance of granules.  
This allows the nuclear chromatin to combine with the granule products and cytoplasmic 
proteins.  The cell membrane eventually ruptures and the NETs are released.  The process of 
oxidant dependent NET formation results in eventual cell death and is distinct from 
apoptosis and necrosis being termed NETosis [94, 99]. 
The Raf-MEK-ERK pathway has also been implicated in NET formation [100] which occurs 
upstream of NADPH oxidase.  Neutrophil elastase translocates from the granules to the 
nucleus and degrades histones leading to chromatin decondensation and consequently has 
been implicated in NETosis [101].  It is thought that histone citrullination may also play a 
role in NET formation.  This process is catalysed by the enzyme peptidylarginine deiminase 4 
(PAD-4), which is abundant in neutrophils and converts histone arginine to citrulline.  This is 
a vital step in the decondensation of DNA [102-104]. 
Other pathways of NET formation have been described.  The oxidant independent pathway 
results in a rapid NET formation and does not result in cell death, allowing activated 
neutrophils to perform their numerous anti-microbial actions.  Neutrophils incubated with 




passed through the cytoplasm and acquired granule products.  The vesicles were then 
exocytosed and the chromatin released from the neutrophil in a NET.  This process was not 
dependent upon ROS production [105]. 
Although controversial, the oxidant dependent release of mitochondrial DNA in response to 
granulocyte macrophage colony stimulating factor (GM-CSF) and Complement factor 5a 
(C5a) has been described.  This process is dependent on ROS production.  It does not induce 
cell death and thus the neutrophil is able to conduct its other anti-microbial actions [62].  
This pathway remains contentious as the detection of mitochondrial NETs may actually be a 
consequence of cell lysis. 
As yet the clinical relevance of NETs is undetermined.  Bacteria that express DNases may 
disseminate more efficiently in the host and thereby entrapment by NETs should be avoided 
[106, 107].  Conversely, NETs may be particularly important in the entrapment of large 
pathogens that are not readily phagocytosed [67]. 
NETs may also have detrimental effects on the host by inducing autoimmune disease.  This 
occurs by the exposure of ‘self’ molecules extracellularly leading to the formation of auto-
antibodies against chromatin and neutrophil components [108].  Platelet-induced NETs have 
been linked with hepatotoxicity in sepsis [109] and platelet adherence to NETs implicates 
them in thromboembolic disease [110]. 
1.5.1.3 Communication with Other Immune Cells 
Neutrophils are one of the first cell types to arrive at sites of infection or inflammation and 
they have a vital role in communicating with other immune cells.  Neutrophils secrete 




thus establish the correct environmental conditions for the adaptive immune system.  
Neutrophils undergo a transcriptional burst which facilitates the synthesis of signalling 
molecules [111, 112]. 
The initial neutrophil cytokine response is for re-enforcement via the production of IL-8 
[113].  Neutrophil derived IL-1β and TNF-α induce other cells to produce chemoattractants.  
Neutrophils also release other signalling mediators which include, granule products, lipids 
and ROS products, such as hydrogen peroxide [114-116] and they can also communicate by 
cell to cell contact [117]. 
Neutrophils have roles in recruiting monocytes and macrophages and can modulate 
monocyte and macrophage cytokine production [118].  Neutrophils also recruit and activate 
dendritic cells and induce their maturation [117].  It has also been proposed that neutrophils 
activate natural killer cells directly or in combination with dendritic cells in a positive 
feedback loop [119].   
Amazingly, neutrophils have been found to extensively communicate with lymphocytes at 
opposite ends of the immune spectrum and it has been shown that neutrophils and T-cells 
impact upon each other’s functions [120].  Neutrophils have suppressive effects on T-cells 
via L-arganine depletion by the release of arginase which inhibits T-cell responses [121] and 
by hydrogen peroxide mediated suppression, as proposed in a cancer model [116].  
Neutrophil modulation of the adaptive immune system appears to be extremely complex 






1.5.1.4 Resolution of Inflammation 
Apoptosis is a key component of inflammation resolution.  After conducting their anti-
microbial activities, neutrophils die by the process of apoptosis, or programmed cell death.  
The process of neutrophil apoptosis also produces signals to abolish the recruitment of 
further neutrophils indicating a resolution of inflammation.  Neutrophil survival is prolonged 
by inflammatory mediators (GM-CSF, LPS) and by environmental factors such as hypoxia.  It 
is well established that signalling networks regulate cell survival and can be either anti-
apoptotic which favours cell survival (Mcl-1 and A-10) or pro-apoptotic which favours cell 
death (Bad, Bax, Bak, Bid and caspases) [122].   
Several proteins are proposed to have anti-apoptotic effects.  Survivin is one such protein 
which is highly expressed in immature neutrophils, but its expression is restored in mature 
cells in the presence of inflammatory mediators (G-CSF, GM-CSF) and is subsequently 
identified at sites of inflammation [123].  Likewise, cyclin-dependent kinases function as 
anti-apoptotic factors in neutrophils and their inhibition induces caspase-dependent 
apoptosis [124].   
In the resolution of inflammation it is vitally important that the apoptotic cells are 
appropriately cleared.  Apoptotic neutrophils are ingested by macrophages which in turn 
drives the production of anti-inflammatory cytokines, tumour growth factor-β (TGF-β) and 
IL-10 [123].  If apoptotic cells are not cleared then the resultant secondary necrosis re-
establishes pro-inflammatory signals. 
In the resolution of inflammation a major lipid mediator class shift is also apparent.  The 




neutrophil.  At the commencement of inflammation the neutrophil produces pro-
inflammatory lipid mediators, such as prostaglandins and leukotrienes.  Conversely, at the 
termination of inflammation, neutrophils interact with many cell types (epithelial cells, 
endothelial cells, fibroblasts, platelets and leukocytes) and together they synthesise anti-
inflammatory lipid mediators, such as lipoxins, resolvins and protectins [115]. 
1.5.2 Distinct Functions of Neutrophils in Cancer 
Chronic inflammation has been associated with an increased susceptibility to the 
development of cancer, for example, inflammatory bowel disease and colorectal cancer 
[125] and Hepatitis B and hepatocellular carcinoma [126].  Neutrophils have been 
implicated in inflammation driven tumourogenesis but have also been found to limit tumour 
growth and metastatic progression which suggests that neutrophils have both pro-tumour 
and anti-tumour properties [127]. 
It has been suggested that neutrophils are not a homogenous population of cells and may 
consist of pro-tumour and anti-tumour subpopulations.  The ‘polarisation’ of neutrophils 
towards a pro-tumour or anti-tumour phenotype may be mediated by the ‘chemokine 
landscape’ in the tumour microenvironment [128].  
In the context of cancer, interferon-β (INF-β) demonstrates anti-tumour properties and is 
responsible for the inhibition of tumour cell proliferation and the promotion of tumour cell 
apoptosis [129].  INF-β is also responsible for initiating an anti-tumour immune response 
through the activation of T-cells, natural killer cells and macrophages [130].  With regard to 




MMP9).  This results in the suppression of tumour vascularisation [131] and inhibition of the 
formation of a pre-metastatic niche [132]. 
Conversely, tumour growth factor-β (TGF-β) appears to promote an immunosuppressive 
tumour microenvironment with a particular role in the suppression of anti-tumour 
neutrophil cytotoxicity.  It has been demonstrated that in the absence of TGF-β the cellular 
composition of the tumour changes and neutrophils recruited to tumours have an anti-
tumour phenotype (N1) indicating that TGF-β polarises neutrophils towards a pro-tumour 
phenotype (N2) [133-135]. 
Anti-tumour (N1) Phenotype 
Anti-tumour (N1) neutrophils act to limit tumour growth and metastatic progression [127] 
through various mechanisms. 
1. Direct Cytotoxicity:  Neutrophils generate a wide variety of antimicrobial proteins.  
Although these are mostly non-toxic to host cells they have been found to be directly 
involved in anti-tumour neutrophil cytotoxicity, in particular the superoxides 
associated with NADPH oxidase [136-138]. 
2. Antibody Dependent Cell-mediated Cytotoxicity:  Neutrophils express numerous 
receptors that can target antibody labelled tumour cells and it has been established 
that they participate in antibody dependent cell-mediated cytotoxicity in various 
cancer types [127]. 
3. Stimulation of T-cells:  Neutrophils are required to initiate adaptive anti-tumour 




cells.  They have also been implicated in the presentation of antigens to directly 
stimulate T-cell responses [139]. 
4. Neutrophil Extracellular Traps (NETs):  It has been proposed that NETs are involved in 
cancer immunoediting.  Their exact role, however is yet to be determined.  NETs 
have been implicated in T-cell priming [140] and in the propagation of anti-tumour 
immune responses [141].  Conversely, they have also been linked to cancer 
progression, development of metastases and cancer-associated thrombosis. 
Pro-tumour (N2) Phenotype 
In the context of cancer, neutrophil function can be modified to promote tumour growth 
and the formation of metastases.  The mechanisms of pro-tumour (N2) neutrophils are 
outlined below. 
1. Pro-tumour Cytokines:  Depending upon the ‘cytokine landscape’ in the tumour 
microenvironment neutrophils are capable of producing multiple growth factors.  
One such growth factor is EGF and it, along with its receptor EGFR, has been 
implicated in the pathogenesis and progression of multiple cancer types, including 
colorectal cancer [142].  It has also been demonstrated that amplifications of the 
EGFR occur in patients with cancer and it is also associated with angiogenesis, 
increased tumour proliferation, anti-apoptosis and enhanced tumour cell motility 
[143].  Another important neutrophil derived growth factor is platelet derived 
growth factor (PDGF) which has been implicated in the growth and metastasis of 
epithelial tumours [142].  Furthermore, neutrophils secrete other cytokines which 




implicated in the promotion of tumour growth by modifying peri-tumoural stromal 
cell function and are involved in angiogenesis and anti-apoptosis [144-149].  
2. Angiogenesis:  It has not yet been elucidated how tumour associated neutrophils 
modulate tumour angiogenesis, but it has been proposed that they are involved in 
the process by remodelling the extracellular matrix, a process crucial for 
angiogenesis, under the influence of VEGF.  The activated neutrophils have been 
shown to highly express VEGF and MMP9 which are responsible for the initiation of 
the ‘angiogenic switch’ which is necessary to support angiogenesis in tumours [131]. 
3. Tumour Cell Dissemination:  Neutrophils can secrete soluble proteases and cytokines 
that can activate endothelial and parenchymal cells and it has been suggested that 
this improves adhesion of circulating tumour cells to distant sites [150-153] and a 
pro-metastatic state.  It is thought that neutrophils may also tether circulating 
tumour cells to distant endothelial sites (liver and lung) mediated by the β2 integrin 
family of proteins which engage with endothelial ligands, namely the ICAM-1, on the 
tumour cells [153-155]. 
4. Neutrophil Extracellular Traps (NETs):  It has been demonstrated that NET formation 
occurs within primary tumours and is associated with adverse clinical outcomes 
[141].  It has been proposed that NETs may act within the primary tumour and 
promote tumour progression, although the antimicrobial proteins and peptides 
associated with NETs, including MMP9, neutrophil elastase and cathepsin G, have 
been implicated in tumour progression without specific reference to NETs [156].    
Therefore it is theorised that NETs expose tumour cells to high concentrations of 
biologically active proteins which favour tumour proliferation, anti-apoptosis and 




that NETs can sequester tumour cells and promote early adhesion of the tumour to 
distant metastatic sites.  Following the dissemination, tumour cells must be able to 
proliferate to form stable metastatic foci.  NETs may play a direct proliferative role 
and may also inhibit tumour cell apoptosis [157].  NETs have also been implicated as 
potential facilitators of tumour progression in the context of post-operative sepsis.  
This is of particular interest as the majority of patients diagnosed with cancer 
undergo at least one surgical procedure and post-operative infections occur with an 
incidence approaching 40% in some series [158]. 
5. Pre-metastatic Niche:  Neutrophils are mobilised and accumulate in ‘future sites’ of 
metastases where they partake in the formation of a supportive metastatic 
microenvironment which is called the pre-metastatic niche [159-161].  Here 
neutrophils produce molecules that are capable of influencing tumour cell 
proliferation, survival and migration [162-163]. 
6. Suppression of T-cells:  As previously stated neutrophils can present antigens to T-
cells to stimulate their anti-tumour immunity, conversely, it has been demonstrated 
that neutrophils can suppress antigen-nonspecific T-cell proliferation [164, 165].  
This has been attributed to granulocytic myeloid derived suppressor cells and 
immature neutrophils [166-168]. 
Neutrophil heterogeneity is a consequence of the remarkable ability of the neutrophil to 
respond to changes in the chemokine landscape of the tumour microenvironment.  The 
distinct neutrophil phenotypes described, anti-tumour (N1) and pro-tumour (N2), suggests 




and are capable of phenotypic plasticity.  This opens up the possibility of therapeutic 
intervention to enhance anti-tumour and suppress pro-tumour properties.  
Table 1.8 Characteristics of Anti-tumour (N1) and Pro-tumour (N2) Neutrophil 
Phenotypes 











Suppressive for T-cells 
Immuno-suppressive 
 
The polarisation of neutrophils towards an anti-tumour (N1) phenotype or a pro-tumour (N2) phenotype may 
be mediated by the chemokine landscape in the tumour microenvironment and results in neutrophils with 












1.5.3 Neutrophil Extracellular Traps in Cancer Progression 
Neutrophils have been increasingly recognised as important players in the tumour 
microenvironment and both anti-tumour and pro-tumour properties have been 
demonstrated.  Neutrophils appear to adopt phenotypic plasticity and a heterogeneous 
population of neutrophils can exert contradictory roles in the context of cancer [127]. 
NETs have been recognised as an effective antimicrobial mechanism in response to various 
stimuli.  They appear to have an extended role in tumour biology and have been implicated 
in tumour progression, tumour dissemination and in tumour-associated thrombosis [156].    
Exposure of primed neutrophils to bacterial products (LPS, fMLP, PMA) results in NET 
formation as well as physical interaction with activated platelets, which is of particular 
relevance in the context of cancer [93, 169-172].  Additionally, cytokines (TNF-α and IL-8) 
have been shown to facilitate NET formation and these cytokines are highly expressed by a 
number of tumour types [173-175]. 
Neutrophil Extracellular Traps and the Primary Tumour 
The role of NETs in tumour progression is poorly understood but the evidence to date does 
propose an association between intra-tumoural NET deposition and tumour progression in 
both experimental models and in patients with cancer [157,176, 177]. 
The ability of tumours to predispose neutrophils to produce NETs has been demonstrated 
and various tumour types have predisposed circulating neutrophils to produce NETs [178].  
The evidence supports the theory that primary tumours can facilitate NET production in 





In the setting of lymphoma, NET formation within the primary tumour has been shown to 
enhance B-cell proliferation.  It has therefore been proposed that NETs directly influence 
tumour cell behaviour and promote tumour growth [157]. 
It is believed that NETs operate within the primary tumour to promote tumour progression, 
but no mechanism has been outlined for this observation. 
Neutrophil Extracellular Traps and Metastatic Progression 
Neutrophils play a vital role in circulating tumour cell metastases.  This has been shown in-
vitro and in-vivo where neutrophils facilitate circulating tumour cell adhesion to both 
pulmonary and hepatic endothelial surfaces [174, 176, 179-181].  The direct contact of 
circulating tumour cells and neutrophils is an important precursor to the development of 
metastatic disease [179, 180] 
In the context of systemic sepsis, widespread NET deposition occurs within the 
microvasculature of a host organ (liver, lung) and promotes adhesion of circulating tumour 
cells.  It has been revealed that these NETs can sequester circulating tumour cells and 
promote metastases [158].  Trapped circulating tumour cells can not only survive 
interactions with NETs but NETs may also have a direct proliferative role and anti-apoptotic 
role on the tumour cells and therefore may promote the development of macrometastases 
[157].   
The literature supports a pro-metastatic role of NETs and it is suggested that they may 
promote early adhesive events, thus increasing sequestration of malignant cells in end 
organs.  NETS may also be responsible for promoting a pro-tumour phenotype in neoplastic 




Neutrophil Extracellular Traps in the context of Cancer Surgery 
Loco-regional control in the form of a complete oncological resection remains the mainstay 
of treatment for the majority of solid tumours and provides improved disease-free and 
overall survival [182].  Unfortunately, surgery can lead to increased number of circulating 
tumour cells [183] and it is associated with complications, particularly post-operative 
infectious complications which can approach 40% in some series [158].   It is well 
established that infectious complications in patients with cancer are associated with adverse 
oncological outcomes independent of the morbidity associated with the infectious insult 
[184-187] and they are associated with an increased mortality as a consequence of 
metastatic disease [187-191].   
As a consequence of the association of severe infection and tumour progression 
experimental models (murine caecal ligation and puncture model) were undertaken to test 
the hypothesis that NETs could trap circulating tumour cells, promote early adhesion of 
tumour cells to distant sites and facilitate metastatic disease progression.  It was 
demonstrated that sepsis induced by a caecal ligation and puncture model resulted in 
widespread deposition of NETs and that systemic sepsis promoted the development of gross 
metastases (by increased tumour cell adhesion to hepatic and pulmonary microvasculature).  
This was attenuated by the administration of inhibitors of NET formation (DNase, neutrophil 
elastase inhibitor).  It was also revealed that tumour cells were trapped within NETs and this 
was associated with the development of metastases [158]. 
Interestingly, in this experimental model NET formation in-vivo was inhibited by the 
exogenous administration of DNase and neutrophil elastase inhibitor with favourable 




possibility that mitigating the adverse oncological outcomes associated with severe 
infection in patients with cancer is theoretically possible. 
Clinical and experimental evidence suggests that activated neutrophils may facilitate 
metastatic progression in the context of systemic infection [192-195].  Therapeutic 
strategies aimed at modifying tumour-neutrophil interactions may therefore maximise the 
therapeutic benefit of surgery in the context of cancer. 
Neutrophil Extracellular Traps as Therapeutic Targets 
It appears logical to attempt to suppress NET formation and prevent the mechanism that 
may predispose tumour progression and dissemination. 
As previously mentioned, in an experimental model, NET formation is inhibited by the 
exogenous administration of DNase and neutrophil elastase inhibitor with favourable 
oncological outcomes. 
DNase has been used in the treatment of empyema, cystic fibrosis and systemic lupus 
erythematous (SLE) in humans without adverse effects [196].  No human cancer trials 
investigating the effect of DNase have been performed to date, however, a number of 
animal studies have been conducted which fascinatingly demonstrate an anti-metastatic 
effect in a variety of tumour models [197, 198]. 
It is known that excessive neutrophil elastase function is associated with NET formation and 
that this is implicated in tumour progression and dissemination [156] and elevated levels of 
neutrophil elastase have been detected in a variety of cancer types [199-201].  Individuals 
who are α1-antitrypsin deficiency heterozygotes have increased frequency of many tumour 




negative regulator for neutrophil elastase which appears responsible for tumour 
development [202]. In bronchoalveolar adenocarcinoma elevated neutrophil elastase levels 
appear to enhance tumour cell shedding and possibly intra-pulmonary spread [200].  
Elevated post-operative levels of neutrophil elastase have been identified following thoracic 
surgery which is associated with adverse pulmonary outcomes including Acute Respiratory 
Distress Syndrome (ARDS) [200, 202-205]. The neutrophil elastase inhibitor, Sivelastat, has 
been examined in a randomised controlled trial in the setting of video-assisted thoracic 
surgery for primary oesophageal cancer.  This revealed that peri-operative Sivelestat was 
safe and associated with a significantly reduced SIR compared to placebo [205].  A further 
randomised control trial in the setting of video-assisted thoracoscopic oesophagectomy, 
revealed a reduction in duration of mechanical ventilation, reduced duration of SIR, a more 
rapid reduction in CRP and reduced length of ICU stay in patients treated with Sivelestat 
compared with placebo [203].  Peri-operative neutrophil elastase inhibition appears to 
decrease the SIR to surgery.   
The evidence suggests that it is conceivable to implement a therapeutic strategy in the peri-
operative period to reduce the systemic inflammation associated with surgery, minimise 








1.6 HMG-CoA Reductase Inhibitors 
HMG-CoA Reductase Inhibitors (statins) inhibit 3-hydroxy-3-methylglutaryl coenzyme A 
reductase and were developed as lipid-lowering agents.  They are one of the most 
commonly prescribed medications worldwide and it is estimated that they are prescribed to 
approximately 7 million people per year in the UK [206-210].  Six statins are currently 
available for use in the UK; atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, 
simvastatin.  Simvastatin and atorvastatin are the most commonly prescribed statins and 
account for 85% of the total use.  They are well tolerated medications with a low side effect 
profile, mainly hepatic dysfunction and muscle toxicity, for which approximately only 4% of 
patients discontinue the medication [208, 211]. 
Statins have been extensively studied and have proven efficacy in the primary and 
secondary prevention of cardiovascular morbidity and mortality in a variety of populations 
[212-217]. Their main mechanism of action is reduction of serum cholesterol by means of 
competitive inhibition of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, which 
is the rate limiting enzyme in the mevalonate synthesis pathway.  Consequently, statins 
reduce the intermediate products of cholesterol synthesis, namely mevalonate and the 
down-stream isoprenoid intermediaries (isopentenyl-pyrophospate, farnesyl-
pyrophosphate, geranylgeranyl-pyrophosphate).  These molecules play a vital role in several 
intracellular signalling pathways which include protein prenylation via GTPases (Rho, Rac) 
[206,207, 218-221].  This leads to a reduction in endogenous cholesterol biosynthesis and a 





1.6.1 HMG-CoA Reductase Inhibitors and The Pleiotropic Effect  
The cholesterol independent effects of HMG-CoA reductase inhibition are known as 
‘pleiotropic’ effects.  These pleiotropic effects have been shown to modulate the innate and 
adaptive immune systems and have anti-inflammatory effects which counteract the 
detrimental effects of inflammation.  It has been proposed that statins may be novel 
therapeutic agents for the treatment and prevention of sepsis and that their use in the peri-
operative period may reduce surgical complications by modulating the post-operative pro-
inflammatory response.  In fact, statins have been demonstrated to reduce the release of 
pro-inflammatory mediators (CRP, TNF-α, IL-6, IL-8) and evidence from randomised control 
trials has demonstrated improved outcomes in cardiovascular disease and bacterial 
pneumonia with statin induced CRP reduction [221-230]. 
1.6.2 HMG-CoA Reductase Inhibitors and Cancer 
In view of their pleiotropic effects it has been suggested that statins may affect cancer risk 
by means of cancer chemoprevention.  It has been demonstrated in pre-clinical studies that 
statins exert anti-neoplastic effects; pro-apoptotic, anti-angiogenic and immune-modulatory 
effects all of which may prevent cancer growth [231, 232].  Observational studies and meta-
analyses have demonstrated a reduced risk of prostate, hepatocellular, gastric and 
oesophageal cancer associated with statin use [233-236].  Statins have also been 
investigated in the context of a potential role in the modification of cancer outcomes and 
mortality.  It is has been demonstrated that patients who take statins prior to their cancer 




The relationship between statins and colorectal cancer has been investigated, but the 
results are inconclusive both with regard to cancer risk, cancer outcomes and mortality.  
Epidemiology studies have examined the risk of colorectal cancer with conflicting results 
from very protective [238] to moderately harmful [239].  A recent meta-analysis of 40 
published studies concluded that statins did not strongly reduce the overall risk of colorectal 
cancer in the general population at the low doses used for managing hypercholesterolaemia 
and cardiovascular disease.  There was, however, evidence to suggest an overall risk 
reduction with statin use; Randomised Control Trials (RR=0.89, 95%CI=0.74-1.07, n=8), 
Cohort Studies (RR=0.92, 95%CI=0.83-1.00, n=13), Case-control Studies (RR=0.92, 
95%CI=0.87-0.98, n=19) [240]. 
The effect of statins may differ according to cancer type, as cancer is not a homogenous 
entity, and patient population.  It has been suggested that basic science research should be 
performed to ascertain which cancer types and patient populations are more likely to 
benefit from statins, either as a primary chemopreventative intervention or as an adjunct to 
other treatments [240]. 
1.6.3 HMG-CoA Reductase Inhibitors and Surgery 
Following major cardio-vascular surgery a reduction in post-operative cardiac complications 
and a reduction in post-operative infective complications has been documented in patients 
taking statins pre-operatively [241-245].  In the context of general surgery, pre-operative 
statin use has been independently associated with a decreased risk of major, non-cardiac 
complications, respiratory complications, venous thrombo-embolic events and infective 
complications [246-248].  Overall, the pre-operative use of statins appears to be associated 




associated with a reduction in mortality after bacteraemia in transplant recipients, a 
reduction in candida infection in patients with diabetes and a decreased need for surgery in 
adhesive small bowel obstruction [247].   
Specifically in the context of colorectal surgery, statin use is associated with a significantly 
lower incidence of SIRS and a lower incidence of surgical site infection [248].  There appears 
to be no difference however in overall mortality, total complications or median hospital 
length of stay between statin users and non-statin users undergoing major colorectal 
resection [246, 247].   
Studies have demonstrated contradictory results regarding the association of peri-operative 
statin therapy and anastomotic leak and a beneficial effect of peri-operative statin therapy 
on the incidence of anastomotic leak cannot be ruled out [249, 250].  Patients on peri-
operative statins appear to have a greater baseline peri-operative risk compared to non-
statin users, but they achieve equivalent outcomes overall suggesting that peri-operative 
statin therapy may reduce morbidity after elective colorectal resection [248, 250]. 
It has been proposed that the use of statins in the peri-operative period may reduce surgical 
complications by modulating the post-operative pro-inflammatory response.  It seems 
logical to think that the pleiotropic effects (anti-inflammatory, immune-modulatory, anti-
platelet, anti-thrombotic, protective against oxidative stress, anti-microbial [221-230]) could 
be advantageous in the setting of surgery.  In particular, the use of statins in the context of 
cancer surgery may reduce the systemic inflammation associated with surgery and minimise 





1.6.4 HMG-CoA Reductase Inhibitors and Neutrophil Function 
Previous work conducted in our laboratory has examined neutrophil migration in a healthy 
elderly population (Greenwood, 2013).  A generic, robust migratory phenotype, 
characterised by a maintained speed of migration but with reduced migratory accuracy was 
identified in an ageing population. This phenotype was demonstrated to be driven by 
dysregulated PI3Kinase activity and was proven to be amenable to correction with 
simvastatin through PI3Kinase inhibition [293].  It was concluded that aberrant migration 
may cause increased collateral damage to otherwise healthy tissue and manifest as delayed 
arrival to the site of infection and raised systemic inflammation, ultimately compromising 
host defences and contributing to the increased rates of morbidity and mortality observed 
in an ageing population [293]. 
Further work conducted in our laboratory has studied neutrophil function in the context of 
systemic sepsis (Patel, 2014).  It has been demonstrated that neutrophils display a specific 
phenotype, characterised by a failure of migration, a propensity to degranulate and 
generate ROS with preserved phagocytic capacity while suppressing NET formation and 
suspending apoptosis.  In-vitro treatment with simvastatin was observed to attenuate both 
ROS production and NET formation [294].  It was inferred that neutrophils contribute to the 
pathogenesis of organ dysfunction in sepsis secondary to a failure of appropriate migration.  
This enables pathogen dissemination and sepsis propagation in conjunction with increased 
systemic activation leading to collateral tissue damage.  It was suggested that statins may be 
of benefit in the setting of early sepsis, particularly in the elderly, and further investigation 




In summary, work conducted in our laboratory to date has demonstrated modulation of 
neutrophil function with simvastatin in the following circumstances:  
1. The reduction in NET formation observed in patients with sepsis (mild sepsis, but not 
severe sepsis) was attenuated by in-vitro treatment with simvastatin [294]. 
2.  The increase in ROS production observed in patients with sepsis was attenuated by 
in-vitro treatment with simvastatin [294].  
3. The age-related decline in neutrophil migration was corrected by in-vivo treatment 




















1.7 Histone Acetylation and Deacetylation 
Histone acetylation regulates inflammatory gene expression and is responsible for a number 
of diverse functions including DNA repair, cell proliferation and apoptosis [251, 252].  In the 
resting cell, DNA is tightly compacted around a core of histones. Specific residues in the N-
terminal tails of histones can be post-translationally modified by acetylation leading to the 
release of the tightly wound DNA.  Conversely, histone deacetylation is thought to re-
establish the tight nucleosomal structure [251, 252]. Histone acetylation is regulated by a 
dynamic balance between histone acetyltransferase (HAT), which is associated with an open 
chromatin state and transcriptional activation, and histone deacetylase (HDAC), which is 
associated with a closed chromatin state and transcriptional repression [253]. 
 
Histone deacetylation in cancer 
Changes in histone acetylation patterns have been described in the context of cancer.  It has 
been demonstrated that HDACs regulate the expression of a large number of genes by 
directly interacting with transcription factors, for example E2f, Stat3, p53 [254].  HDACs 
have also been implicated in the deacetylation chromatin proteins, leading to altered gene 
transcription regulation and the deacetylation of non-histone proteins that regulate cellular 
homeostasis (cell-cycle progression and differentiation) [255].  HDAC inhibitors have 
subsequently been investigated for a potential anti-tumour effect.  Interestingly, HDAC 
inhibitors have been found to induce apoptosis in a number of tumour types [256, 257]. 
Histone deacetylation in inflammation 
Recent evidence from animal models (arthritis [258] and airway hyper-responsive [259] 




inflammatory agents.  Although it was initially believed that HDAC inhibitors did not induce 
apoptosis in non-malignant cells [257, 258] this has been subsequently disproven.  HDAC 
inhibitors have been found to enhance apoptosis in human neutrophils and eosinophils both 
in the presence and absence of survival-prolonging cytokines [253].  This suggests that HDAC 
inhibitors could potentially resolve neutrophilic and eosinophilic inflammation by inducing 
apoptosis. 
Histone Deacetylase Enzymes 
Eighteen HDAC enzymes have been identified and they can be subdivided into four different 
classes as outlined below. 
 
Table 1.9 Histone Deacetylase Enzyme Classes 
 
Class I HDAC-1, HDAC-2, HDAC-3, HDAC-8 
Class IIa 
Class IIb 
HDAC-4, HDAC-5, HDAC-7, HDAC-9 
HDAC-6, HDAC-10 
Class III SIRT-1, SIRT-2, SIRT-3, SIRT-4, SIRT-5, SIRT-6, SIRT-7 
Class IV HDAC-11 
 
Eighteen HDAC enzymes have been identified and they can be subdivided into four different classes: Class I, 
Class II (Class IIa and Class IIb), Class III, Class IV.  Table adapted from [260]. 
 
Class I HDACs have a nuclear location and are universally expressed in human cell lines and 
tissues.  Class II HDACs exhibit tissue specific expression and can move between the nucleus 
and cytoplasm suggesting that they may be involved in deacetylation of non-histone 




pattern of tissue specific expression is not yet known.  HDAC-11 is the only member of Class 
IV and is homologous with Class I and Class II.  Class I and Class II HDACs are sensitive to the 
classical HDAC inhibitor Trichostatin, while Class III HDACs require a co-factor (coenzyme 
NAD+) [260].  
HDACs can induce aberrant transcription of key genes in the context of cancer and 
inflammation causing dysregulation of cellular functions.  Consequently, HDACs are 
promising therapeutic target for cancer treatment and the resolution of inflammation. 
 
Histone deacetylation and HMG-CoA Reductase Inhibitors 
As previously documented, the rate limiting step in the melavonate pathway is catalysed by 
HMG-CoA reductase which converts HMG-CoA to mevalonate.  This reaction is inhibited by 
statins (HMG-CoA reductase inhibitors) [206].   It has been demonstrated that statins target 
epigenetic mechanisms including histone deacetylation and epigenetic studies have shown 
simvastatin to be a direct inhibitor of HDAC-1 and HDAC-2.  Simvastatin caused HDAC 
downregulation via the RAS/PI3Kinase/mTOR pathway [261] and by direct competitive 
inhibition [262].  A competitive inhibition of HDAC-2 has been associated with an increased 
histone-H3 acetylation and the subsequent expression of P21 which is responsible for cell 
cycle arrest.  A statin induced cell cycle arrest with accumulation of P21 has been shown in 
lymphoma [263] and it has therefore been proposed that statins may act by this mechanism 
and inhibit epigenetically influenced diseases such as cancer [264]. 
The epigenetic consequences of HMG-CoA reductase inhibitors certainly warrant further 
investigation and the inhibition of histone deacetylases could prove to be a novel 





Neutrophils are key mediators in the SIR and in the resolution of inflammation.  It is 
appreciated that an uncontrolled inflammatory response should be avoided in an attempt to 
minimise damage to the host.  In the context of cancer surgery, an overwhelming SIR may 
suppress the anti-tumour immunity and promote tumour progression and dissemination.  It 
is also recognised that post-operative infective complications result in further compromise 
of the anti-tumour immune response to residual disease and are associated with a poor 
oncological outcome and increased mortality secondary to metastatic disease.   
The interaction between tumour immunity and systemic immunity is likely to be complex.  
The delivery of appropriate immune-modulatory therapies to modify the peri-operative 
inflammatory response could be utilised to preserve anti-tumour immune competency in 
the host.  It has been proposed that the pleiotropic effects of statins could be utilised in the 
peri-operative period in an attempt to modulate the SIR and prevent infective 
complications.  The use of statins in the context of cancer surgery may therefore influence 
oncological outcomes. 
In the context of cancer, neutrophils appear to have two distinct phenotypes, anti-tumour 
(N1) and pro-tumour (N2), suggesting that neutrophils differ in their contribution to the 
progression and dissemination of cancer and are capable of phenotypic plasticity.  This 
opens up the possibility of therapeutic intervention to enhance anti-tumour and suppress 
pro-tumour functional properties.  Modifications in neutrophil function and phenotype have 
been demonstrated with simvastatin treatment in-vitro and in-vivo, but not in the context 





1.9 Thesis Hypothesis 
1. It was hypothesised that the impact of surgery would replicate the neutrophil 
functional changes observed in patients with sepsis: 
i. Reduced NET formation 
ii. Reduced apoptosis 
iii. Increased phagocytosis  
2. It was hypothesised that HMG-CoA reductase inhibitors (statins) would restore 




















1.10 Thesis Objectives 
This study was conducted to: 
1. Characterise neutrophil function in the peri-operative period. 
i. NET Formation 
ii. Neutrophil Apoptosis 
iii. Neutrophil Phagocytosis 
2. Investigate whether NET Formation is associated with patient characteristics, 
operative characteristics, patient outcomes and existing validated prognostic scores. 
3. Evaluate the effect of HMG-CoA Reductase Inhibitors (statins) on neutrophil function 
in-vivo and in-vitro over the peri-operative period. 
4. Explore the role of Histone Deacetylase as a potential epigenetic marker of 















RETROSPECTIVE COHORT STUDY 
Is HMG-CoA Reductase Inhibitor Use Associated with Improved 














HMG-CoA Reductase Inhibitors 
HMG-CoA reductase inhibitors (statins) have been extensively studied and have proven 
efficacy in the primary and secondary prevention of cardiovascular morbidity and mortality 
in a variety of populations [212-217]. Their main mechanism of action is reduction of serum 
cholesterol by means of competitive inhibition of hepatic 3-hydroxy-3-methylglutaryl 
coenzyme A reductase, which is the rate limiting enzyme in the mevalonate synthesis 
pathway.  Consequently, statins reduce the intermediate products of cholesterol synthesis, 
namely mevalonate and the down-stream isoprenoid intermediaries, which play a vital role 
in several intracellular signalling pathways leading to a reduction in endogenous cholesterol 
biosynthesis and a reduction in low-density lipoprotein which is a major risk factor for 
cardiovascular disease [206,207, 218-221].    
HMG-CoA Reductase Inhibitors and The Pleiotropic Effect 
The cholesterol independent effects of HMG-CoA reductase inhibition are known as 
‘pleiotropic’ effects.  These pleiotropic effects (anti-inflammatory, immune-modulatory, 
anti-platelet, anti-thrombotic, protective against oxidative stress, anti-microbial [221-230]) 
are thought to counteract the detrimental effects of inflammation.  In fact, statins have 
been demonstrated to reduce the release of pro-inflammatory mediators (CRP, TNF-α, IL-6, 
IL-8) and evidence from randomised control trials has demonstrated improved outcomes in 
cardiovascular disease and bacterial pneumonia with statin induced CRP reduction [221-
230].  Interestingly a dose dependent anti-inflammatory response has been observed where 




Coronary Syndrome [265] and reduced periodontal and carotid inflammation in periodontal 
disease [266]. 
HMG-CoA Reductase Inhibitors and Cancer 
It has been suggested that statins may influence cancer risk by means of cancer 
chemoprevention.  Statins, in pre-clinical studies, have been demonstrated to exert anti-
neoplastic effects (pro-apoptotic, anti-angiogenic, immune-modulatory) which may prevent 
cancer growth [231, 232].  Observational studies and meta-analyses have demonstrated a 
reduced risk of prostate, hepatocellular, gastric and oesophageal cancer associated with 
statin use [233-236]. Statins have also been investigated in the context of a potential role in 
the modification of cancer outcomes and mortality and it has been demonstrated that 
patients who take statins prior to their cancer diagnosis are less likely to die from any cause 
or specifically from cancer [237]. 
The relationship between statins and colorectal cancer has been investigated, but the 
results are inconclusive both with regard to cancer risk, cancer outcomes and mortality.  
Epidemiology studies have examined the risk of colorectal cancer with conflicting results 
from very protective [238] to moderately harmful [239].  A recent meta-analysis of 40 
published studies concluded that statins did not strongly reduce the overall risk of colorectal 
cancer in the general population at the low doses used for managing hypercholesterolaemia 
and cardiovascular disease.  There was, however, evidence to suggest an overall risk 






HMG-CoA Reductase Inhibitors and Surgery 
Following major cardio-vascular surgery a reduction in post-operative cardiac complications 
and a reduction in post-operative infective complications has been documented in patients 
taking statins pre-operatively [241-245].  Interestingly a dose dependent modulation of 
inflammation has been observed in coronary artery surgery where high-dose statins almost 
completely prevented the SIR associated with surgery and virtually entirely suppressed 
surgery related changes in plasma concentrations of TNF-α and IL-6 [267]. 
In the context of general surgery, pre-operative statin use has been independently 
associated with a decreased risk of major, non-cardiac complications, respiratory 
complications, venous thrombo-embolic events and infective complications [246-248].  
Overall, the pre-operative use of statins appears to be associated with a reduction in major 
complications [246, 247].   
Specifically in the context of colorectal surgery, statin use is associated with a significantly 
lower incidence of SIRS and a lower incidence of surgical site infection [248].  There appears 
to be no difference however in overall mortality, total complications or median hospital 
length of stay between statin users and non-statin users undergoing major colorectal 
resection [246, 247].  Studies have demonstrated contradictory results regarding the 
association of peri-operative statin therapy and anastomotic leak and a beneficial effect of 
peri-operative statin therapy on the incidence of anastomotic leak cannot be ruled out [249, 
250].  Patients on peri-operative statins appear to have a greater baseline peri-operative risk 
compared to non-statin users, but they achieve equivalent outcomes overall suggesting that 
peri-operative statin therapy may indeed be of benefit and may reduce morbidity after 




It is well established that infectious complications in patients with cancer are associated 
with adverse oncological outcomes independent of the morbidity associated with the 
infectious insult [184-187] and that they are associated with an increased mortality as a 
consequence of metastatic disease [187-191].  It has been proposed that the use of statins 
in the peri-operative period may reduce surgical complications by modulating the post-

















It seems logical to think that statins could be advantageous in the setting of cancer surgery 
where they may reduce systemic inflammation and post-operative complications with a 
consequent improvement in oncological outcomes. 
It was therefore investigated whether statin use is associated with reduced post-operative 
complications and improved clinical outcomes in patients undergoing elective colorectal 
















Miss Charlotte Robert-Rhodes (Intercalating Medical Student at the University of 
Birmingham, UK) assisted in database validation and statistical analysis as part of a BMedSc 
Research Project.  The Research Project was designed by myself and offered to students to 
help develop skills in critical thinking and data analysis.  Statistical support was provided by 
Dr. Peter Nightingale (Statistician, University Hospitals NHS Foundation Trust, Birmingham, 
UK).  The results of this Chapter have been included in the BMed Sc Dissertation of Miss 
Charlotte Robert-Rhodes (Do HMG-CoA Reductase Inhibitors Influence Surgical Outcomes? 
BMedSc Dissertation, University of Birmingham, UK, 2015). 
2.3.2 Study Methodology 
A retrospective review of prospectively collected data was conducted for all elective 
colorectal cancer resections performed at a single institution (University Hospitals 
Birmingham NHS Foundation Trust, Birmingham, UK) within an established enhanced 
recovery programme, between June 2008 and July 2013.  
2.3.3 Data Acquisition 
Data was extracted from existing robust electronic patient databases (Prescribing 
Information and Communication System and Clinical Portal) by the Bio-informatics 
Department at University Hospital Birmingham to produce a working dataset.  All data was 
independently controlled for accuracy.  Data was manually extracted from the electronic 




dataset. Any data field from the sample that was less than 100% accurate was then 
manually extracted from the electronic databases for all patients in the working dataset. 
Patients were divided into non-statin and statin users.  Statin users were defined as patients 
who were prescribed statins at admission and who were prescribed statins within a five day 
post-operative period.  Statin dose was classified as low-dose, moderate-dose or high-dose 
and defined as; low-dose ≤ 20mg simvastatin, moderate-dose = 40mg simvastatin, high-dose 
> 40mg simvastatin (or equivalent doses of other statins).  All statins currently available for 
use in the UK were included (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, 
simvastatin). 
Data extracted from the electronic patient databases is outlined below.  
Table 2.1 Data Extracted from the Electronic Databases - Patient Demographics, 
Patient Co-morbidities, Tumour Characteristics and Operative 
Characteristics  
 




Patient Co-morbidities Chronic Kidney Disease 
Diabetes Mellitus  
Heart Failure 
Hypertension 
Ischaemic Heart Disease 
Lung Disease 












Table 2.2 Data Extracted from the Electronic Databases - Post-operative 
Complications, Re-operations, Post-operative Antibiotic Use, Length of Stay, 
Re-admissions and Mortality 
 
Post-operative Complications Abdominal Collection 





Lower Respiratory Tract Infection 
Re-operations Re-operation (any cause) 




Length of Stay (LOS) Critical Care LOS 
Total LOS 
Re-admissions 30-day readmission 









Table 2.3 Data Extracted from the Electronic Databases – Pre-operative and Post-




















The following definitions were applied to the extracted data. 
 Post-operative complications ≤ 30 days after surgery were recorded for all 
patients and were defined as follows: 
– Abdominal Collection was defined as a radiologically diagnosed collection 
of the abdominal cavity or pelvis that required intervention or prolonged 
hospital stay.   
– Acute Kidney Injury was defined as a percentage increase in serum 
creatinine ≥ 50% from baseline.  
– Anastomotic Dehiscence was defined as surgically confirmed dehiscence 
and/or radiologically diagnosed dehiscence (fluid collection in close 
proximity to an anastomosis that was drained yielding purulent fluid or 
gas and/or evidence of contrast leak).   
– Bacteraemia was defined as the presence of a positive microbiology 
culture from a central or peripheral blood sample.   
– Cardio-respiratory Events included a confirmed diagnosis of myocardial 
infarction, pulmonary embolism and/or cardiac dysrhythmia (which was 
not as a consequence of infection) that required appropriate treatment. 
– Intestinal Obstruction was defined as a confirmed radiological diagnosis 
of mechanical or functional intestinal obstruction which resulted in a 
prolonged hospital stay.  
– Lower Respiratory Tract Infection was defined as a confirmed diagnosis of 
pneumonia that required antibiotic therapy. 




 Re-admissions were defined as a return to hospital ≤ 30 days of the index procedure 
requiring a hospital stay ≥ 24 hours. 
 Critical Care LOS was defined by the number of days on critical care requiring level-2 
or level-3 care. 
  Total LOS was defined by the number of days in hospital including the day of 
surgery. 
 Post-operative Antibiotic Use was defined as a prescription for co-amoxiclav, 
piperacillin-tazobactam, meropenem or vancomycin ≤ 30 days after surgery and was 
used as a surrogate marker for post-operative infective complication. 
 Mortality was recorded and categorised into 30-day, 90-day, 12-month, 24-month 
and 60-month mortality.  
Pre-operative inflammatory markers included pre-operative values closest to the day of 
surgery and not including the day of surgery. 
Post-operative inflammatory markers included the minimum, maximum and mean values 
within a 7 day post-operative period. 
2.3.4 Statistical Analysis 
Statistical comparisons between non-statin and statin groups were calculated using Mann-
Whitney U test and χ2 test or Fisher Exact test for continuous and categorical data 
respectively. 
Univariate linear and logistic regression analyses were performed for continuous and 
categorical data respectively.  Multivariate analysis was then performed including all 




Survival was evaluated using Kaplan-Meier graphs.  Tarone-Ware p-values were used as a 
measure of significance.  Multivariate survival analysis was performed using Cox Regression 
analysis. 
Statistical analyses were performed by using SPSS version 17 (IBM SPSS Statistics, IBM 
Corporation, Armonk, NY). 


















A total of 703 patients undergoing elective colorectal cancer resection within an established 
enhanced recovery programme, between June 2008 and July 2013 were reviewed.  246 
(35.0% [246/703]) patients were statin users, defined as patients who were prescribed 
statins at admission and who were prescribed statins within a five day post-operative 
period.  The mean number of statin doses omitted during the index admission was 
1.36doses (95%CI=1.04-1.67doses). 
The majority of patients were on simvastatin (76.0% [186/246]) and the remainder were on 
atorvastatin (18.3% [45/246]), pravastatin (2.9% [7/246]), rosuvastatin (2.4% [6/246]) and 
fluvastatin (0.4% [1/246]).  The majority of patients were on moderate-dose statin (64.6% 
[159/246]) and the remainder were on low-dose (26.0% [64/246]) and high-dose (9.4% 
[23/246) statins high-dose statins. 











Table 2.4 Population Characteristics and Data Completeness 
Variable Total (n=703) Data Completeness (%) 
Age, median (IQR) 69 (60-76) 100 
Gender, n (%), M/F 410 / 293 (58.3 / 41.7) 100 
BMI, median (IQR), kg/m
2
 26.58 (23.7-30.4) 67 
Smoking Status, n (%), 1/2/3
a 
88 / 238 / 322 (12.5 / 33.9 / 45.8) 92 
Chronic Kidney Disease, n (%), y 27 (3.8) 100 
Diabetes Mellitus, n (%), y 111 (15.8) 100 
Heart Failure, n (%), y 14 (2.0) 100 
Hypertension, n (%), y 316 (45.0) 100 
Ischaemic Heart Disease, n (%) y 88 (12.5) 100 
Lung Disease, n (%), y 106 (15.1) 100 
Cancer Location, n (%), 1/2
b
  368 / 335 (52.3 / 47.6) 100 
T-Stage, n (%), 0/1/2/3/4 10 / 57 / 86 / 365 / 174 (1.4 / 8.1 / 12.2 / 51.9 / 24.8) 99 
N-Stage, n (%), 0/1/2 396 / 199 / 101 (56.3 / 28.3 / 14.4) 99 
M-Stage, n (%), 0/1 587 / 111 (83.5 / 15.8) 99 
Neo-adjuvant Therapy, n (%), y
 
140 (19.9) 100 
Operation Type, n (%), 1/2
c 
329 / 374 (46.8 / 53.2) 100 
Operation Technique, n (%), 1/2
d
  480 / 223 (68.3 / 31.7) 100 
 
y = yes,  1/2/3
a
 = active / former / never,  1/2
b
 = colon / recto-sigmoid junction and rectum,  1/2
c
 = segmental / 
rectal,  1/2
d
 = open and laparoscopic converted to open / laparoscopic 
 
The median age of the population was 69 years (IQR 60-76 years) with 58.3% of male 
gender.    Fifty three percent of patients underwent a resection involving the rectum and 
31.7% of procedures were completed entirely laparoscopically.  Data completeness was 
generally high for the different variables.   








Table 2.5 Population Outcomes and Data Completeness 
Outcomes Total (n=703) Data Completeness (%) 
Abdominal Collection, n (%), y 25 (3.6) 100 
Acute Kidney Injury, n (%), y 14 (2.0) 100 
Anastomotic Dehiscence, n (%), y 28 (4.0) 100 
Bacteraemia, n (%), y 7 (1.0) 100 
Cardio-respiratory Event, n (%), y 31 (4.4) 100 
Intestinal Obstruction, n (%), y 43 (6.1) 100 
Lower Respiratory Tract Infection, n (%), y 38 (5.4) 100 
Re-operation, n (%), y 19 (2.7) 100 
Stoma, n (%), y 186 (26.5) 100 
Post-operative Antibiotic Use, n(%), y
 
 424 (60.3) 100 
Critical Care Admission, n (%), y 
Critical Care LOS, median (range, IQR), days 
111 (15.8) 
0 (0-72, 0-0) 
100 
100 
Total LOS, median (range, IQR), days 9 (1-277, 6-15) 100 
Readmission, n (%), y
 
Mortality, n (%), 1/2/3/4/5
a 
63 (9.0) 




y = yes,  1/2/3/4/5
a
 = 30-day / 90-day / 12-month / 24-month / 60-month  
 
15.8% of patients required admission to Critical Care following surgery.  60.3% of patients 
received post-operative antibiotic therapy.  4.0% of patients had a confirmed anastomotic 
dehiscence.  Only 2.7% of patients required a re-operation.  The median length of stay was 9 
days (IQR 6-15 days) and 9.0% of patients were readmitted up to 30 days from the index 
procedure.  30-day, 90-day, 12-month, 24-month and 60-month mortality was 1.1%, 2.3%, 
7.7%, 11.7%, 20.6% respectively with a median follow-up of 51 months (Range 22-82 
months, IQR 35-66 months). Data completeness was 100% for all outcomes. 
 








Table 2.6 Population Characteristics According to Statin Use 
Variable Statin User (n=246) Non-statin User (n=457) P-value 
Age, median (IQR) 71 (65-78) 67 (58-76) <0.0001 
Gender, n (%), M/F 146 / 100 (59.3 / 40.7) 264 / 193 (57.8 /42.2) 0.6894 
BMI, median (IQR), kg/m
2
 27.5 (24.8-31.7) 26.0 (22.9-29.6) 0.0005 
Smoking Status, n (%), 1/2/3
a 
28 / 87 / 112 (11.4 / 35.4 / 45.5) 53 / 147 / 234 (11.6 / 32.2 / 51.2) 0.4882 
Chronic Kidney Disease, n (%), y 14 (5.7) 13 (2.8) 0.2000 
Diabetes Mellitus, n (%), y 76 (30.9) 35 (7.6) <0.0001 
Heart Failure, n (%), y 12 (4.8) 2 (0.4) <0.0001 
Hypertension, n (%), y 163 (66.3) 153 (33.5) <0.0001 
Ischaemic Heart Disease, n (%) y 71 (28.8) 17 (3.7) <0.0001 
Lung Disease, n (%), y 39 (15.9) 67 (14.7) 0.6734 
Cancer Location, n (%), 1/2
b
  148 / 98 (60.2 / 39.8) 220 / 237 (48.1 / 51.9) 0.0023 
T-Stage, n (%), 0/1/2/3/4 18  / 33  /136 / 56 (7.3 / 13.4 / 55.2 / 22.7) 37 / 54 / 229 / 117 (8.1 / 11.8 / 50.1 / 25.6) 0.6544 
N-Stage, n (%), 0/1/2 145 / 60 / 39 (58.9 / 24.4 / 15.9) 252 / 139 / 62 (55.1 / 30.4 / 13.6) 0.2185 
M-Stage, n (%), 0/1 210 / 35 (85.4 / 14.2) 377 / 76 (82.5 / 16.7) 0.4480 
Neo-adjuvant Therapy, n (%), y
 
38 (15.4) 102 (22.3) 0.0298 
Operation Type, n (%), 1/2
c 
142 / 104 (57.7 / 42.3) 224 / 233 (49.0 / 51.0) 0.0275 
Operation Technique, n (%), 1/2
d
  163 / 83 (66.3 / 33.7) 317 / 140 (69.4 / 30.6) 0.3988 
 
y = yes,  1/2/3
a
 = active / former / never,  1/2
b
 = colon / recto-sigmoid junction and rectum,  1/2
c
 = segmental / 
rectal,  1/2
d
 = open and laparoscopic converted to open / laparoscopic 
 
Statin users were significantly older (71 vs. 67, p<0.0001), had a higher BMI (27.5 vs. 26.0, 
p=0.0005), had a higher incidence of medical co-morbidities including diabetes mellitus, 
heart failure, hypertension and ischaemic heart disease (All p<0.0001).  Interestingly, statin 
users were significantly more likely to have a colonic cancer than a rectal cancer (60.2 vs. 
48.1, p=0.0023) and this reflects significantly fewer rectal resections, a reduced requirement 
for neo-adjuvant therapy and fewer stomas formed.   
 








Table 2.7 Population Outcomes According to Statin Use 
Outcomes Statin User (n=246) Non-statin User (n=457) P-value 
Abdominal Collection, n (%), y 7 (2.9) 18 (3.9) 0.3829 
Acute Kidney Injury, n (%), y 7 (2.9) 7 (1.5) 0.5274 
Anastomotic Dehiscence, n (%), y 13 (5.3) 15 (3.3) 0.7003 
Bacteraemia, n (%), y 3 (1.2) 4 (0.2) 0.3273 
Cardio-respiratory Event, n (%), y 11 (4.5) 20 (4.4) 1.0000 
Intestinal Obstruction, n (%), y 18 (7.3) 25 (5.4) 0.2631 
Lower Respiratory Tract Infection, n (%), y 16 (6.5) 22 (4.8) 0.2258 
Re-operation, n (%), y 7 (2.9) 12 (2.6) 0.8640 
Stoma, n (%), y 52 (21.1) 134 (29.3) 0.0199 
Post-operative Antibiotic Use, n(%), y
 
 156 (63.4) 268 (58.6) 0.2175 
Critical Care Admission, n (%), y 51 (20.7) 60 (13.1) 0.0094 
Critical Care LOS, median (range, IQR), days 0 (0-72, 0-0) 0 (0-35, 0-0) 0.0049 
Total LOS, median (range, IQR), days 10 (1-277, 7-17) 9 (1-246, 6-13) 0.0142 
Readmission, n (%), y
 





























y = yes 
 
No statistical differences were identified in post-operative complications, post-operative 
antibiotic use, re-operations and re-admissions. Without appropriate statistical adjustment 
statin users appeared to have an increased rate of Critical Care admission, Critical Care 
length of stay and total length of stay.  It also appeared that statin users had a greater 
mortality at 12-months, 24-months and 60-months.   
The pre-operative and post-operative inflammatory markers according to statin use are 







Table 2.8 Pre-operative and Post-operative Inflammatory Markers According to Statin 
Use 
Inflammatory Markers Statin User (n=246) Non-statin User (n=457) P-value 
Pre-operative 















Absolute White Cell Count [x10
9
/L]       
Min, median (IQR) 
Max, median (IQR) 




Min, median (IQR) 
Max, median (IQR) 




Min, median (IQR) 
Max, median (IQR) 




Min, median (IQR) 
Max, median (IQR) 
Mean, median (IQR) 
C-reactive Protein [mg/L] 
Min, median (IQR) 
Max, median (IQR) 






















































































Post-operative results are presented as minimum, maximum and mean values which accounts for different 
post-operative recovery time periods of the study participants (presented as median [IQR]. 
 
There were no statistically significant differences in pre-operative inflammatory markers 
between statin and non-statin users.  In particular there was no difference in pre-operative 
NLR.   
Post-operatively, statin users had a higher maximum absolute white cell count (13.1 vs. 
12.4, p=0.0418) but a lower minimal platelet count (198.0 vs. 208.5, p=0.0217) and minimal 
CRP level (32.0 vs. 42.0, p=0.0188). 
Univariate analysis was performed to identify differences between the outcomes of statin 




Table 2.9 Statin Use - Univariate Logistic Regression Analysis and Univariate Linear 
Regression Analysis (indicating ‘Odds Ratio’ and ‘Change in Risk’ for statin 
use respectively) 
Outcomes Odds Ratio 95% Confidence Interval P-value 





0.29 - 1.73 
 
0.4570 
Acute Kidney Injury 1.88 0.65 - 5.43 0.2420 
Anastomotic Dehiscence ** 1.64 0.77 - 3.51 0.1990 
Bacteraemia 1.40 0.31 - 6.30 0.6630 
Cardio-respiratory Event 1.02 0.48 - 2.17 0.9530 
Intestinal Obstruction ** 1.36 0.73 - 2.55 0.3310 
Lower Respiratory Tract Infection ** 1.38 0.71 - 2.67 0.3460 
Re-operation 1.09 0.59 - 1.98 0.7910 
Stoma ** 0.65 0.45 - 0.93 0.0190 
Post-operative Antibiotic Use ** 1.17 0.84 - 1.64 0.3470 
Critical Care Admission ** 1.91 1.23 - 2.97 0.0040 
Readmission 1.25 0.73 - 2.12 0.4140 
Outcomes Change in Risk (%) 95% Confidence Interval P-value 
Univariate Linear Regression 




0.67 - 7.31 
 
0.1020 
Total LOS ** 14 0.012 - 0.10 0.0130 
 
Univariate analysis demonstrated significant increases in the rate of admission to Critical 
Care (OR=1.91, 95%CI=1.23-2.97, p=0.0040) and in the total length of stay (14% increase in 
LOS, 95%CI=0.012-0.10, p=0.0130) in statin users.  Statin users were significantly less likely 
to require a stoma after elective colorectal cancer resection (OR 0.65, 95%CI 0.45-0.93, 
p=0.0190). 
Multivariate analysis was performed to identify differences between the outcomes of statin 
users and non-statin when appropriately adjusted for age and gender.  Outcome measures 
from univariate analyses which are marked with ** underwent further multivariate analysis.  
The criteria for inclusion into multivariate analysis was p<0.4000, event incidence ≥28 and 







Table 2.10 Statin Use - Multivariate Logistic Regression Analysis and Multivariate 
Linear Regression Analysis (indicating ‘Odds Ratio’ and ‘Change in Risk’ for 
statin use respectively) 
Outcomes Odds Ratio 95% Confidence Interval P-value 
Multivariate Logistic Regression    
Anastomotic Dehiscence 1.40 0.65 - 3.05 0.3940 
Intestinal Obstruction 1.50 0.78 - 2.89 0.2210 
Lower Respiratory Tract Infection 1.24 0.63 - 2.43 0.5360 
Stoma 0.65 0.45 - 0.95 0.0280 
Post-operative Antibiotic Use 1.36 0.96 - 1.92 0.0870 
Critical Care Admission 1.83 1.16 - 2.87 0.0090 
Outcomes Change in Risk (%) 95% Confidence Interval P-value 
Multivariate Linear Regression 




-0.01 - 0.28 
 
0.0650 
Total LOS  12 0.002 - 0.10 0.0420 
 
After adjustment for age and gender differences, multivariate analysis demonstrated 
significant increases in rate of admission to Critical Care (OR=1.83, 95%CI=1.16-2.87, 
p=0.0090) and in the total length of stay (12% increase in LOS, 95%CI=0.002-0.10, p=0.0420) 
in statin users.  Statin users were significantly less likely to require a stoma after elective 
colorectal cancer resection (OR 0.65, 95%CI 0.45-0.95, p=0.0280) than non-statin users.  
Survival analysis was conducted to identify any differences in overall mortality in statin users 
and non-statin users. Firstly, univariate survival analysis was conducted using Kaplan-Meier 
graphs and Tarone-Ware p-values were used as a measure of significance.  Multivariate 
survival analysis was then performed using Cox Regression analysis which adjusted for age 
and gender.  The Kaplan-Meier survival analysis is displayed in graphical form in Figure 2.1 











P = 0.045 




Univariate survival analysis using Kaplan-Meier graphs and a Tarone-ware p-value indicates a statistically 
significant difference in survival with improved survival in Non-statin Users when compared with Statin Users 
(p=0.045)   
 
 
Table 2.11 Statin Use – Cox Regression Survival Analysis  
Outcomes Hazard Ratio 95% Confidence Interval P-value 
Mortality 1.21 0.90 – 1.62 0.2120 
 
Multivariate Cox Regression survival analysis revealed no significant difference in survival when comparing 








Univariate survival analysis revealed an increased mortality rate associated with statin use 
(Tarone-Ware p-value = 0.045).  When adjusted for age and gender, multivariate Cox 
Regression analysis revealed no significant difference associated with statin use (HR=1.21, 
95%CI=0.90-1.62, p=0.2120). 
Univariate and multivariate analyses were conducted to determine whether a dose 
dependent effect on clinical outcomes between statin users and non-statin users existed. 
Statin dose was classified as low-dose, moderate-dose or high-dose and defined as; low-
dose ≤ 20mg simvastatin, moderate-dose = 40mg simvastatin, high-dose > 40mg simvastatin 
(or equivalent doses of other statins). 
The number of statin users on low-dose, moderate-dose and high-dose statins were 64 
(26.0%), 159 (64.6%) and 23 (9.4%) respectively.  There were no statistical differences in 
patient characteristics according to statin dose. 
Univariate analysis was performed to identify any dose dependent differences in patient 
outcomes according to statin dose (low-dose, moderate-dose and high-dose) and is 












Table 2.12 Dose Response - Univariate Logistic Regression Analysis and Univariate 
Linear Regression Analysis (indicating ‘Odds Ratio’ and ‘Change in Risk’ for 
increasing dose of statin respectively) 
Outcomes Odds Ratio 95% Confidence Interval P-value 
Univariate Logistic Regression 




0.99 - 1.12 
 
0.0810 
Acute Kidney Injury ** 1.01 0.88 – 1.16 0.0937 
Anastomotic Dehiscence  0.98 0.90 – 1.06 0.5500 
Bacteraemia 0.91 0.81 - 1.02 0.1150 
Cardio-respiratory Event 0.98 0.91 – 1.06 0.6210 
Intestinal Obstruction  0.62 0.91 - 1.06 0.6210 
Lower Respiratory Tract Infection  0.99 0.97 – 1.05 0.7600 
Re-operation ** 0.95 0.89 - 1.00 0.0580 
Stoma  0.99 0.97 – 1.02 0.4590 
Post-operative Antibiotic Use 1.00 0.97 – 1.02 0.7120 
Critical Care Admission  1.00 0.96 – 1.04 0.8960 
Readmission 1.01 0.97 – 1.04 0.7500 
Outcomes Change in Risk (%) 95% Confidence Interval P-value 
Univariate Linear Regression 




-0.69 - 0.85 
 
0.8360 
Total LOS ** 4 1.00 – 1.22 <0.0001 
 
Univariate analysis demonstrated a significant increase in the total length of stay (4% 
increase in LOS, 95%CI=1.00-1.22, p.0.0001) with increasing dose of statin.   
Multivariate analysis was performed to identify any dose dependent differences in patient 
outcomes according to statin dose (low-dose, moderate-dose and high-dose) when 
appropriately adjusted for age and gender.  Outcome measures from univariate analyses 
which are marked with ** underwent further multivariate analysis.  The criteria for inclusion 
into multivariate analysis was p<0.4000 and data completeness of 100%.  The outcome, 
‘bacteraemia’ was not included in the multivariate analysis as only three events occurred in 








Table 2.13 Dose Response – Multivariate Logistic Regression Analysis and Multivariate 
Linear Regression Analysis (indicating ‘Odds Ratio’ and ‘Change in Risk’ for 
increasing dose of statin respectively) 
Outcomes Odds Ratio 95% Confidence Interval P-value 
Multivariate Logistic Regression    
Abdominal Collection 0.97 0.94 - 1.06 0.0960 




0.90 – 1.03 
0.90 – 1.06 
0.2500 
0.5500 
Outcomes Change in Risk (%) 95% Confidence Interval P-value 
Multivariate Linear Regression    
Total LOS  269 -0.004-0.001 0.2700 
 
After adjustment for age and gender multivariate analysis demonstrated no significant 
differences in rates of abdominal collection, acute kidney injury, re-operation or total length 
of hospital stay with increasing dose of statin. 
Survival analysis was conducted to identify any dose dependent difference in overall 
mortality in statin users.  Firstly, univariate survival analysis was conducted using Kaplan-
Meier graphs and Tarone-Ware p-values were used as a measure of significance.  
Multivariate survival analysis was then performed using Cox Regression analysis which 
adjusted for age and gender.  The Kaplan-Meier survival analysis is displayed in graphical 
















P = 0.049 




Univariate survival analysis using Kaplan-Meier graphs and a Tarone-ware p-value indicates a statistically 
significant difference in survival with improved survival in patients receiving High-dose statin (p=0.049)   
 
 
Table 2.14 Dose Response – Cox Regression Survival Analysis 
Outcomes Hazard Ratio 95% Confidence Interval P-value 
Mortality 0.67 0.41 – 1.09 0.1100 
 
Multivariate Cox Regression survival analysis revealed no significant difference in survival when comparing 
High-dose, Moderate-dose and Low-dose statin use (indicating ‘Hazard Ratio’ for High-dose statin use) 
 
Survival Function 




Univariate survival analysis revealed a reduction in mortality associated with high-dose 
statin (Tarone-Ware p-value = 0.049).  When adjusted for age and gender, multivariate Cox 
Regression analysis revealed no significant dose dependent difference in mortality 


















35.0% of patients undergoing elective colorectal cancer resection were on statins.  The 
published literature documents the incidence of statin use in a general surgical population 
ranges from 10.5–32.0% [246,249,250].  The largest colorectal cancer patient cohort, form 
Denmark, revealed 18.8% (518/2755) of patients received statins in the peri-operative 
period [246].  This discrepancy may reflect differences in prescribing policy between 
different nations and/or true differences in levels of health in the patient populations as 
statins are principally used for primary and secondary prevention of cardiovascular 
morbidity and mortality in a variety of populations [212-217]. 
The mean percentage of statin doses omitted during the index admission was 8.5%, which 
equates to one missed dose per statin user, indicating that patients resumed statin therapy 
as they resumed enteral nutrition and their regular medications  (median LOS in statin users 
= 10 days [IQR 7-17 days]). 
In terms of population characteristics, statin users were significantly different from non-
statin users.  Those patients on statins were significantly older, had a higher BMI and were a 
more co-morbid population (diabetes mellitus, heart failure, hypertension and ischaemic 
heart disease).  Despite these differences, statin users had equivalent outcomes in 
frequency of post-operative complications (abdominal collection, acute kidney injury, 
anastomotic dehiscence, bacteraemia, cardio-respiratory event, lower respiratory tract 
infection), post-operative antibiotic use (used as a surrogate to indicate post-operative 
infective complication), re-operations and re-admissions and there was no statistically 
significant difference in mortality after appropriate age and gender adjustments with a 




It is known that patients with pre-existing co-morbidities are at an increased peri-operative 
risk of developing complications as the surgical insult increases the demand on organs with 
already compromised function [268].  It has also been demonstrated that elevated BMI, in 
conjunction with advanced age, is predictive of morbidity and mortality following general 
surgery [269].  Despite a greater base-line peri-operative risk, evidenced by an older more 
co-morbid population, statin users had analagous outcomes and complication profiles to 
non-statin users.   
Univariate analysis, however, demonstrated significant increases in the rate of admission to 
Critical Care and in the total length of stay in statin users compared to non-statin-users and 
these findings remained statistically significant, after adjustment for age and gender 
differences, in multivariate analysis.  Statin users were 1.83 times more likely to need 
Critical Care support (OR =1.83, 95%CI=1.16-2.87, p=0.0090) and had a hospital length of 
stay 12% longer than non-statin users (p=0.042).  This is not only a reflection of an increased 
co-morbidity but a sign of a prolonged functional recovery and it may also represent an 
additional patient need for assistance with physiotherapy, occupational therapy and stoma 
therapy in this specific patient group.   
There were no differences in pre-operative markers of inflammation between statin and 
non-statin users.  Post-operatively differences were identified.  Statin users had a higher 
maximum absolute white cell count than non-statin users, but conversely lower minimum 
platelet and CRP levels.  It is known that IL-6 is the primary mediator of inflammation 
following surgery and is responsible for the production of CRP.  IL-6 has been demonstrated 
to predict post-operative complications [270] and it has been shown that IL-6 is suppressed 
by statin therapy [271,272].  This would therefore explain the significant reduction in post-




This is the first study to attempt to determine if a dose dependent effect of statin therapy 
on patient outcomes following elective colorectal cancer resection exists.  There were no 
observed differences in post-operative complications, post-operative antibiotic use, re-
operations, admission to Critical Care, Critical Care length of stay, total length of stay and re-
admissions with increasing dose of statin.  Univariate analysis demonstrated a significant 
increase in the total length of stay with increasing dose of statin but this finding did not 
remain statistically significant after adjustment for age and gender in multivariate analysis. 
Regarding survival, univariate survival analysis revealed a reduction in mortality associated 
with high-dose statin (p=0.049), but when adjusted for age and gender, multivariate Cox 
Regression analysis revealed no significant dose dependent difference in mortality although  
it is suggestive of an overall risk reduction with increasing dose of statin (HR=0.67, 
95%CI=0.41-1.09, p=0.1100). 
There were no observed differences in operative technique or tumour stage between statin 
and non-statin users.  Interestingly, statin users were significantly more likely to have a 
colonic cancer (60.2% vs. 48.0%, p=0.0023) than a rectal cancer (39.8% vs. 51.9%, p=0.0023) 
and consequently significantly fewer rectal resections, a reduced requirement for neo-
adjuvant therapy and fewer stomas formed.  In multivariate analysis statin users were 
significantly less likely to require a stoma after elective colorectal cancer resection than non-
statin users (OR=0.65, 95%CI=0.45-0.95, p=0.0280).  It is known that of the 10,000 or so 
patients undergoing surgery for rectal cancer each year in the UK (Anterior Resection, 
Abdominoperineal Resection, Hartmann’s Resection) over 80% undergo stoma formation of 




an Anterior Resection [13] and so this finding, in the context of fewer rectal cancer 
incidences, is not surprising. 
The finding of relatively fewer rectal cancers compared to colon cancers has been reported 
in the published literature in cohorts from the USA and the Netherlands which describe a 
risk reduction for rectal cancer of 30-40% [273-275] in statin users.  This finding has not 
been described in a patient cohort from the United Kingdom to date.  It has been proposed 
that statins may affect cancer genotype [276] and they have been associated with a reduced 
incidence of KRAS-wild-type mutations which have a tendency to affect the rectum [277], 
perhaps by their role in prenylation of KRAS [278].  Statins have also been found to inhibit 
the production of cyclogenoxygenase-2 [279] which is also commonly found to be 
overexpressed in rectal cancer [280].  These molecular differences may, in part, explain the 
observed increased incidence of colonic versus rectal cancers in statin users. 
This retrospective analysis has several limitations.  As with any retrospective analysis, the 
study is limited by the patient groups not being matched at baseline and consequently this 
can introduce confounding with the potential for unmeasured factors influencing the 
observed results.  Examples include the use of aspirin and metformin which, conceivably, 
would have been used more frequently in statin users and have been associated with 
reduced cancer related mortality [281-284].  Although peri-operative care was provided 
within the setting of an established enhanced recovery programme, which utilises a 
standardised surgical protocol, confounders in patient management cannot be excluded. 
The definition of statin user was dependent upon the prescription of statins at admission 
and who were prescribed statins within a five day post-operative period.  There was an 
assumption that patients prescribed statins at admission were taking statins regularly pre-




pleiotropy.  Post-operatively only 8.5% of post-operative statin doses were omitted which 
equated to one dose per statin user (median=1, IQR 0-2 doses). 
 
The strengths of this study include prospective data collection, high data completeness 
(associated with the use of robust electronic patient databases [Prescribing Information and 
Communication System and Clinical Portal)] and vigorous data validated) and the use of 























This study has explored the impact of peri-operative statin therapy on post-operative 
outcomes after elective colorectal cancer resection.  Despite statin users having a higher 
peri-operative risk (significant increases in age, BMI and co-morbidity), they had equivalent 
outcomes in frequency of post-operative complications, post-operative antibiotic use, re-
operations, re-admissions and there was no statistically significant difference in mortality 
after appropriate age and gender adjustments.  Statin users were more likely to need 
Critical Care support and had an increased hospital length of stay than non-statin users.  
This may reflect a higher peri-operative risk but also an additional patient need for 
assistance with physiotherapy, occupational therapy and stoma therapy in this specific 
patient group.  No statistically significant dose related differences were identified in patient 
outcomes although an overall risk reduction in mortality with increasing dose of statin 
remains possible.  Statin users achieved equivalent short-term and long-term outcomes to 
non-statin users despite an increased operative risk and their use in the peri-operative 
period, particularly at high doses, merits further investigation. 

























3.1 Study Methodology 
3.1.1 Study Design 
A favourable ethical opinion was awarded by the NRES Committee, West Midlands on 30th 
December 2013 (13/WM/0485). 
A prospective, observational, cohort evaluation of consecutive consenting patients 
undergoing elective colorectal resection for cancer, within an established enhanced 
recovery programme, at the Heart of England NHS Foundation Trust, UK was conducted. 
The cohorts evaluated were patients receiving peri-operative statin (statin users) and 
patients not receiving peri-operative statin (non-statin users).  Statin users were defined as, 
‘patients were prescribed and had taken a statin ≤ 5 days before the index procedure and 
who were prescribed and received a statin ≤ 5 days after the index procedure’.  All statins 
currently available for use in the UK were included (atorvastatin, fluvastatin, lovastatin, 
pravastatin, rosuvastatin and simvastatin). 
Potential recruits were identified at the Colorectal Cancer Multi-disciplinary Team Meeting 
and patients were asked if they would consider taking part in research by members of the 
direct healthcare team and subsequently by a member of the study team.  At all times 
patients were allowed as much time as they needed to read the Patient Information Sheet 
(Appendix 1) and were able to ask questions about the research study. 
All patients over the age of 18 who were undergoing elective colorectal resection for cancer 
and were able to give written informed consent were eligible to be included in the study.  
Patients were excluded from the study if they were an acute presentation, pregnant or 




bowel disease (Ulcerative Colitis, Crohn’s Disease), synchronous or metachronous 
malignancy or patents receiving any known immune-modulatory therapies (suppression 
immune-modulatory therapies; corticosteroids, monoclonal antibodies and activation 
immune-modulatory therapies; granulocyte-colony stimulating factor [G-CSF]) were also 
excluded from the study. 
Written informed consent was obtained from patients prior to enrolment into the study.  A 
suitably trained person, who had attended a UK regulations Good Clinical Practice training 
course, obtained written informed consent from each patient prior to participation in the 
study.  This followed adequate explanation of the aims, methods, anticipated benefits and 
potential hazards of the study.  This was recorded on a Patient Consent Form (Appendix 2). 
The patient outcomes evaluated were: 
1. Post-operative complications up to 30 days after surgery using pre-defined criteria 
and graded by the Clavien-Dindo classification system (Appendix 3). 
2. Return to theatre within 28 days of the index procedure. 
3. Admission to and length of stay on the Intensive Care Unit. 
4. Total hospital length of stay. 
5. Readmissions to hospital within 30 days of the index procedure requiring a hospital 
stay ≥ 24 hours. 
6. 30 day and 90 day mortality. 
Functional recovery and quality of life was assessed using the Surgical Recovery Scale.  This 
is a validated, comprehensive multidimensional recovery questionnaire and was 




Pre-operative and post-operative haematological and biochemical parameters were 
collected prospectively from the hospital pathology system.  These parameters, in 
conjunction with physiological indices, were used to determine a predicted mortality (CR-
POSSUM [Appendix 5]) and a prognostic score (mGPS [Table 1.6]) for each patient. 
Patient demographics, patient co-morbidities, pre-operative risk prediction, tumour 
characteristics and operative characteristics were collected by direct patient questioning 
















Table 3.1 Patient Demographics, Patient Co-morbidities, Pre-operative Risk 
Prediction, Tumour Characteristics and Operative Characteristics recorded 
from study participants 









Chronic Kidney Disease 
Diabetes Mellitus 
Pre-operative Risk Prediction 
Colorectal-POSSUM Score 






Extra-mural Venous Invasion 
Resectional Completeness 
Total Mesorectal Excision Grade Neo-
adjuvant Therapy 




Intra-operative Blood Loss 
Operation Time 
Post-operative Level of Care 
 
Patients underwent peripheral blood tests pre-operatively (Day-0) and post-operatively 
(Day-1 and Day-3) to assess neutrophil function at these specific time points.  Blood tests 
were performed by an experienced medical practitioner by peripheral venepuncture or from 
a peripheral arterial cannula.  A total of 24mls of blood was taken from each patient at each 
time point and deposited into 4x6ml lithium-heparin vacutainers (Becton-Dickinson, Oxford, 




3.1.2 Data and Sample Management 
Data was collected on Case Report Forms until the study participants were discharged from 
hospital.  Data was anonymised and reviewed for completeness before entering onto a 
computer database which was stored securely against unauthorised access and accidental 
loss.  All essential documents and study records were archived in conformance with the 
applicable regulatory requirements. 
Samples were stored in a coded format in alarmed freezers at -80⁰C located within the 
University of Birmingham Research Laboratories in accordance with the Human Tissue Act. 
3.1.3 Study Regulations and Administration 
The study complied with the principles of Good Clinical Practice, the requirements and 
standards set out by the EU Directive 2001/20/EC and the applicable regulatory 
requirements in the UK. 
The study was conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki and was approved by the NRES Committee, West Midlands on 
30th December 2013 (13/WM/0485). 








3.2 Neutrophil Isolation 
Processing began within 45 minutes of obtaining the blood sample.  Blood collected in 
lithium-heparin vacutainers (Becton-Dickinson) was transferred into a 50ml sterile Falcon-
TM tube (Becton-Dickinson).  4mls of 2% Dextran (Sigma-Aldrich, Dorset, UK) was added to 
24mls of blood (1ml per 6mls of blood) and gently mixed by inversion.  The solution was 
incubated at room temperature for 30 minutes to sediment the erythrocytes. 
The leucocyte-rich plasma was carefully layered on a Percoll (Sigma-Aldrich) density 
gradient consisting of 2.5mls of 80% Percoll and 5mls of 56% Percoll in a 15ml sterile Falcon-
TM tube.  Isolating neutrophils with Percoll has been demonstrated to induce minimal 
neutrophil activation [285] and was therefore utilised in the experiments conducted in this 
thesis.  This was then centrifuged at 220G for 20 minutes at room temperature without 
acceleration or brake.  The neutrophils were then isolated from the 80% and 56% gradient 
interface.   
The neutrophils were suspended and subsequently washed in Phosphate Buffered Saline 
(PBS; Gibco Invitrogen, Paisley, UK) at 440G for 10minutes at room temperature.  The 
resultant supernatant was removed and the neutrophils re-suspended in RPMI-1640 (Sigma-
Aldrich) at a concentration of 1x106/ml. 
The purity and the viability of the neutrophil yield were checked using Giemsa stain (Diff-
Quick, Gentaur Europe, Brussels, Belgium) and Tryptan-Blue exclusion respectively.  A purity 






3.3 Neutrophil Function Assays 
3.3.1 Quantification of Neutrophil Extracellular Trap Formation 
To ensure sterility the neutrophils were re-suspended in RPMI-1640 with 2nM L-Glutamine, 
100U/ml Streptomycin and 100ug/ml Penicillin (all from Sigma-Aldrich) at a concentration of 
1x106/ml.   
6x106 neutrophils were divided equally into two 15ml sterile Falcon-TM tubes (Becton-
Dickinson). 333µl of RPMI-1640 with GPS was added to one 15ml sterile Falcon-TM tubes 
containing 3x106 neutrophils (un-primed [1:10 dilution]) and 333µl of TNF-α (Sigma-Aldrich) 
was added to the other 15ml sterile Falcon-TM tubes containing 3x106 neutrophils (primed 
[1:10 dilution]).   These were gently mixed by inversion, incubated for 15 minutes at 37°C 
with 5% CO2 and centrifuged at 400G for 10 minutes at room temperature.  The resultant 
supernatant was removed and the neutrophils re-suspended in RPMI-1640 with GPS at a 
concentration of 1x106/ml. 
1x105 un-primed neutrophils, at a concentration of 1x106/ml, were sited in 20 wells of a 96-
well flat bottomed plate (Becton-Dickinson).  An additional 75μl of RPMI-1640 with GPS was 
added to each well.  25μl of RPMI-1640 with GPS and 25μl Phorbol-12-myristate-13-acetate 
(PMA) (1mg/ml [1:800 then 1:10 dilution]) were each added to four wells as negative and 
positive controls respectively.  Additionally, 25μl of the following stimulants (all from Sigma-
Aldrich) were each added to four wells: interleukin-8 (IL-8) (6.25μM [1:625 dilution]), 
Lipopolysaccharide (LPS) (1mg/ml [1:1250 dilution]) and N-formylmethionyl-leucyl-
phenylalanine (fMLP) (10mM [1:500 dilution]). The entire process was then repeated using 




The wells of the 96-well flat bottomed plate were arranged as outlined in Figure 3.1 prior to 
incubation for 3 hours at 37°C with 5% CO2. 
 
Figure 3.1 Arrangement of 96-well flat bottomed plate prior to incubation for 
Quantification of Neutrophil Extracellular Trap Formation Assay 
Unstim = Unstimulated (RPMI-1640 with GPS), PMA = Phorbol-12-myristate-13-acetate,  IL-8 = Interleukin-8,  
LPS = Lipopolysaccharide,  fMLP = N-formylmethionyl-leucyl-phenylalanine 
 
After the 3 hour incubation period, each well was then treated with 200units of Micrococcal 
Nuclease (MNase; Sigma-Aldrich) and 1μM of SYTOX-Green (Gibco Invitrogen) and 
incubated for 10 minutes at room temperature in the dark.  This process stained and 
digested the extra-cellular DNA. 
The contents of each of the wells were then transferred into individual 500μl eppendorfs 
and pelleted at 5000rpm for 10 minutes.  160μl of the DNA containing supernatant was 
transferred into a black 96-well flat bottomed plate (CoStar, Sigma-Aldrich) and 
fluorescence measured in a BioTek-Synergy-2 fluorometric plate reader (NorthStar Scientific 
 Un-primed Cells Primed Cells 
A Unstim Unstim Unstim Unstim Unstim Unstim Unstim Unstim 
B PMA PMA PMA PMA PMA PMA PMA PMA 
C IL-8 IL-8 IL-8 IL-8 IL-8 IL-8 IL-8 IL-8 
D LPS LPS LPS LPS LPS LPS LPS LPS 




Ltd, Leeds, UK) with a filter setting of 485nm excitation and 530nm emission.  NETs were 
recorded in arbitrary fluorescent units (AFU) and the mean was calculated from the 4 wells 
for each stimulant. 
To account for the variation in number of circulating neutrophils between individuals the 
Absolute NET Production Potential (ANPP) was determined.  This unique measure was 
calculated as follows: 
ANPP (AFU / no. of neutrophils x105 / L) = NETs per 100,000 neutrophils (AFU) x Absolute 
Neutrophil Count (x109 / L)  10,000 
3.3.2 Neutrophil Apoptosis 
Neutrophil apoptosis was assessed using a commercially available assay and was carried out 
as per the manufacturer’s instructions. 
2x106 neutrophils suspended in RPMI-1640 (Sigma-Aldrich), at a concentration of 1x106/ml 
were divided equally into two cytometric tubes.  One cytometric tube containing 1x106 
neutrophils was incubated for 4 hours at 37°C with 5% CO2 and the other was incubated in 
the same conditions for 24 hours. 
Following incubation the neutrophils were pelleted at 500G for 5 minutes at room 
temperature.  The pellet was washed twice with PBS (Gibco Invitrogen) at 500G for 
5minutes at room temperature and then re-suspended in Annexin Buffer (BD Biosciences) at 
a concentration of 1x106/ml. 
1x105 neutrophils were transferred into four cytometric tubes.   5µl PE-Annexin-V, 5µl 7-AAD 
and 5µl PE-Annexin-V and 5µl of 7-AAD (both from BD Biosciences) were added to three of 




neutrophils were gently vortexed and incubated for 15 minutes at 25°C in the dark.  Then 
400µl of Annexin Buffer was added to each cytometric tube prior to immediate flow 
cytometric analysis using the Accuri-C6 (BD Accuri™) flow cytometer.  
Apoptosis is characterised by specific morphological features which include loss of plasma 
membrane, condensation of cytoplasm and nucleus, and inter-nucleosomal cleavage of 
DNA. Loss of plasma membrane is evident in early apoptosis.  Phosphatidylserine, a 
membrane phospholipid, is translocated from the inner to the outer plasma membrane 
and is exposed to the external cellular environment.  Annexin-V is a calcium dependent 
phospholipid-binding protein that has a high affinity for phosphatidylserine and binds to 
cells that expose it.  Annexin-V is conjugated to the fluorochrome phycoerythrin (PE) and 
is a sensitive probe for flow cytometric analysis of cells that are undergoing apoptosis, 
even at an early stage.  PE Annexin-V staining precedes loss of membrane integrity and 
cell death and therefore the vital dye, 7-Amino-Actinomycin (7-AAD), is used in 
combination with PE Annexin-V.  Cells are permeable to 7-AAD when membrane integrity 
is lost.  Viable cells with intact membranes exclude 7-AAD and dead or damaged cells are 
permeable to 7-AAD and can be detected by flow cytometric analysis.  Therefore, 
neutrophils that stain negative for PE Annexin-V and 7-AAD are alive and not undergoing 
measurable apoptosis.  Neutrophils that stain positive for PE Annexin-V and negative for 
7-AAD are undergoing early apoptosis.  Neutrophils that stain positive for both PE 
Annexin-V and 7-AAD are undergoing late apoptosis.  Neutrophils that stain negative for 
PE Annexin-V and positive for 7-AAD are considered necrotic. 
When conducting flow cytometry analysis cell debris was eliminated using appropriate side 




is represented as the percentage of neutrophils in the different stages of apoptosis (alive, 
early apoptosis, late apoptosis and necrosis). 
The entire process was then repeated for the remaining neutrophils after 24 hours 
incubation at 37°C with 5% CO2.  
An example of a flow cytometry plot is demonstrated in Figure 3.2 revealing cells in 
different stages of apoptosis in different quadrants of the plot (LL = alive, LR = early 









Figure 3.2 Flow Cytometry Plot for Neutrophil Apoptosis  
Flow cytometry plot using Study Participant S37 on Day-0 at 4-hours [A] and 24-hours [B].  FL2-A (PE Annexin-







3.3.3 Neutrophil Phagocytosis 
Neutrophil phagocytosis was assessed using a commercially available assay and was carried 
out as per the manufacturer’s instructions.   
The assay uses Eschrichia coli (E.Coli) and Staphylococcus aureus (S.Aureus) bio-particles 
conjugated to pHrodo (Gibco Invitrogen), a fluorescent dye that only fluoresces in the acidic 
environment of the phagolysosome. 
2ml Hanks Balanced Salt Solution (HBSS) with 20mM HEPES (Sigma-Aldrich), was added to 
E.Coli and S.Aureus bio-particles conjugated to pHrodo and sonicated for 10 minutes. 
1x105 neutrophils suspended in RPMI-1640 (Sigma-Aldrich) at a concentration of 1x106/ml, 
were added to 2 eppendorfs on ice.  50μl of pHrodo E.Coli was added to one eppendorf and 
and 50μl of pHrodo S.Aureus was added to the other.  These were the negative controls (‘0-
minute’).  1x105 neutrophils, suspended in RPMI-1640 at a concentration of 1x106/ml, were 
added to the wells of a 96-well ‘U’ bottomed plate (Becton-Dickinson) as shown in Figure 
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CD16 Alone X   
0-minute  
Added after 60 
minutes on ice 
with pHrodo 
Added after 60 
minutes on ice 
with pHrodo 
30-minute  X X 
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Figure 3.3 Arrangement of 96-well ‘U’ bottomed plate for Neutrophil Phagocytosis 
Assay 
 
50μl of pHrodo E.Coli and 50μl of pHrodo S.Aureus were added to the respective ‘pHrodo 
Alone’ and ‘60-minute’ wells.  The plate was then incubated at 37⁰C with 5% CO2 in the dark.  
After 15 minutes and 30 minutes 50μl of pHrodo E.Coli and 50μl of pHrodo S.Aureus were 
added to the ’45-minute’ and ’30-minute’ wells respectively.  After completing a further 30 
minutes of incubation (60 minutes in total) the plate was removed from the incubator and 
placed on ice.  The negative controls (‘0-minutes’) were then added to the plate.  In 
addition, 50μl of 2% Bovine Serum Albumin in PBS (Gibco Invitrogen) was added to the 




minutes at 4⁰C and the supernatant was removed.  The cells were re-suspended in 100μl of 
2% Bovine Serum Albumin in PBS. 
1μl of CD16 was added to the ‘CD16 Alone’, ‘0-minute’, ’30-minute’, ’45-minute’ and ’60-
minute’ wells and 1μl of IgG was added to the ‘IgG Alone’ wells.  The plate was then kept on 
ice for 20 minutes.  An additional 100μl of 2% Bovine Serum Albumin in PBS was added to 
each well and the plate was centrifuged at 400G for 5 minutes at 4⁰C.  The supernatant was 
removed and the cells were re-suspended in 200μl of 2% Bovine Serum Albumin in PBS and 
transferred to cytometric tubes for immediate flow cytometry analysis using the Accuri-C6 
(BD Accuri™) flow cytometer.   
When conducting flow cytometry analysis cell debris was eliminated using appropriate side 
and forward scatter gating.  Data was analysed using the Accuri-C6 integrated software.  
Neutrophil phagocytotic function was represented by the Phagocytosis Index which 
provided a quantitative measure of neutrophil phagocytotic function.  It was calculated as 
follows: 



























Figure 3.4 Flow Cytometry Plot for Neutrophil Phagocytosis  
A flow cytometry plot using Study Participant S37 on Day-0 in response to Staphylococcus aureus bio-particles 




A Determines Neutrophils by size 
and granularity (configured with 
‘Unstained’ cells) 
B Determines neutrophils by width 
(to eliminate couplet cells) 
C Determines pHrodo positivity 
(configured with ‘CD16 Alone’) 
D Determines CD16 positivity 
(configured with ‘pHrodo Alone’) 





3.4 In-vitro Investigation with HMG-CoA Reductase Inhibitors 
3.4.1 Dose Selection 
The HMG-CoA reductase inhibitor used in the in-vitro experiments was simvastatin (Sigma-
Aldrich).   
The experiments previously conducted in our laboratory in establishing neutrophil function 
modulation with simvastatin suggest that the optimal in-vitro dose that can modify 
neutrophil function is 1μM (Greenwood, 2013 and Patel, 2014) [293, 294]. 
The dose used to investigate the in-vitro effects of simvastatin on neutrophil function was 
1μM for the reasons outlined below: 
 The 1μM dose of simvastatin was chosen as it represents the predicted plasma 
concentration following ingestion of 40mg simvastatin. This is calculated on the 
theory that simvastatin has high-first pass metabolism resulting in approximately 5% 
bio-availability.  The concentration is calculated as follows: 
(40mg x 0.05) / 5000ml [circulating volume] = 0.4μg/ml 
Molecular Weight of simvastatin = 418μg/ml 
This equates to an approximate 1μM concentration 
 
In addition, the pleiotropic effects of simvastatin are thought to be dose-dependent with 
the greatest effects demonstrated at higher doses.  Following ingestion of high-dose 
simvastatin (≥40mg) the plasma concentration is approximately 1μM (IQR 0.46-3.5μM), 





3.4.2 The Effect of Dimethyl Sulfoxide 
The solvent Dimethyl Sulfoxide (DMSO; Sigma-Aldrich) is the vehicle control for simvastatin.  
The potential confounding effect of DMSO on NET formation was tested in ten separate 
experiments (Patel, 2014).  No significant differences in NET formation were observed when 
testing unstimulated neutrophils with 1μM simvastatin or the equivalent dilution of DMSO 
(p=0.436) [294]. 
Quantification of Neutrophil Extracellular Trap Formation (3.3.1) and Neutrophil Apoptosis 
(3.3.2) assays were repeated after isolated neutrophils, suspended in RPMI-1640 (Sigma-
Aldrich) at a concentration of 1x106/ml, were incubated with 1μM simvastatin (Sigma-














3.5 Histone Deacetylase Investigation 
3.5.1 Histone Deacetylase Activity Assay 
HDAC activity of neutrophils was evaluated using an HDAC Fluorometric Activity Assay Kit 
(Cayman Chemical) as per manufacturer’s instructions. 
The assay provides a fluorescent-based method of measuring HDAC activity.  Firstly a lysine 
substrate is incubated with samples containing HDAC.  Deacetylation sensitises the 
substrate such that treatment with the HDAC developer releases a fluorescent product that 
can be measured using a fluorescence plate reader. 
Sample Preparation 
1x107 neutrophils were suspended in 1ml of cold lysis buffer (10mM Tris-HCl, Gibco 
Invitrogen) in a sterile falcon-TM tube (Becton-Dickinson), then vortexed for 10 seconds and 
kept on ice for 15 minutes.  4mls of cold lysis buffer was then added and the neutrophils 
were then centrifuged at 1,300G for 10 minutes at 4⁰C.  The supernatant was removed and 
the resultant nuclei pellet was re-suspended in 1ml of cold lysis buffer which was 
centrifuged at 1,300G for 10minutes at 4⁰C and the supernatant was discarded. 
The nuclei pellet was suspended in 200µl of extraction buffer (50mM HEPES, Gibco 
Invitrogen) in an eppendorf, sonicated for 30 seconds and incubated on ice for 30 minutes.  
It was spun at 10,000G for 10 minutes at 4⁰C in a micro-centifuge.  The supernatant, 






Performing the Assay 
The following were added to Deacetylated Standard Wells, HDAC-1 Positive Control Wells 
and Sample Wells: 
 Deacetylated Standard Wells (used to prepare a standard curve for quantitative 
determination of HDAC activity).   
– 200µl of standard was diluted with 1.8ml of diluted assay buffer to obtain 
a stock solution of standard.  The stock standard was then diluted as 
shown in Table 3.2. 
– 150µl of diluted assay buffer and 10µl of standard (A-F) were added to 12 
wells (duplicate) of a black 96-well flat bottomed plate (CoStar; Sigma-
Aldrich). 
 HDAC-1 Positive Control Wells 
– 140µl of diluted assay buffer and 10µl of diluted HDAC-1 were added to 
four wells of the black 96-well flat bottomed plate. 
 Sample Wells 
– 140µl of diluted assay buffer and 10µl of each sample were added to four 









Table 3.2 Standard Preparation for Histone Deacetylase Activity Assay 
Tube Standard Stock (µl) Assay Buffer (µl) Standard Concentration (µM) 
A 0 1000 0 
B 50 950 10.5 
C 100 900 21 
D 200 800 42 
E 400 600 84 
F 800 200 168 
 
 
10µl of Trichostatin A was added to two of the positive control wells and to two of each of 
the sample wells.  Trichostatin A eliminates all HDAC activity and is used as a control for 
generating sample background values.  10µl of diluted assay buffer were added to the 
remaining two wells of the positive controls and to the remaining two wells of each sample. 











 1 2 3 4 5 6 7 8 9 10 11 12 
A A A 1 1 5 5 9 9 13 13 17 17 
B B B 1T 1T 5T 5T 9T 9T 13T 13T 17T 17T 
C C C 2 2 6 6 10 10 14 14 18 18 
D D D 2T 2T 6T 6T 10T 10T 14T 14T 18T 18T 
E E E 3 3 7 7 11 11 15 15 19 19 
F F F 3T 3T 7T 7T 11T 11T 15T 15T 19T 19T 
G H H 4 4 8 8 12 12 16 16 20 20 
H HT HT 4T 4T 8T 8T 12T 12T 16T 16T 20T 20T 
 
Figure 3.5 Arrangement of 96-well black plate for Histone Deacetylase Activity Assay 
A – F = Standards A – F,  H = HDAC-1 Positive Control,  HT = Positive Control + Trichostatin A,  1 – 20 = Samples 
1 – 20,  1T – 20T = Samples 1 -20 + Trichostatin A 
 
10µl of HDAC substrate was then added to all of the wells and the plate was covered and 
incubated on a shaker for 30 minutes at 37⁰C.  40µl of Developer was then added to all of 
the wells and the plate was covered and incubated for 15 minutes at 25°C.  Fluorescence 
was then measured in a BioTek-Synergy-2 fluorometric plate reader (NorthStar Scientific 
Ltd) with a filter setting of 360nm excitation and 465nm emission.  
Calculations and Analysis 
The average fluorescence of each standard, positive control, positive control + Trichostatin 




The average fluorescence of Standard A was subtracted from itself and all other standards 
and plotted as a function of the deactylated standard. 
The average fluorescence of the Trichostatin A treated samples was subtracted from the 
fuorescence of its corresponding samples to give the corrected sample fluorescence (CSF) 
The deacetylated concentration was then calculated as follows: 
Deacetylated Compound (µM) = [(CSF – y-intercept)/slope] 
The HDAC activity was calculated as follows: 
HDAC Activity (nmol/min/ml) = [µM/30 minutes] x sample dilution 
3.5.2 Quantitative Real-time PCR 
Quantitative real-time PCR firstly requires RNA isolation and complementary DNA formation 
as outlined below.  
RNA Isolation 
Total RNA was extracted from neutrophils using NucleoSpin® RNA isolation kit (Macherney-
Nagal) according to the manufacturer's protocol.   
1x107 neutrophils were lysed by the addition of 350µl of Buffer RA1 and 3.5µl of β-
mercaptoethanol and vortexed vigorously.  The lysate was then cleared by filtration using 
the Nucleospin® Filter (Macherney-Nagal) and centrifuged at 11,000G for 1 minute.  350µl 
of ethanol (70%) was then added to the homogenised lysate and mixed by pipetting.  The 
lysate was then transferred to a Nucleospin® RNA Column (Macherney-Nagal) and 
centrifuged at 11,000G for 30 seconds.  350µl of Membrane Desalting Buffer was then 




10µl of reconstituted rDNase was added to 90µl of reaction buffer for rDNase and 95µl of 
DNase reaction mixture was added to the centre of the silica membrane of the Nucleospin® 
RNA Column and incubated for 15 minutes at 25 ⁰C. 
The Nucleospin® RNA Column was washed with 200µl Buffer RAW2 and then 600µl Buffer 
RA3 at 11,00G for 30 seconds.  A subsequent wash was performed with 250µl Buffer RA3 at 
11,00G for 2 minutes and the Nucleospin® RNA Column was placed into a nuclease-free 
collection tube. 
The RNA was eluted in 60µl of RNase-free H2O and centrifuged at 11,000G for 1 minute. 
All RNA samples had high integrity and purity as assessed by NanoDrop ND1000 (NanoDrop 
Technologies). 
Complementary DNA Formation 
Complementary DNAs (cDNAs) were generated by reverse transcription using High Capacity 
RNA-to-cDNA Kit (Life Technologies).   
20µl of the reverse transcriptase mix was added to each RNA sample (2µg total RNA per 
sample) of a 96-well plate.  The plate was then loaded into a thermal cycler (37⁰C for 60 
minutes, 95⁰C for 5 minutes then 4⁰C thereafter) to begin the reverse transcription reaction 
and produce the cDNAs required for real-time PCR. 
Quantitative Real-time PCR 
Quantitative real-time PCR was performed under the expert guidance of Dr. Vijay D’Souza 
(Post-doctoral Research Scientist of the Institute of Inflammation and Ageing at the 




Quantitative real-time PCR was performed on the cDNA samples using the TaqMan® Gene 
Expression Assay and SYBR-green reagent (Applied Biosystems) as per manufacturer’s 
instructions.  SYBR-green dye is a double-stranded DNA binding dye that detects double-
stranded DNA generated during PCR which negates the need to target specific probes.   
GAPDH was used as the reference gene and the Class I (HDAC-1, HDAC-2, HADC-3) and Class 
II (HDAC-4, HDAC-7, HDAC-9) HDAC genes were the genes of interest. 
The primer sequences and corresponding assay ID’s used with the TaqMan® Gene 
Expression Assay are listed in Table 3.3. 
 
Table 3.3 Primer Sequences and Assay IDs used with the TaqMan® Gene Expression 





Reference Gene GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA HS99999905_m1 



















































Calculations and Analysis 
Relative transcript abundance values of the genes of interest are expressed as ΔCt values 
(ΔCt = Ctreference – Cttarget) and they were used to calculate the statistical significance 
between groups.   
The reciprocal values of the relative transcript abundance are expressed as 1/ΔCt and they 















3.6 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism Version 6 (La Jolla, California, USA). 
Categorical data was analysed using Fisher’s Exact tests for two variables or χ2 tests for 
greater than two variables. 
Continuous data was analysed using non-parametric statistical models.  Mann-Whitney U 
tests were used for independent samples and Wilcoxon Signed Rank tests for related 
samples for two groups.  Kruskal-Wallis tests were employed for independent samples and 
Freidmann’s tests for related samples for greater than two groups. 
Correlation was calculated using Spearman’s Rank Correlation test to measure the 
association between two non-parametric variables.  Results were represented as the 
correlation co-efficient and the 95% confidence interval.   
All statistical tests performed were two-tailed and results were considered a significance 











3.7 Sample Size Calculation 
Sample size was based upon a power calculation related to NET formation.  42 patients 
were required to demonstrate a difference in NET production from Day-0 to Day-1 based 
upon a 2-tailed power calculation (80% power, p=0.05) using preliminary data (n=10) where 
a mean reduction of 3,045AFU (SD 4,929AFU) in NET formation in response to stimulation 
with fMLP was observed.  To allow for experimental failure it was planned to recruit 45 
































Neutrophils function as the first-line of defence against infections and are responsible for 
the containment and elimination of pathogens.  They are prevalent at sites of tissue trauma 
and are the hallmark of acute inflammation [61].  Neutrophils are also appreciated to have 
an important role in cancer progression and dissemination [64].  It has been suggested that 
neutrophils are not a homogenous population of cells and may consist of pro-tumour and 
anti-tumour subpopulations.  The polarisation of neutrophils towards a pro-tumour or anti-
tumour phenotype may be mediated by the chemokine landscape in the tumour 
microenvironment [128]. The distinct anti-tumour and pro-tumour neutrophil phenotypes 
suggest that neutrophils differ in their contribution to the progression and dissemination of 
cancer and are capable of phenotypic plasticity.  The characteristics of anti-tumour and pro-
tumour neutrophil phenotypes are summarised in Table 1.8. 
 NETs are extra-cellular neutrophil derived DNA webs which have been implicated in cancer 
progression and in the development of metastases.  NETs have been demonstrated to trap 
circulating tumour cells with a subsequent increase in the gross macro-metastatic disease 
burden, following tumour cell injection, in a murine model of infection of caecal ligation and 
puncture [158].   Activated neutrophils can undergo ‘NETosis’.  This is an active form of cell 
death that leads to the release of decondensed chromatin into the extracellular space [93, 
94].  The process of oxidant dependent NET formation results in eventual cell death which is 
distinct from apoptosis and necrosis [94, 99].  NETs are recognised as an effective 
antimicrobial mechanism whereby microbes are trapped and exposed to high local 
concentrations of anti-microbials [96].  Conversely, NETs have been shown to have 




neutrophil components [108] and the adherence of platelets [109, 110] which has 
implicated them in autoimmune and thromboembolic diseases respectively.   
NETs have been implicated in T-cell priming [140] and in the propagation of anti-tumour 
immune responses [141].  Conversely, and more frequently, they have been incriminated in 
tumour progression and tumour dissemination [64, 141, 157].  The role of NETs in tumour 
progression is poorly understood but the evidence to date proposes an association between 
intra-tumoural NET deposition and tumour progression in both experimental models and in 
patients with cancer [157,172,177].  The ability of tumours to predispose neutrophils to 
produce NETs has been demonstrated in murine models and various tumour types have 
been shown to predispose circulating neutrophils to produce NETs via NETosis [178].  The 
evidence supports the theory that primary tumours, through a systemic effect on the host, 
can induce an increase in peripheral blood neutrophils which are predisposed to NET 
formation. 
It is anticipated that a greater understanding of neutrophil function in patients with 
colorectal cancer may help to elucidate their role and prognostic significance.  It was 










The objectives of this chapter were: 
1. To define neutrophil function in patients with colorectal cancer with specific 
reference to: 
i. NET formation 
ii. Neutrophil apoptosis 
iii. Neutrophil phagocytosis 
2. To determine the effect of priming neutrophils with TNF-α on NET formation. 
3. To investigate the impact of cancer location and stage on NET formation. 
4. To evaluate the differences in NET formation defined by patient outcomes with 
specific reference to: 
i. Post-operative Complications  
ii. Total Hospital Length of Hospital Stay 
iii. Mortality 
5. To investigate the association between NET formation and existing validated 
prognostic scores: 
i. Neutrophil-Lymphocyte Ratio 










Dr. Hongxia Mei (International Research Fellow from the Hospital of Wenzouh Medical 
University, China) assisted with the Neutrophil Phagocytosis experiments.  The short life-
span of neutrophils meant that neutrophil functional experiments were conducted 
simultaneously and it was impossible for all experiments to be performed by one individual 
in entirety. 
4.3.2 Recruitment of Patients 
Patients undergoing an elective colorectal resection for cancer, within an established 
enhanced recovery programme, who satisfied the specific inclusion and exclusion criteria, 
were recruited to the study as outlined in Section 3.1.1. 
Patient Demographics, Patient Co-morbidities, Pre-operative Risk Prediction, Tumour 
Characteristics and Operative Characteristics were recorded from study participants as 
outlined in Table 3.1.  
Patient outcomes were collected prospectively and included: 
1. Post-operative complications up to 30 days after surgery using pre-defined criteria 
and graded by the Clavien-Dindo classification system (Appendix 3). 
2. Return to theatre within 28 days of the index procedure. 
3. Admission to and length of stay on the Intensive Care Unit. 




5. Readmissions to hospital within 30 days of the index procedure requiring a hospital 
stay ≥ 24 hours. 
6. 30 day and 90 day mortality. 
Functional and quality of life was assessed using the Surgical Recovery Scale (Appendix 4).   
Haematological and biochemical parameters were collected prospectively from the hospital 
pathology system.  These parameters, in conjunction with physiological indices, were used 
to determine a CR-POSSUM (Appendix 5), a NLR, and an mGPS (Table 1.6) for each patient. 
4.3.3 Sample Collection 
Patients underwent peripheral blood tests.  Blood tests were performed by an experienced 
medical practitioner by peripheral venepuncture or from a peripheral arterial cannula.  A 
total of 24mls of blood was taken from each patient and deposited into 4x6ml lithium-
heparin vacutainers (Becton-Dickinson, Oxford, UK).  The samples were thenne placed on ice 
and transported to the laboratory for processing. 
4.3.4 Neutrophil Isolation 
Processing began with 45 minutes of obtaining the blood sample.  Neutrophils were isolated 
by following the method outlined in Section 3.2.  A purity of ≥95% and a viability of ≥97% 
were routinely achieved. 
4.3.5 Neutrophil Functional Assays 
Quantification of Neutrophil Extracellular Trap Formation was conducted following the 




To account for the variation in number of circulating neutrophils between individuals the 
Absolute NET Production Potential (ANPP) was determined.  It was calculated as follows: 
ANPP (AFU / no. of neutrophils x105 / L) = NETs per 100,000 neutrophils (AFU) x Absolute 
Neutrophil Count (x109 / L)  10,000 
Neutrophil Apoptosis and Neutrophil Phagocytosis were assessed using commercially 
available assays which were carried out as per the manufacturer’s instructions as outlined in 
Sections 3.3.2 and 3.3.3 respectively.  Neutrophil Apoptosis was represented as the 
percentage of neutrophils in the different stages of apoptosis (alive, early apoptosis, late 
apoptosis and necrosis).  Neutrophil phagocytotic function was represented by the 
Phagocytosis Index which provided a quantitative measure of neutrophil phagocytotic 
function.  It was calculated as follows: 
Phagocytosis Index = (Percentage of pHrodo ‘bright’ cells  100) x Median Fluorescent Intensity 
4.3.6 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism Version 6 (La Jolla, California, USA). 
Categorical data was analysed using Fisher’s Exact tests for two variables or χ2 tests for 
greater than two variables. Continuous data was analysed using non-parametric statistical 
models.  Mann-Whitney U tests were used for independent samples and Wilcoxon Signed 
Rank tests for related samples for two groups.  Receiver operator characteristic (ROC) 
curves were used to measure how well diagnostic tests distinguish between two diagnostic 
groups.  Correlation was calculated using Spearman’s Rank Correlation test and results were 
represented as the correlation co-efficient and the 95% confidence interval.  All statistical 





4.4.1 Population Characteristics 
55 patients were identified at the MDT meeting and approached for inclusion into the study.  
45 patients (81.8%) were successfully recruited into the study, between March 2014 and 
March 2015, and were followed up for a median of 21.3 months (IQR 16.7-23.5 months).  
Consent was refused from the remaining 10 patients (18.2%).  The baseline population 
characteristics are shown in Table 4.1. 
Table 4.1 Population Characteristics 
Patient Demographics N=45 
Age, median (IQR) 69.0 (63.0-75.0) 
Gender, n (%), M/F 26 / 19 (57.8 / 42.2) 
BMI, median (IQR), kg/m
2
 26.8 (22.5-28.7) 
Smoking Status, n (%), 1/2/3
a 
9 / 9 / 27 (20.0 / 20.0 / 40.0) 
ASA, n (%), 1/2/3/4 
Co-morbidity, n (%), 0/1/2/≥3 
Medications, n, 1/2/3/4
b 
CR-POSSUM (Predicted Mortality [%]), median (IQR) 
mGPS, n (%), 0/1/2 
NLR, median (IQR) 
Surgical Recovery Score (Pre-operative [%]), median (IQR)  
4 / 25 / 14 / 2 (8.9 / 55.6 / 31.1 / 4.4) 
10 / 21 / 10 / 4 (22.2 / 46.7 / 22.2 / 8.9) 
21 / 9 / 11 / 7 
2.5 (1.3-3.9) 




Presentation, n (%), 1/2
c 
Cancer Location, n (%), 1/2
d
 
39 / 6 (86.7 / 13.3) 
27 / 18 (60.0 / 40.0) 
Tumour  Characteristics N=44 
Neo-adjuvant Therapy, n (%), y
 
11  (24.4) 
T-Stage, n (%), 0/1/2/3/4 2 / 2 / 9 / 22 / 9 (4.5 / 4.5 / 20.5 / 50.0 / 20.5) 
N-Stage, n (%), 0/1/2 32 / 8 / 4 (72.7 / 18.2 / 9.1) 
M-Stage, n (%), 0/1 
Dukes’ Stage, n(%), A/B/C/D 
Differentiation, n (%), 1/2
e 
Extra-mural Venous Invasion, n(%), y
 
42 / 2 (95.5 / 4.5) 
9 / 22 / 11 / 2 (20.5 / 50.0 / 25.0 / 4.5) 
39 / 5 (88.6 / 11.4) 
14 (32.6) 
 
y = yes,  1/2/3
a
 = active / former / never,  1/2/3/4
b
 = antihypertensive / β-antagonist / anti-platelet / oral 
hypoglycaemic,  1/2
c
 = symptomatic / screened,  1/2
d
 = colon / recto-sigmoid junction and rectum,  1/2
e
 = well 




The median age of the population was 69 years (IQR 63-75 years) and 26 patients (57.8%) 
were male.  The median BMI was 26.75kg/m2 (IQR 22.5-28.7 kg/m2).  14 patients (31.1%) 
had two or more significant co-morbidities and 16 patients (35.6%) had an ASA score of 3 or 
4.  The predicted mortality of the population, calculated by the CR-POSSUM, was 2.5% (IQR 
1.3-3.9%). 
39 patients (86.7%) were symptomatic and the remaining 6 patients (13.3%) were identified 
through the NHS Bowel Cancer Screening Programme.  27 patients (60.0%) had colonic 
cancer whereas 18 patients (40.0%) had rectal cancer or a cancer of the recto-sigmoid 
junction and 11 patients (24.4%) underwent neo-adjuvant therapy (10; long-course chemo-
radiotherapy, 1; short-course radiotherapy) prior to surgery.  31 patients (70.5%) had early 
stage disease (Dukes’ A or B) versus 13 patients (29.5%) who had late stage (node positive 
or metastatic) disease (Dukes’ C or D). 
44 patients (97.8%) underwent surgical resection.  1 patient was deemed unfit for surgery 
on the day of surgery and never progressed to surgical resection.  The operative 
characteristics are outlined in Table 4.2. 
Table 4.2 Operative Characteristics 
Operative Characteristics N=44 
Operation Type, n (%), 1/2
a 
Operation technique, n (%), 1/2
b 
Stoma Formation, n (%), y 
25 / 19 (56.8 / 43.2) 
27 / 17 (61.4 / 38.6) 
16 (36.4) 
Length of Operation (minutes), median (IQR)  174 (129-240) 
Post-operative Level of Care, n (%), 1/2
c 
27 / 17 (61.4 / 38.6)  
 
y = yes,  1/2
a
 = segmental / rectal,  1/2
b
 = laparoscopic / open and laparoscopic converted to open,  1/2
c
 = ward 





27 procedures (61.4%) were completed entirely laparoscopically and the median operative 
time for all operations was 174 minutes (IQR 129-240 minutes).   16 patients (36.4%) 
underwent stoma formation, the majority of which were temporary ileostomies (10 patients 
[62.5%]) to cover a colorectal anastomosis.   17 patients (38.6%) required admission to 
Critical Care following surgery, the majority were planned admissions (12 patients [70.6%]) 
and a reflection of the patients’ co-morbidity.  The patient outcomes are shown in Table 4.3. 
Table 4.3 Patient Outcomes 
Patient Outcomes N=44 
Complication, n (%), y 
Clavien-Dindo Classification, n (%), I/II/III/IV/V 
Re-operation, n (%) 
Critical Care Admission, n (%), y 
Total LOS, median (range, IQR) 
Surgical Recovery Score (Post-operative [%]), median (IQR) 
Readmission, n (%), y 
Disease Recurrence, n (%) 







12 / 4 / 2 / 2 / 2 (27.3 / 9.1 / 4.5 / 4.5 / 4.5) 
3 (6.8) 
19 (43.2) 
8.0 (4.0-67.0, 5.3-10.0) 









Y = yes 
 
22 patients (50.0%) developed a complication, although only 6 patients (13.6%) developed a 
significant complication (Clavien-Dindo ≥ 3).  The median length of stay was 8 days (IQR 5.3-
10.1 days) and only 3 patients (6.8%) were readmitted up to 30 days of the index procedure.  
30-day, 90-day and 12-month mortality was 2.3%, 4.5% and 6.8% respectively with a median 
follow-up of 21.3 months (IQR 16.7-23.5 months).   During the entire study period, 5 




Of the patients that developed complications the most frequent were cardio-resiratory 
events (14) which encompassed lower respiratory tract infection (4), ischaemic events (4), 
arrhythmias (4) and cardiac failure (2). This was followed by mechanical / functional bowel 
obstruction (7) and surgical site infection (7).  3 patients (6.8%) underwent re-operation; 
Anastomotic repair and defunctioning loop ileostomy (1), Evacuation of haematoma and 
defunctioning ileostomy (1), Re-suture of abdominal wall (1).  The cumulative complication 
type is outlined in Table 4.4. 
Table 4.4 Cumulative Complication Type 
 Complication Frequency 
Abdominal Collection 
Acute Kidney Injury 
Anastomotic Dehiscence 
Bacteraemia 
Blood Product Transfusion 
Cardio-respiratory Event 
Intestinal Obstruction 
Lower Respiratory Tract Infection 
Multi-organ Dysfunction Syndrome 
Surgical Site Infection 














Functional and quality of life assessment was conducted pre-operatively and post-
operatively (day 3-5) in the form of the Surgical Recovery Score.   A median reduction of 
33.9% (75.3% to 41.4%) function was identified which indicates the impact of resectional 







4.4.2 Neutrophil Extracellular Trap Formation 
Quantification of NET formation was performed in patients with colorectal cancer (n=45).  
The baseline population characteristics and NET production is summarised in Table 4.5.  NET 
production is plotted graphically in Figure 4.1.  The effect of priming neutrophils with TNF-α 
was assessed in patients with colorectal cancer.  NET production is displayed in Table 4.6 
and Figure 4.2. 
 





Age, median (IQR) 69.0 (63.0-75.0) 
Gender, n (%),  M/F 26 / 19 (57.8 / 42.2) 



























Figure 4.1 NET Production in Patients with Colorectal Cancer 
Box and Whisker Plot (10-90 percentile) of NET production in response to No stimulant (Unstim), PMA, IL-8, 
LPS and fMLP in patients with a confirmed diagnosis of Colorectal Cancer (n=45). 
 









































The effect of priming neutrophils with TNF-α on NET Production in patients with Colorectal Cancer (n=45).  





Figure 4.2 NET Production in Un-primed and Primed Neutrophils 
Box and Whisker Plot (10-90 percentile) of NET production demonstrating the effect of priming neutrophils 
with TNF-α on NET production in patients with Colorectal Cancer (n=45) in response to No stimulant (Unstim), 
PMA, IL-8, LPS and fMLP.  Statistical significance, measured by Wilcoxon Signed Rank test, is denoted by * 
(p<0.05), ** (p<0.01) and *** (p<0.001). 
 
 
When neutrophils from a colorectal cancer population were primed with TNF-α, NET 
production was significantly increased in response to No stimulant, IL-8, LPS and fMLP.  







4.4.3 Neutrophil Apoptosis 
Neutrophil apoptosis was assessed in patients with colorectal cancer (n=43).  Neutrophil 
apoptosis was represented as the percentage of neutrophils in the different stages of 
apoptosis (alive, early apoptosis, late apoptosis and necrosis).  The baseline population 
characteristics and stage of apoptosis is summarised in Table 4.7.  Neutrophil apoptosis at 4-
hours and 24-hours is plotted graphically in Figure 4.3. 
Table 4.7 Age, Gender and Stage of Apoptosis at 4-hours and 24-hours in Patients 





Age, median (IQR) 69.0 (63.0-74.0) 
Gender, n (%),  M/F 25 / 18 (58.1 / 41.9) 
Stage of Apoptosis (%) 











Stage of Apoptosis (%) 
















Figure 4.3 Stage of Apoptosis in Patients with Colorectal Cancer at 4-hours and 24-
hours 
Bar graphs depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 4-hours (A) and 24-hours (B) incubation in patients with 







































4.4.4 Neutrophil Phagocytosis 
Neutrophil phagocytosis was assessed in patients with colorectal cancer (n=27).  Neutrophil 
phagocytotic function was represented by the Phagocytosis Index which provided a 
quantitative measure of neutrophil phagocytotic function. The baseline population 
characteristics and Phagocytosis Index in response to E.Coli and S.Aureus is shown in Table 
4.8 and represented graphically in Figure 4.4. 
Table 4.8 Age, Gender and Phagocytosis Index in response to E.Coli and S.Aureus in 





Age, median (IQR) 69.6 (64.0–76.0) 
Gender, n (%),  M/F 18 / 9 (66.7 / 33.3) 





































Figure 4.4 Phagocytosis Index in Patients with Colorectal Cancer in response to E.Coli 
and S.Aureus  
Box and Whisker Plot (10-90 percentile) of Phagocytosis Index represented by Area Under Curve (considering 
30, 45 and 60 minute time points) in response to E.Coli (EC) and S.Aureus (SA) in patients with a confirmed 

















4.4.5 The Impact of Cancer Location and Stage on NET Production  
The impact of cancer location and stage of disease on NET formation was investigated.  To 
account for the variation in number of circulating neutrophils between individuals the 
Absolute NET Production Potential (ANPP) was also determined.  NET production and ANPP 
in patients with rectal cancer compared to colonic cancer is outlined in Table 4.9 and Figure 
4.5.  NET Production and ANPP in patients with early stage (Dukes’ A/B) compared to late 
stage (Dukes’ C/D) colorectal cancer is summarised in Table 4.10 and Figure 4.6. 
The use of neo-adjuvant therapy, which is generally reserved for late stage rectal cancers, 
was also analysed to determine the effect on NET production and ANPP and is displayed in 


















Table 4.9 NET Production, Absolute NET Production Potential and Absolute 
Neutrophil Count in Patients with Rectal Cancer vs. Colonic Cancer  
 
 



























































































A comparison of NET Production, Absolute NET Production Potential and Absolute Neutrophil Count in 
patients with Rectal Cancer (n=18) versus Colonic Cancer (n=27).  Statistical significance was measured by the 



















Figure 4.5 NET Production and Absolute NET Production Potential in Patients with 
Rectal vs. Colonic Cancer 
Box and Whisker Plots (10-90 percentile) of NET production and Absolute NET Production Potential in patients 
with Rectal Cancer (n=18) versus Colonic Cancer (n=27) in response to No stimulant (Unstim), PMA, IL-8, LPS 
and fMLP.  Statistical significance, measured by Mann Whitney U test, is denoted by * (p<0.05), ** (p<0.01) 












Table 4.10 NET Production, Absolute NET Production Potential and Absolute 




Early Stage (Dukes’ A/B) 
(n=32) 
Late Stage (Dukes’ C/D) 
(n=13) 
P-value 






















































































A comparison of NET Production, Absolute NET Production Potential and Absolute Neutrophil Count in 
Patients with with Early Stage (n=32) vs. Late Stage (n=13) Colorectal Cancer.  Statistical significance was 





















Figure 4.6 NET Production and Absolute NET Production Potential in Patients with 
Early Stage vs. Late Stage Colorectal Cancer 
Box and Whisker Plots (10-90 percentile) of NET production and Absolute NET Production Potential in patients 
with Early Stage Colorectal Cancer (n=32) versus Late Stage Colorectal Cancer (n=13) in response to No 
stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical significance, measured by Mann Whitney U test, is 
















Table 4.11 NET Production, Absolute NET Production Potential and Absolute 
Neutrophil Count in Patients who were treated with Neo-adjuvant Therapy 





Straight to Surgery 
 (n=34) 
P-value 






















































































A comparison of NET Production, Absolute NET Production Potential and Absolute Neutrophil Count in 
Patients who were treated with Neo-adjuvant Therapy (n=11) vs. Patients who went Straight to Surgery 






















Figure 4.7 NET Production and Absolute NET Production Potential in Patients who 
were treated with Neo-adjuvant Therapy vs. Patients who went Straight to 
Surgery 
Box and Whisker Plots (10-90 percentile) of NET production and Absolute NET Production Potential in patients 
who were treated with Neo-adjuvant Therapy (n= 11) versus Patients who went Straight to Surgery (n=34) in 
response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical significance, measured by Mann 












No significant differences were identified in NET production when comparing rectal and 
colonic cancers, however, when taking into account the variation in circulating neutrophils 
significant increases in ANPP were identified in patients with colonic cancer in response to 
No stimulant, PMA, IL-8, LPS and fMLP.   
Similarly, no significant differences were identified in NET production when comparing early 
stage and late stage colorectal cancer.  There was a notable reduction in ANPP in late stage 
cancer compared to early stage cancer but this only reached statistical significance in 
response to IL-8. 
Interestingly, no significant differences in NET production or ANPP were identified when 
comparing patients who received neo-adjuvant therapy compared to those patients who 
went straight to surgery. 
When analysing absolute neutrophil counts between groups a significant difference was 
identified when comparing patients with rectal cancer and colonic cancer which reached a 
greater level of significance than when analysing ANPP.  No significant differences were 
identified in absolute neutrophil count when comparing early stage and late stage colorectal 
cancer and when comparing patients who received neo-adjuvant therapy compared to 










4.4.6 Changes in NET Production Defined by Patient Outcome 
An evaluation of NET formation according to patient outcome was performed.  The patient 
outcomes investigated included; post-operative complications categorised into minor or no 
Complications (Clavien-Dindo <3) and significant complications (Clavien-Dindo ≥3), total 
hospital length of stay (LOS) categorised into LOS ≤ 5 days and LOS > 5 days, and mortality 
after a median follow-up of 21.3 months (IQR 16.7-23.5 months).  To account for the 
variation in number of circulating neutrophils between individuals the ANPP was also 
determined.   
NET production and ANPP in patients categorised by post-operative complication, LOS and 
mortality are outlined in Table 4.12 and Figure 4.8, Table 4.13 and Figure 4.9 and Table 4.14 
















Table 4.12 NET Production, Absolute NET Production Potential and Absolute 
Neutrophil Count in Patients who developed Minor or No Complications 






Clavien-Dindo ≥3  
(n=6) 
P-value 






















































































A comparison of NET Production, Absolute NET Production Potential and Absolute Neutrophil Count in 
Patients who developed Minor or No Complications (Clavien-Dindo <3) (n=38) versus Patients who developed 






















Figure 4.8 NET Production and Absolute NET Production Potential in Patients who 
developed Minor or No Complications (Clavien-Dindo <3) vs. Patients who 
developed Significant Complications (Clavien-Dindo ≥3) 
Box and Whisker Plots (10-90 percentile) of NET production and Absolute NET Production Potential in Patients 
who developed Minor or No Complications (Clavien-Dindo <3) (n=38) versus Patients who developed 
Significant Complications (Clavien-Dindo ≥3) (n=6) in response to No stimulant (Unstim), PMA, IL-8, LPS and 
















Table 4.13 NET Production, Absolute NET Production Potential and Absolute 
Neutrophil Count in Patients who had a Total Length of Stay ≤ 5 days vs. 
Patients who had a Total Length of Stay > 5 days 
 
 
LOS ≤ 5 days 
(n=15) 
LOS > 5 days  
(n=29) 
P-value 

























































































A comparison of NET Production, Absolute NET Production Potential and Absolute Neutrophil Count in 
Patients who had a Total Length of Stay ≤ 5 days (n=15) vs. Patients who had a Total Length of Stay > 5 days 



















Figure 4.9 NET Production and Absolute NET Production Potential in Patients who had 
a Total Length of Stay ≤ 5 days vs. Patients who had a Total Length of Stay > 
5 days 
Box and Whisker Plots (10-90 percentile) of NET production and Absolute NET Production Potential in Patients 
who had a Total Length of Stay ≤ 5 days (n=15) vs. Patients who had a Total Length of Stay > 5 days (n=29) in 
response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical significance, measured by Mann 
















Table 4.14 NET Production, Absolute NET Production Potential and Absolute 






























































































A comparison of NET Production, Absolute NET Production Potential and Absolute Neutrophil Count in 
Patients who Survived (n=40) vs. Patients who Died (n=5) following Colorectal Cancer Resection to a median 



















Figure 4.10 NET Production and Absolute NET Production Potential in Patients who in 
Survived vs. Patients who Died  
Box and Whisker Plots (10-90 percentile) of NET production and Absolute NET Production Potential in who 
Survived vs. Patients who Died following Colorectal Cancer Resection to a median follow-up of 21.3 months 
(IQR 16.7-23.5 months in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical significance, 












An increase in both NET production and ANPP was evident in patients who went on to 
develop significant complications (Clavien-Dindo ≥3) compared to patients who experienced 
minor or no complications (Clavien-Dindo <3).  This reached statistical significance in 
response to fMLP for both NET production and ANPP. 
Similarly, an increase in NET production and ANPP was evident in patients with a LOS > 5 
days compared to those patients with a LOS ≤ 5 days.  Again, this reached statistical 
significance is response to fMLP for NET production and ANPP. 
Likewise, an increase in NET production and ANPP was evident in patients who died 
compared to those patients who survived, but this only reached statistical significance in 
response to fMLP for ANPP. 
It appears that adverse outcomes (mortality, Clavien-Dindo ≥3, LOS > 5 days) are all 
associated with increased pre-operative NET production.   
No statistical significant differences were identified when comparing absolute neutrophil 
counts between the groups. 
To assess the potential diagnostic ability of the quantification of NET formation assay in 
predicting post-operative complications, a prolonged hospital stay and mortality, ROC curve 
analyses were performed in patients with colorectal cancer who underwent surgical 
resection.  When stimulated with fMLP, the area under the ROC curve (AUC) values for the 
development of a significant complication (Clavien-Dindo ≥ 3), LOS > 5 days and mortality 
were 0.7906 (95%CI=0.6259-0.9553, p=0.0232), 0.6851 (95%CI=0.5049-0.8652, p=0.0463) 




production in response to stimulation with fMLP for the development of significant post-
operative complications (Clavien-Dindo ≥ 3) is displayed in Figure 4.11. 
 
 
Figure 4.11 ROC Curve Analysis of the Quantification of NET Formation Assay for the 
development of Significant Post-operative Complications (Clavien-Dindo ≥3) 
To assess the diagnostic ability of the quantification of NET formation assay in predicting post-operative 
complications ROC curve analysis was performed in patients with colorectal cancer who underwent surgical 
resection.  When stimulated with fMLP, the area under the ROC curve (AUC) values for the development of a 










4.4.7 The Association Between NET Production and Validated Prognostic Scores 
The association between NET production and NLR and mGPS was investigated.   
Firstly, it was explored whether differences in NET production existed when categorised by 
NLR (NLR < 5 vs. NLR ≥ 5) as summarised in Table 4.15 and Figure 4.12.  It was then 
investigated whether NET production and NLR correlated and this is displayed in Table 4.16 
and Figure 4.13. The association and correlation between NLR and mGPS was also 
interrogated. 
Secondly, it was explored whether differences in NET production and ANPP existed when 
categorised by mGPS (mGPS < 2 vs. mGPS ≥ 2) as outlined in Table 4.17 and Figure 4.14.  It 
was then determined whether correlation existed between NET production and mGPS and 
ANPP and mGPS, as summarised in Table 4.18.  The association and correlation between 















Table 4.15 NET Production and Modified Glasgow Prognostic Score in Patients with 
NLR < 5 vs. Patients with NLR ≥ 5 
 
 
NLR < 5 
(n=36) 
NLR ≥ 5 
 (n=9) 
P-value 










































A comparison of NET Production and Modified Glasgow Prognostic Score in Patients with a NLR < 5 (n=36) 






























Figure 4.12 NET Production and Modified Glasgow Prognostic Score in Patients with 
NLR < 5 vs. Patients with NLR ≥ 5 
Box and Whisker Plot (10-90 percentile) of NET production in Patients with NLR < 5 versus Patients with NLR ≥ 
5 in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical significance, measured by Mann 














Table 4.16 Spearman’s Rank Correlation Analysis of NET Production and Modified 
Glasgow Prognostic Score with Neutrophil-Lymphocyte Ratio in Patients 
with Colorectal Cancer 
 
 
Spearman r 95% Confidence Interval P-value 













-0.2732 – 0.3298 
-0.0003 – 0.5530 
-0.3530 - 0.2487 
-0.2491 – 0.3526 























Figure 4.13 NET Production vs. Neutrophil-Lymphocyte Ratio 
A scatter plot of NET production in response to PMA and Neutrophil Lymphocyte Ratio demonstrating a line of 
best fit.  Spearman’s Rank Correlation Analysis indicates a weakly positive, but statistically significant 
correlation (Spearman r = 0.3015, 95%CI=-0.0003-0.5530, p=0.0441). 
 
Spearman Rank Correlation 
Spearman r 0.3015 





No significant differences in NET production were identified when categorised by NLR.  As 
expected, the documented association between NLR and mGPS was apparent in the studied 
population.   
Spearman’s Rank Correlation test was performed to determine if a correlation existed 
between NET production and NLR.  It was identified that a weak, but significant correlation 
existed between NET production and NLR in response to PMA (Spearman r = 0.3015, p = 
0.0441).  As anticipated, the mGPS and NLR were also positively and significantly correlated 




















Table 4.17 NET Production, Absolute NET Production Potential, Absolute Neutrophil 
Count and Neutrophil-Lymphocyte Ratio in Patients with mGPS < 2 vs. 
Patients with mGPS ≥ 2 
 
 
mGPS < 2 
(n=37) 
mGPS ≥ 2 
 (n=8) 
P-value 































































































A comparison of NET Production, Absolute NET Production Potential, Absolute Neutrophil Count and 
Neutrophil-Lymphocyte Ratio in Patients with mGPS < 2 (n=37) versus Patients with mGPS ≥ 2 (n=8).  Statistical 

























Figure 4.14 Absolute NET Production Potential in Patients with mGPS < 2 vs. Patients 
with mGPS ≥ 2  
Box and Whisker Plot (10-90 percentile) of NET production in Patients with mGPS <2 (n=37) versus Patients 
with mGPS ≥ 2 (n=8) in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical significance, 












Table 4.18 Spearman’s Rank Correlation Analysis of NET Production, Absolute NET 
Production Potential, Absolute Neutrophil Count and Neutrophil-


















-0.1223 – 0.4621 
0.2101 – 0.3882 
-0.1422 – 0.4460 
-0.2446 – 0.3568 























0.1386 – 0.6425 
0.0511 – 0.5876 
0.1878 – 0.6712 
0.0400 – 0.5803 


























No significant differences in NET production were identified when categorised by mGPS.  
However, when taking into account the variation in circulating neutrophils, significant 
increases in ANPP were identified in patients with an mGPS ≥ 2 in response to No stimulant, 
IL-8 and fMLP.  This may be accounted for by the significant increase in absolute neutrophil 
count in patients with an mGPS ≥ 2.  Interestingly, no demonstrable differences were 
identified in NLR when categorised by mGPS.   
Spearman’s Rank Correlation test was performed to determine whether a correlation 
existed between NET production and mGPS.  No significant correlation was identified.  
Significant weak to moderate positive correlation did exist between ANPP and mGPS in 
response to No stimulant, PMA, IL-8, LPS and fMLP.  Significant moderate positive 




anticipated, NLR and mGPS were significantly and positively correlated, although only weak 




























The experiements performed in this chapter defined NET production, Neutrophil Apoptosis 
and Neutrophil Phagocytosis in a population of patients with a confirmed diagnsis of 
Colorectal Cancer (pre-operatively) which will enable serial analysis of neutrophil function 
over the peri-operative period as oulined later in this thesis. 
It has been proposed that primary tumours can facilitate NET production in circulating 
neutrophils. This effect has been attributed, in part, to granulocyte-colony stimulating factor 
(G-CSF) production by tumours [178].  In addition, TNF-α and IL-8 have been shown to 
facilitate NET formation and these cytokines are highly expressed by a number of tumour 
types, including colorectal cancer [173-175].  The findings of this chapter provide additional 
support to this theory, particulary as neutrophils primed with TNF-α had significantly 
increased NET production under controlled experimental conditions in response to all 
stimulants. 
Despite the accumulating evidence that suggests an association between NETs and tumour 
progression, the experimental evidence outlined in this study revealed no significant 
differences in NET production in patients with more advanced disease when patients with 
early stage and late stage colorectal cancer were compared.  In addition, no significant 
differences were identified in NET production in patients treated with neo-adjuvant therapy 
compared to patients who went straight to surgery or when comparing cancer location.   
Cancer associated inflammation, both in the systemic circulation and in the tumour 
microenvironment, is now widely recognised to be a key determinant of disease progression 
and survival in cancer.  A chronic dysregulation of the immune system may account for the 




activation by micro-metastases or as a result of disease which induces tissue injury [35, 36].  
It is now established that the systemic inflammatory response to a tumour is a negative 
prognostic factor in primary operable [40] and metastatic colorectal cancer [16, 41-44].  It is 
also known that infectious complications in patients with cancer are associated with adverse 
oncological outcomes and an increased mortality as a consequence of metastatic disease 
[187-191].   
The analysis performed in this study suggests that adverse patient outcomes (post-operative 
complications, prolonged hospital recovery and mortality) are associated with increased 
pre-operative NET production, which indicates increased neutrophil activation, conceivably 
as a result of cancer associated inflammation.  Significant increases in NET production in 
response to stimulation with fMLP were demonstrated in patients who developed a post-
operative complication (Clavien-Dindo ≥ 3) and in patients who had a prolonged hospital 
stay (LOS > 5 days).  ROC curve analyses were also able to distinguish between patients who 
developed post-operative complications and had a prolonged hospital stay with significance.  
NET production, particularly in response to stimulation with fMLP, therefore has potential 
prognostic significance and further investigation into their predictive value is justified.  fMLP 
stimulation of neutrophils activates a wide variety of intra-cellular signalling pathways 
mediated by phospholipase C (PLC), phospholipase D (PLD), phospholipase A2 (PLA2), 
phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPKs) to 
induce various cellular functions [291].  Both PLC and PLD have been reported to be 
involved in superoxide generation and degranulation of neutrophils [292, 293] and this may 




The ANPP is a novel calculation that attempts to account for the variation in circulating 
neutrophils.  It attempts to quantify the ‘potential’ NET formation in an individual which is 
inferred from the laboratory experiments.  It is an interesting concept which attempts to 
provided a measure of the quanity of circulating NETs in-vivo and merits further review, 
particularly with regard to its prognostic value in predicting post-operative complications, a 
prolonged hospital length of stay and mortality. 
In view of the potential prognostic value of pre-operative NET production on patient 
outcomes, as outlined above, a correlation analysis was undertaken with existing validated 
prognostic scores; NLR and mGPS.  A significant, weak positive correlation was 
demonstrated between NET production and NLR in response to PMA, but no significant 
correlation was identified between NET production and mGPS, although a significant, 
moderate positive correlation did exist between ANPP and mGPS.  This may suggest that the 
absolute number of circulating neutrophils are more important in prognostication, 
particularly as the NLR and mGPS are also positively correlated.  The evidence presented in 
this chapter certainly indicates that further investigation into the prognostic value of NETs 
and ANPP is justified. 
This experimental study has a number of limitations.  Firstly, the population evaluated was 
small and heterogeneous with regard to patient demographics, patient co-morbidities, 
tumour characteristics and operative characteristics making interpretation of the results 
difficult and limiting the generalisability of the study findings.  Secondly, comparative 
analyses stratifying patients according to cancer location, cancer stage and patient 
outcomes is subject to misinterpretation as potential confounding variables were not 




was low making interpretation of patient outcomes challenging.  Fourthly, in-vitro 
experiments performed to assess neutrophil function were conducted outside of the 
biological context and consequently there are challenges in extrapolating the results and it 
must be acknowledged that they cannot be readily transposed to, and predict the reaction 
of, the entire organism in-vivo.  Lastly, the patient group was not compared to a control 
population and therefore it was not possible to determine if differences in neutrophil 
function existed in patients with colorectal cancer when compared to a matched healthy 
















It has been demonstrated that adverse patient outcomes; post-operative complications, 
prolonged hospital recovery and mortality were all associated with increased pre-operative 
NET production.  It is therefore conceivable that NET production may play a 
pathophysiological role for the development of adverse outcomes.  NETs represent 


















SERIAL CHARACTERISATION OF NEUTROPHIL FUNCTION AFTER 















It is increasingly appreciated that outcomes in patients with cancer are not exclusively 
determined by the characteristics of the tumour.  Cancer-associated inflammation, both in 
the systemic circulation and in the tumour microenvironment, is now widely recognised to 
be a key determinant of disease progression and survival in cancer [35, 36].  In the context 
of cancer surgery, an overwhelming systemic inflammatory response (SIR) may suppress 
anti-tumour immunity and promote tumour progression and dissemination [58].  The  SIR 
can be assessed by examining changes in concentrations of circulating acute phase proteins, 
such as CRP, serum cytokines (TNF-α, IL-6, IL-8, IL-10) and low levels of circulating albumin 
[17, 18].  Pre-operatively, these factors have been demonstrated to be stage-independent 
prognostic factors in many cancer types [19-24].  The cellular components of the SIR, such a 
neutrophils, lymphocytes, monocytes and platelets have all been reported to have 
prognostic value in patients with cancer [26-30].  The SIR results in changes in circulating 
white blood cells and the neutrophil-lymphocyte ratio (NLR) has been used to predict overall 
and cancer specific survival in numerous solid organ malignancies, including colorectal 
cancer [31]. 
Loco-regional control in the form of a complete oncological resection remains the mainstay 
of treatment for the majority of solid tumours and provides improved disease-free and 
overall survival [182].  Cancer surgery, however, elicits a high-grade, non-specific SIR.  This 
overwhelming, systemic inflammation suppresses systemic cell-mediated immunity and 
consequently compromises the tumour immunity in the host [58, 59].  This has been 
described as the ‘immune-hit’ [58].  The immune-hit can be exacerbated by pre-operative 




perforation, confers a higher risk of disease recurrence independent of the stage of disease 
[40].  Additionally, the development of post-operative complications and the associated 
post-operative SIR increases the risk of disease recurrence [38] and is associated with poor 
oncological outcomes and increased mortality secondary to metastatic disease [187-191].  It 
is therefore appreciated that major surgical resection for colorectal cancer presenting as an 
emergency or in the presence of a post-operative infective complication results in further 
compromise of the immune response to residual disease [40, 58].  This is consistent with the 
negative prognosis associated with the presence of SIR in patients affected by most tumour 
types at any stage of disease [40]. 
It is believed that neutrophils play a vital role in circulating tumour cell metastases.  This has 
been demonstrated in-vitro and in-vivo where neutrophils facilitate circulating tumour cell 
adhesion to both pulmonary and hepatic endothelial surfaces [174, 176, 179-181] and the 
direct contact of circulating tumour cells and neutrophils is thought to be an important 
precursor to the development of metastatic disease [179, 180].  Following dissemination, 
tumour cells must proliferate to form a stable metastatic foci and it is proposed that NETs 
may play a direct proliferative role and may inhibit tumour cell apoptosis [181].   
This study was conducted to characterise neutrophil function in the peri-operative period of 
patients undergoing major colorectal cancer resection, focussing on NET formation, 
apoptosis and phagocytosis, and to determine whether differences in peri-operative NET 
formation, classified by cancer location, cancer stage, operative technique, operation type 






It was hypothesised that the impact of surgery would replicate the neutrophil functional 
changes observed in patients with sepsis: 
1. Reduced NET formation 
2. Reduced apoptosis 


















The objectives of this chapter were: 
1. To characterise neutrophil function in the peri-operative period with specific 
reference to: 
i. NET formation 
ii. Neutrophil apoptosis 
iii. Neutrophil phagocytosis 
2. To evaluate the differences in peri-operative NET formation classified by operative 
technique and operation type. 
3. To evaluate the differences in peri-operative NET formation classified by: 
i. Post-operative Complications  















Dr. Hongxia Mei (International Research Fellow from the Hospital of Wenzouh Medical 
University, China) assisted with the Neutrophil Phagocytosis experiments.  The short life-
span of neutrophils meant that neutrophil functional experiments were conducted 
simultaneously and it was impossible for all experiments to be performed by one individual 
in entirety. 
5.4.2 Recruitment of Patients 
Patients undergoing an elective colorectal resection for cancer, within an established 
enhanced recovery programme, who satisfied the specific inclusion and exclusion criteria, 
were recruited to the study as outlined in Section 3.1.1. 
Patient Demographics, Patient Co-morbidities, Pre-operative Risk Prediction, Tumour 
Characteristics and Operative Characteristics were recorded from study participants as 
outlined in Table 3.1.  
Patient outcomes were collected prospectively and included: 
1. Post-operative complications up to 30 days after surgery using pre-defined criteria 
and graded by the Clavien-Dindo classification system (Appendix 3). 
2. Return to theatre within 28 days of the index procedure. 
3. Admission to and length of stay on the Intensive Care Unit. 




5. Readmissions to hospital within 30 days of the index procedure requiring a hospital 
stay ≥ 24 hours. 
6. 30 day and 90 day mortality. 
Functional and quality of life was assessed using the Surgical Recovery Scale (Appendix 4).   
Haematological and biochemical parameters were collected prospectively from the hospital 
pathology system.  These parameters, in conjunction with physiological indices, were used 
to determine a CR-POSSUM (Appendix 5), a NLR, and an mGPS (Table 1.6) for each patient. 
5.4.3 Sample Collection 
Patients underwent peripheral blood tests pre-operatively (Day-0) and post-operatively 
(Day-1 and Day-3) to assess neutrophil function at these specific time points.  Blood tests 
were performed by an experienced medical practitioner by peripheral venepuncture or from 
a peripheral arterial cannula.  A total of 24mls of blood was taken from each patient at each 
time point and deposited into 4x6ml lithium-heparin vacutainers (Becton-Dickinson, Oxford, 
UK).  The samples were then placed on ice and transported to the laboratory for processing. 
5.4.4 Neutrophil Isolation 
Processing began with 45 minutes of obtaining the blood sample.  Neutrophils were isolated 
by following the method outlined in Section 3.2.  A purity of ≥95% and a viability of ≥97% 
were routinely achieved. 
5.4.5 Neutrophil Functional Assays 
Quantification of Neutrophil Extracellular Trap Formation was conducted following the 




To account for the variation in number of circulating neutrophils between individuals the 
Absolute NET Production Potential (ANPP) was determined.  It was calculated as follows: 
ANPP (AFU / no. of neutrophils x105 / L) = NETs per 100,000 neutrophils (AFU) x Absolute 
Neutrophil Count (x109 / L)  10,000 
Neutrophil Apoptosis and Neutrophil Phagocytosis were assessed using commercially 
available assays which were carried out as per the manufacturer’s instructions as outlined in 
Sections 3.3.2 and 3.3.3 respectively.  Neutrophil Apoptosis was represented as the 
percentage of neutrophils in the different stages of apoptosis (alive, early apoptosis, late 
apoptosis and necrosis).  Neutrophil phagocytotic function was represented by the 
Phagocytosis Index which provided a quantitative measure of neutrophil phagocytotic 
function.  It was calculated as follows: 
Phagocytosis Index = (Percentage of pHrodo ‘bright’ cells  100) x Median Fluorescent Intensity 
5.4.6 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism Version 6 (La Jolla, California, USA). 
Categorical data was analysed using Fisher’s Exact tests for two variables or χ2 tests for 
greater than two variables.  Continuous data was analysed using non-parametric statistical 
models.  Mann-Whitney U tests were used for independent samples and Wilcoxon Signed 
Rank tests for related samples for two groups.  Freidmann’s tests were used for related 
samples for greater than two groups.  All statistical tests performed were two-tailed and 






Neutrophil function assay results on sequential peri-operative days are displayed in full in 
the Appendix (Appendix 7). 
5.5.1 Population Characteristics 
55 patients were identified at the MDT meeting and approached for inclusion into the study.  
45/55 patients (81.8%) were successfully recruited into the study and were followed up for a 
median of 21.3 months (IQR 16.7-23.5 months).   Consent was refused from the remaining 
10/55 patients (18.2%).  44/45 patients (97.8%) underwent surgical resection.  1/45 patient 
(2.2%) was deemed unfit for surgery on the day of surgery and did not progress to surgical 
resection.  The baseline population characteristics, operative characteristics and patient 













5.5.2 Neutrophil Extracellular Trap Formation 
Quantification of NET formation was conducted on Day-0 (n=45), Day-1 (n=44) and Day-3 
(n=22) in an attempt to characterise NET production over the peri-operative period.  In an 
attempt to account for the variation in number of circulating neutrophils between 
individuals the ANPP was also determined.   NET production and ANPP on sequential peri-
operative days is represented graphically in Figure 5.1 and Figure 5.2 respectively.  The fold 
change, for both NET production and ANPP, from Day-0 to Day-1 and from Day-1 to Day-3 





























Figure 5.1 NET Production in patients with Colorectal Cancer on Sequential Peri-
operative Days 
Box and Whisker Plot (10-90 percentile) of NET Production in patients with Colorectal Cancer on sequential 
peri-operative days in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP (A).  Statistical significance, 
measured by Friedman test, is denoted by * (p<0.05), ** (p<0.01) and *** (p<0.001).  NET Production in 
patients with Colorectal Cancer on sequential peri-operative days in response to fMLP (B).  Statistical 

















Statistically significant differences were identified in NET formation over the peri-operative 
period in response to No stimulant, IL-8, LPS and fMLP as determined by the Friedman test. 
Statistically significant reductions in NET formation from Day-0 to Day-1 were identified in 
response to No stimulant (11,347AFU vs. 8,654AFU, p=0.0006), IL-8 (11,925AFU vs. 
9,388AFU, p=0.0003), LPS (12,473AFU vs. 9,582AFU, p=0.0001) and fMLP (12,194AFU vs. 
8,680AFU, p<0.0001) as calculated by the Wilcoxon Signed Rank test.  Although 









Figure 5.2 Absolute NET Production Potential in patients with Colorectal Cancer on 
Sequential Peri-operative Days.   
Box and Whisker Plot (10-90 percentile) of Absolute NET Production Potential in patients with Colorectal 
Cancer on sequential peri-operative days in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  
















Statistically significant differences were identified in ANPP over the peri-operative period in 
response to No stimulant, PMA, IL-8, LPS and fMLP as determined by the Friedman test.  A 
significant difference in absolute neutrophil count was also observed over the peri-
operative period (p < 0.0001). 
Statistically significant increases in ANPP from Day-0 to Day-1 were identified in response to 
No stimulant (5.29 vs. 7.47, p=0.0028), PMA (16.53 vs. 33.32, p<0.0001), IL-8 (5.33 vs. 7.45, 
p=0.0002), LPS (5.98 vs. 7.87, p=0.0012) and fMLP (5.19 vs. 7.75, p=0.0005) and significant 
reductions in ANPP from Day-1 to Day-3 were detected to No stimulant (7.47 vs. 6.56, 
p=0.0113), PMA (33.32 vs. 22.35, p=0.0002), LPS (7.87 vs. 6.67, p=0.0178) and fMLP (7.75 vs. 





















Fold Change (AU)  
NET Production, median (IQR) 
Fold Change (AU) 







0.756 (0.515 – 1.180) 
0.898 (0.763 – 1.371) 
0.769 (0.575 – 1.030) 
0.730 (0.514 – 0.907) 
0.740 (0.624 – 0.879) 
1.368 (0.948 – 2.209) 
2.021 (1.452 – 2.872) 
1.543 (1.029 – 2.316) 
1.476 (0.904 – 2.355) 
1.488 (1.037 – 2.152) 
 
Figure 5.3 Fold Change in NET Production (A) and Absolute NET Production Potential 
(B) from Day-0 to Day-1 following Colorectal Cancer Resection 
Box and Whisker Plot (10-90 percentile) and tabulated results of Fold Change (AU) from Day-0 to Day-1 
following Colorectal Cancer Resection in NET Production (A) and Absolute NET Production Potential (B).  
 
From Day-0 to Day-1 there was a reduction in NET production as denoted by a fold change 
<1.  As previously stated, the reductions in NET production were statistically significant in 
response to No stimulant (p=0.0006), IL-8 (p=0.0003), LPS (p=0.0001) and fMLP (p<0.0001) 
as calculated by the Wilcoxon Signed Rank test.  
From Day-0 to Day-1 there was an increase in ANPP as indicated by a fold change > 1.  The 
increases in ANPP were statistically significant in response to No stimulant (p=0.0028), PMA 
(p<0.0001), IL-8 (p=0.0002), LPS (p=0.0012) and fMLP (p=0.0005) as determined by the 








Fold Change (AU) 
NET Production, median (IQR) 
Fold Change (AU) 







1.175 (0.855 – 1.429) 
0.927 (0.656 – 1.280) 
1.170 (0.820 – 1.430) 
1.171 (0.728 – 1.527) 
1.148 (0.832 – 1.437) 
0.719 (0.621 – 1.053) 
0.654 (0.453 – 0.863) 
0.753 (0.573 – 1.083) 
0.655 (0.536 -1.025) 
0.755 (0.532 – 1.055) 
 
Figure 5.4 Fold Change in NET Production (A) and Absolute NET Production Potential 
(B) from Day-1 to Day-3 following Colorectal Cancer Resection 
Box and Whisker Plot (10-90 percentile) and tabulated results of Fold Change (AU) from Day-1 to Day-3 
following Colorectal Cancer Resection in NET Production (A) and Absolute NET Production Potential (B).  
 
From Day-1 to Day-3 there was an increase in NET production as denoted by a fold change 
>1.  Although demonstrable increases in NET production were seen from Day-1 to Day-3, 
these were not statistically significant. 
From Day-1 to Day-3 there was a reduction in ANPP as indicated by a fold change < 1.  





(p=0.0113), PMA (p=0.0002), LPS (p=0.0178) and fMLP (p=0.0064) as calculated by the 




















5.5.3  Neutrophil Apoptosis 
Neutrophil apoptosis was performed at 4-hours incubation on Day-0 (n=43), Day-1 (n=40) 
and Day-3 (n=22) and at 24-hours incubation on Day-0 (n=36), Day-1 (n=33) and Day-3 
(n=12) in an attempt to characterise neutrophil apoptosis over the peri-operative period.  
The stage of apoptosis on sequential peri-operative days, at 4-hours and at 24-hours, is 
represented graphically in Figure 5.5 and Figure 5.6 respectively.  The fold change, for 
apoptosis at 4-hours and 24-hours, from Day-0 to Day-1 and from Day-1 to Day-3 was 









Figure 5.5 Stage of Apoptosis at 4-hours in patients with Colorectal Cancer on 
sequential peri-operative days 
Bar graph depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 4-hours incubation in patients with Colorectal Cancer on 
sequential peri-operative days.  Statistical significance, measured by Friedman test, is denoted by * (p<0.05), 























No statistically significant differences were identified in the stages of apoptosis at 4-hours 
on sequential peri-operative days as determined by the Friedman test. No statistically 
significant differences were detected in the stages of apoptosis at 4-hours from Day-0 to 
Day-1.  From Day-1 to Day-3, however, there was a significant reduction in alive neutrophils 









Figure 5.6 Stage of Apoptosis at 24-hours in patients with Colorectal Cancer on 
sequential peri-operative days 
Bar graph depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 24-hours incubation in patients with Colorectal Cancer on 
sequential peri-operative days.  Statistical significance, measured by Friedman test, is denoted by * (p<0.05), 
** (p<0.01) and *** (p<0.001). 
 
Statistically significant differences were identified in alive, early apoptotic and late apoptotic 























Statistically significant differences were identified from Day-0 to Day-1 in alive (14.05% vs. 
36.90%, p<0.0001), early apoptotic (71.85% vs. 51.80%, p<0.0001), late apoptotic (9.30% vs. 
4.92%, p=0.0130) and necrotic (0.30% vs. 0.60%, p=0.0147) stages indicating impaired 
apoptosis as calculated by the Wilcoxon Signed Rank test.     
From Day-1 to Day-3 significant differences in alive (36.9% vs. 18.10%, p=0.0093) and early 
apoptotic (51.80% vs. 76.79%, p=0.0210) stages indicating favoured (or restored) apoptosis 















Fold Change (AU) 
4-hour Apoptosis, median (IQR) 
Fold Change (AU) 





1.005 (0.935 – 1.090) 
0.944 (0.643 – 1.252) 
1.082 (0.657 – 1.556) 
0.942 (0.647 – 1.780) 
2.265 (1.500 – 3.798) 
0.761 (0.642 – 0.911) 
0.456 (0.336 – 1.010) 
1.667 (0.808 – 4.333) 
 
Figure 5.7 Fold Change in Stage of Apoptosis at 4-hours (A) and 24-hours (B) from Day-
0 to Day-1 following Colorectal Cancer Resection 
Box and Whisker Plot (10-90 percentile) and tabulated results of Fold Change (AU) from Day-0 to Day-1 
following Colorectal Cancer Resection in Stage of Apoptosis at 4-hours (A) and 24-hours incubation (B).  
 
From Day-0 to Day-1, at 24-hours, fold changes are consistent with cell survival and a 









Fold Change (AU) 
4-hour Apoptosis, median (IQR) 
Fold Change (AU) 





0.942 (0.875 – 1.002) 
1.199 (0.926 – 1.584) 
1.329 (0.795 – 1.856) 
1.101 (0.402 – 2.408) 
0.548 (0.322 – 0.945) 
1.261 (0.984 – 2.010) 
0.961 (0.388 – 1.496) 
0.981 (0.265 – 1.500) 
 
Figure 5.8 Fold Change in Stage of Apoptosis at 4-hours (A) and 24-hours (B) from Day-
1 to Day-3 following Colorectal Cancer Resection 
Box and Whisker Plot (10-90 percentile) and tabulated results of Fold Change (AU) from Day-1 to Day-3 
following Colorectal Cancer Resection in Stage of Apoptosis at 4-hours (A) and 24-hours incubation (B).  
 
From Day-1 to Day-3, at 24-hours, fold changes are consistent with cell death and a 









5.5.4  Neutrophil Phagocytosis 
Neutrophil phagocytosis was performed on Day-0 (n=27), Day-1 (n=25) and Day-3 (n=9), in 
response to E.Coli and S.Aureus in an attempt to characterise neutrophil phagocytosis over 
the peri-operative period.  The assay was performed at three time points (30 minutes, 45 
minutes and 60 minutes) and the Phogocytosis Index was calculated for each time point.  
The Phagocytosis Index was represented as AUC which enabled comparisons to be made 


























Figure 5.9 Neutrophil Phagocytosis Index in response to E.Coli (A) and S.Aureus (B) in 
patients with Colorectal Cancer on Sequential Peri-operative days depicted 
by Area Under the Curve (AUC)  
Box and Whisker Plot (10-90 percentile) of Phagocytosis Index represented by Area Under Curve (AU) in 
response to E.Coli (A) and S.Aureus (B) on sequential peri-operative days. Statistical significance, measured by 








































Demonstrable increases in neutrophil phagocytotic activity were revealed on sequential 
peri-operative days, over the peri-operative period, but statistical significance was not 
attained in response to E.Coli (p=0.1828) and S.Aureus (p=0.2313).  From Day-1 to Day-3, 
significant increases in the phagocytotic index were identified in response to E.Coli 
(p=0.0078) but not in response to S.Aureus (p=0.2031). 
A cumulative increase in phagocytotic activity was identified from Day-0 to Day-3 in 
response to both E.Coli and S.Aureus.  The positive fold changes from Day-0 to Day-3 are 























Fold Change (AU) 
E.Coli, median (IQR) 
Fold Change (AU) 




1.742 (1.163 – 4.214) 
1.439 (1.012 – 3.195) 
1.196 (1.086 – 2.771) 
1.257 (0.911 – 1.496) 
1.165 (1.042 – 1.474) 
1.302 (1.130 – 1.772) 
 
Figure 5.10 Fold Change in Neutrophil Phagocytosis Index in response to E.Coli (A) and 
S.Aureus (B) from Day-0 to Day-3 following Colorectal Cancer 
Box and Whisker Plot (10-90 percentile) and tabulated results of Fold Change (AU) from Day-0 to Day-3 













5.5.5 Changes in Peri-operative NET Production Defined by Operative 
Characteristics and Patient Outcomes 
An evaluation of post-operative NET formation, on Day-1 and Day-3, defined by operative 
technique (laparoscopic vs. open) and operation type (rectal resection vs. segmental 
resection), was performed.   To account for the variation in number of circulating 
neutrophils between individuals the ANPP was also determined.   
Post-operative NET production was also analysed with regard to patient outcomes which 
included; post-operative complications (Clavien-Dindo <3 vs. Clavien-Dindo ≥3), total 
hospital length of stay (LOS ≤ 5 days vs. LOS > 5 days) and mortality (Survived vs. Died) after 
a median follow-up of 21.3 months (IQR 16.7-23.5 months).  ANPP was also calculated and 
analysed. 
NET production and ANPP on Day-1 defined by operative characteristics and patient 















Table 5.1 NET Production on Day-1 following Colorectal Cancer Resection Categorised 














Median values presented.  Statistical significance is measured by Mann Whitney U test. 
 
 

























































CD < 3 
(n=38) 

























LOS < 5 days 
(n=15) 




















































Table 5.2 Absolute NET Production Potential on Day-1 following Colorectal Cancer 






















Median values presented.  Statistical significance is measured by Mann Whitney U test. 
 
 

























































CD < 3 
(n=38) 

























LOS < 5 days 
(n=15) 




















































The post-operative NET production and ANPP were evaluated on post-operative Day-1 and 
Day-3 categorised by operative technique and operation type and patient outcomes.  On 
Day-1, significant differences were identified only in the analysis of total hospital length of 
stay (LOS ≤ 5 days vs. LOS > 5 days).  It was found that NET production was significantly 
increased in response to PMA (p=0.0381) and that ANPP was significantly elevated in 
response to PMA (p=0.0136) and fMLP (p=0.0406) in patients with LOS > 5 days.  No 
significant differences were identified in post-operative NET production or ANPP on Day-3. 
When appraising the peri-operative changes in NET production and ANPP it was evident that 
the greatest differences in NET production and ANPP occurred from Day-0 to Day-1.  
Consequently, fold changes were calculated to determine if ‘the change’ in NET production 
or ANPP, when categorised according to operative characteristics and patient outcomes, 
was significant.  The fold changes in NET production and ANPP, from Day-0 to Day-1 are 












Table 5.3 Fold Change in NET Production from Day-0 to Day-1 in Patients with 























Median values presented.  Statistical significance is measured by Mann Whitney U test. 
 
 
Fold Change in NET Production (AU) 
























































CD < 3 
(n=38) 

























LOS < 5 days 
(n=15) 




















































Table 5.4 Fold Change in Absolute NET Production Potential from Day-0 to Day-1 in 
Patients with Colorectal Cancer Categorised by Operative Characteristics 













Median values presented.  Statistical significance is measured by Mann Whitney U test. 
 
Fold Change in Absolute NET Production Potential (AU) 
























































CD < 3 
(n=38) 

























LOS < 5 days 
(n=15) 




















































The fold change in NET production was noted to be significantly reduced in patients who 
died compared to patients who survived, but only in response to fMLP.  No other significant 
differences were identified when investigating operative characteristics and patient 
outcomes. 
The fold change in ANPP was significantly increased in patients undergoing rectal resection 
compared to segmental resection in response to No stimulant, PMA, IL-8, LPS and fMLP.  
Similarly, the fold change was increased in patients undergoing open compared to 
laparoscopic resection, but only achieved statistical significance in response to PMA.  
Regarding patient outcomes, the fold change in ANPP from Day-0 to Day-1 was significantly 














The experiments undertaken in this chapter help to provide a greater understanding of the 
serial changes in neutrophil function over the peri-operative period in patients undergoing 
major resectional surgery for colorectal cancer.  The findings suggest that a novel neutrophil 
phenotype may exist in patients undergoing colorectal resection for cancer. 
Firstly, a significant reduction in NET formation from Day-0 to Day-1 was detected.  This 
observed NET reduction, as a consequence of the surgical insult, may indicate neutrophil 
activation as the findings are supported by in-vitro experiments which studied the 
neutrophil functional changes in patients with sepsis and severe sepsis [294].  When taking 
into account the number of absolute circulating neutrophils, despite an observed reduction 
in NET formation from Day-0 to Day-1, a significant increase in the ANPP was identified from 
Day-0 to Day-1.  This calculation attempts to quantify the ‘potential’ NET formation in an 
individual which is inferred from the laboratory experiments.  It is an interesting concept 
which attempts to provided a measure of the quanity of circulating NETs in-vivo.  This might 
imply that the number of circulating neutrophils are also important when determining 
patient outcomes and this may also explain why the NLR has been used successfully to 
predict overall and cancer specific survival in numerous solid organ malignancies [99].   
Secondly, significant changes indicating delayed apoptosis (increase in alive and reduction in 
apoptotic neutrophils) were detected from Day-0 to Day-1 and significant changes favouring 
apoptosis (reduction in alive and increase in apoptotic neutrophils) were identified from 
Day-1 to Day-3 at 24-hours incubation.  Evidence supports reduced apoptosis of neutrophils 
in inflammation, which is thought to be caused by the activation of nuclear factor-kappa B 




associated with poor patient outcomes [295, 296].  Therefore, delayed apoptosis from Day-0 
to Day-1 is indicative of pro-inflammation and favoured apoptosis from Day-1 to Day-3 is 
suggestive of anti-inflammation.  In this study it was not possible to identify any statistically 
significant results when analysing the stages of neutrophil apoptosis with adverse patient 
outcomes, however, it is hypothesised that neutrophils that exhibit a phenotype 
characterising a prolonged delayed apoptosis may be associated with adverse outcomes as 
it is essential that neutrophils are ‘switched off’, undergo apoptosis and are successfully 
cleared to minimise host damage and a state of chronic inflammation [295]. 
Thirdly, demonstrable increases in neutrophil phagocytotic activity were revealed on 
sequential peri-operative days, over the peri-operative period, but statistical significance 
was not achieved.  Significant increases in phagocytotic index from Day-1 to Day-3 were 
observed to E.Coli which suggests an increase in phagocytotic activity up to the third post-
operative day in response to stimulation with E.Coli.   
It is increasingly recognised that circulating neutrophils are heterogenous comprising of cell 
populations that might favour inflammation or the resolution of inflammation. The 
polarisation of neutrophils towards a pro-inflammatory or anti-inflammatory phenotype, as 
a consequence of the response to the surgical insult, may determine short-term patient 
outcomes and longer-term oncological outcomes.  Neutrophil phenotypic plasticity might 
therefore help to explain the findings that a pre-operative SIR has been shown to be 
independently associated with the risk of developing infective post-operative complications 
in patients undergoing curative colorectal cancer resection [39] and it is well established as 




51-54] and that following colorectal cancer resection post-operative septic complications 
increase the risk of disease recurrence [37, 38]. 
The experimental findings suggest that neutrophils adopt a distinctive phenotype, 
characterised by a reduction in NET formation, inhibition of the apoptosis and increase in 
phagocytosis in response to E.Coli, as a consequence of the surgical insult.  The resultant 
accumulation of activated neutrophils in the circulation following surgery may cause more 
extensive collateral tissue damage and potential organ dysfunction.  The increase in NET 
formation (and reduction in the ANPP) and the restoration of apoptosis in the late post-
operative phase (Day-3) coincides with apparent surgical recovery and therefore an early 
phenotypic switch (from dysregulated to normal neutrophil function) may be desirable.  The 
experimental findings outlined in this study are supported by a specific neutrophil 
phenotype described in the context of inflammation associated with sepsis which 
demonstrates a failure of migration, a propensity to generate ROS with preserved 
phagocytic capacity while suppressing NET formation and suspending apoptosis [294].   
In this chapter it was also investigated whether differences in peri-operative NET production 
were apparent when classifed by operative technique and operation type and when 
classified by post-operative complication, total length of hosital stay and mortality.  No 
significant differences in peri-operative NET production were identified in the analysis of 
operative technique or operation type.  Significant increases in NET production were, 
however, associated with an increased hospital stay and prolonged hospital recovery in 
response to PMA.  No differences were identified in patients who experienced significant 
post-operative complications or died during the study follow-up.  It was also demonstrated 




response to PMA and fMLP which may allude to a potential prognostic role of this novel 
measure.   The fold changes in NET production and ANPP from Day-0 to Day-1 were also 
evaluated.  A significant reduction in the change in NET production and ANPP was observed 
in patients who died in response to fMLP.  This might imply that a reduced fold change in 
NET production as a consequence of surgery may have a role in prognostication and 
mortality prediction.  The evidence indicates that further investigation into the prognostic 
value of NET production is justified and the change in NET production over the peri-
operative may be a promising area to study in relation to patient outcomes. 
This experimental study has a number of limitations.  Firstly, the population evaluated was 
small and heterogeneous with regard to patient demographics, patient co-morbidities, 
tumour characteristics and operative characteristics making interpretation of the results 
difficult and limiting the generalisability of the study findings.  Secondly, in-vitro 
experiments performed to assess neutrophil function were conducted outside of the 
biological context and consequently there are challenges in extrapolating the results and it 
must be acknowledged that they cannot be readily transposed to, and predict the reaction 
of, the entire organism in-vivo.  Thirdly, comparative analyses stratifying patients according 
to cancer location, cancer stage, operative technique, operation type and patient outcomes 
is subject to misinterpretation as potential confounding variables were not accounted for.  
Fourthly, evidence suggests that anaesthetic choice is important in peri-operative 
immunosuppression and has been linked to cancer recurrence and survival.  Total 
intravenous anaesthetics appear to reduce surgical stress, peri-operative 
immunosuppression and angiogenesis compared with volatile inhalational anaesthetics 




remains to be elucidated.  The type of anaesthetic and the possible impact of different 
anaesthetic agents were not investigated in this study.  Lastly, the number of adverse 
patient outcomes in the study population was low making interpretation of patient 
outcomes challenging.   
The benefit of studying a surgical population, compared to patients with other inflammatory 
conditions, for example in patients with sepsis, is that the true impact of a provoked SIR can 
be identified as pre-operative and post-operative evaluation is undertaken.  It is also 
appreciated that the surgical insult is relatively consistent between individuals, particularly 
















A novel neutrophil phenotype has been described in patients undergoing resectional 
surgery for colorectal cancer which demonstrates reduced NET formation, delayed 
apoptosis and increased phagocytosis in response to E.Coli.   
As a consequence of impaired cell death, either by disrupted apoptosis or impaired NETosis, 
an accumulation of activated neutrophils in the circulation could be potentially harmful to 
the host following surgery.  The restoration of the apoptosis and NET production in the later 
post-operative period appears to coincide with surgical recovery and therefore an early 
phenotypic switch (from dysregulated to normal neutrophil function) may be desirable.  
Clinical and experimental evidence suggests that activated neutrophils may facilitate 
metastatic progression and therefore therapeutic strategies aimed at modifying tumour-






























6.1 Introduction  
Cancer surgery elicits a high-grade, non-specific systemic inflammatory response (SIR).  This 
overwhelming, systemic inflammation suppresses systemic cell-mediated immunity and 
consequently compromises the tumour immunity in the host [58, 59].  This has been 
described as the ‘immune-hit’ [58].  The immune-hit can be exacerbated by pre-operative 
SIR, for example, an emergency presentation with colonic obstruction, bleeding or 
perforation, confers a higher risk of disease recurrence independent of the stage of disease 
[40].  Additionally, the development of post-operative complications and the associated 
post-operative SIR increases the risk of disease recurrence [38] and is associated with poor 
oncological outcomes and increased mortality secondary to metastatic disease [187-191].  
Peri-operative immune-modulatory therapies aim to suppress non-specific systemic 
inflammation and maintain an effective anti-tumour, cell-mediated immunity of the host 
which may assist the clearance of circulating tumour cells and the development of occult 
metastases [58].  Accumulating evidence suggests that simple immune-modulatory 
strategies (anti-inflammatories [non-steroidal anti-inflammatory drugs] or immune-
modulatory therapies [corticosteroids, HMG-CoA reductase inhibitors (statins)]) could be 
safely implemented in the peri-operative period, although concerns surrounding their side 
effect profile exist [60].   
Statins have been extensively studied and have proven efficacy in the primary and 
secondary prevention of cardiovascular morbidity and mortality in a variety of populations 
[212-217].  Their main mechanism of action is competitive inhibition of hepatic 3-hydroxy-3-
methylglutaryl coenzyme A reductase leading to a reduction in endogenous cholesterol 




cardiovascular disease [15, 16].  The cholesterol independent effects of statins are known as 
pleiotropic effects and they have been shown to modulate the innate and adaptive immune 
systems and have anti-inflammatory effects which counteract the detrimental effects of 
inflammation [223, 225].   
In the context of colorectal surgery, statin use is associated with a significantly lower 
incidence of SIR and a lower incidence of surgical site infection (SSI) [248].  There appears to 
be no difference in overall mortality, total complications or median hospital length of stay 
between statin users and non-statin users undergoing major colorectal resection [246, 21], 
despite statin users having a greater baseline peri-operative risk compared to non-statin 
users, and it has been proposed that peri-operative statin therapy may reduce morbidity 
after colorectal resection [248, 250].   
There is increasing evidence that statins are able to modulate neutrophil function.  In sepsis 
it has been demonstrated that statins reduce the neutrophil infiltrate following 
lipopolysaccharide (LPS) challenge in bronchoalveolar lavage fluid taken from patients 
receiving simvastatin [297].  In addition, the reduction in neutrophil counts was not 
associated with a decrease in pro-inflammatory mediator expression, which suggests a 
reduced neutrophil response or increased neutrophil apoptosis [297].  Statins have also 
been shown to increase NET formation in healthy individuals with the consequent 
elimination of bacteria in-vitro [298].  Furthermore, during bacterial pneumonia associated 
sepsis, NET production is suppressed with improvements occurring during sepsis resolution 
[299].  It has been proposed that neutrophil functional defects may be restored by the 




This is particularly relevant in the context of cancer surgery as neutrophils are appreciated 
to have an important role in cancer progression and dissemination [158].  Neutrophils play a 
vital role in circulating tumour cell metastases.  This has been shown in-vitro and in-vivo 
where neutrophils facilitate circulating tumour cell adhesion to both pulmonary and hepatic 
endothelial surfaces [174, 176, 179-181].  The direct contact of circulating tumour cells and 
neutrophils is an important precursor to the development of metastatic disease [179, 180].  
Following dissemination, tumour cells must be able to proliferate to form stable metastatic 
foci.  NETs have been implicated in a direct proliferative role and have also been 
demonstrated to inhibit tumour cell apoptosis [158].  The ability of tumours to predispose 
neutrophils to produce NETs has been demonstrated and various tumour types have 
predisposed circulating neutrophils to produce NETs [178].   
The evidence supports the theory that primary tumours can facilitate NET production in 
circulating neutrophils and we propose that neutrophil functional defects in cancer may be 
modulated by statin therapy.  It is anticipated that in-vitro treatment with statin will 
attenuate the neutrophil functional changes observed in patients with a diagnosis of 
colorectal cancer and modulate the neutrophil functional changes exhibited as a 
consequence of the surgical insult.  This may help to explain the observed benefits 









It was hypothesised that HMG-CoA reductase inhibitors would attenuate the neutrophil 
functional changes exhibited in response to the surgical insult, demonstrating: 
1. Increased NET formation 
2. Increased apoptosis 

















The objectives of this chapter were: 
1. To evaluate the effect of HMG-CoA Reductase Inhibitors on neutrophil function, in-
vivo, over the peri-operative period with specific reference to:  
i. NET formation 
ii. Neutrophil apoptosis 
iii. Neutrophil phagocytosis 
2. To investigate the effect of in-vitro treatment with 1μM Simvastatin on NET 
















Dr. Hongxia Mei (International Research Fellow from the Hospital of Wenzouh Medical 
University, China) assisted with the Neutrophil Phagocytosis experiments.  The short life-
span of neutrophils meant that neutrophil functional experiments were conducted 
simultaneously and it was impossible for all experiments to be performed by one individual 
in entirety. 
6.4.2 Recruitment of Patients 
Patients undergoing an elective colorectal resection for cancer, within an established 
enhanced recovery programme, who satisfied the specific inclusion and exclusion criteria, 
were recruited to the study as outlined in Section 3.1.1. 
Patient Demographics, Patient Co-morbidities, Pre-operative Risk Prediction, Tumour 
Characteristics and Operative Characteristics were recorded from study participants as 
outlined in Table 3.1.  
Patient outcomes were collected prospectively and included: 
1. Post-operative complications up to 30 days after surgery using pre-defined criteria 
and graded by the Clavien-Dindo classification system (Appendix 3). 
2. Return to theatre within 28 days of the index procedure. 
3. Admission to and length of stay on the Intensive Care Unit. 




5. Readmissions to hospital within 30 days of the index procedure requiring a hospital 
stay ≥ 24 hours. 
6. 30 day and 90 day mortality. 
Functional and quality of life was assessed using the Surgical Recovery Scale (Appendix 4).   
Haematological and biochemical parameters were collected prospectively from the hospital 
pathology system.  These parameters, in conjunction with physiological indices, were used 
to determine a CR-POSSUM (Appendix 5), a NLR, and an mGPS (Table 1.6) for each patient. 
6.4.3 Sample Collection 
Patients underwent peripheral blood tests pre-operatively (Day-0) and post-operatively 
(Day-1 and Day-3) to assess neutrophil function at these specific time points.  Blood tests 
were performed by an experienced medical practitioner by peripheral venepuncture or from 
a peripheral arterial cannula.  A total of 24mls of blood was taken from each patient at each 
time point and deposited into 4x6ml lithium-heparin vacutainers (Becton-Dickinson, Oxford, 
UK).  The samples were then placed on ice and transported to the laboratory for processing. 
6.4.4 Neutrophil Isolation 
Processing began with 45 minutes of obtaining the blood sample.  Neutrophils were isolated 
by following the method outlined in Section 3.2.  A purity of ≥95% and a viability of ≥97% 
were routinely achieved. 
6.4.5 Neutrophil Functional Assays 
Quantification of Neutrophil Extracellular Trap Formation was conducted following the 




To account for the variation in number of circulating neutrophils between individuals the 
Absolute NET Production Potential (ANPP) was determined.  It was calculated as follows: 
ANPP (AFU / no. of neutrophils x105 / L) = NETs per 100,000 neutrophils (AFU) x Absolute 
Neutrophil Count (x109 / L)  10,000 
Neutrophil Apoptosis and Neutrophil Phagocytosis were assessed using commercially 
available assays which were carried out as per the manufacturer’s instructions as outlined in 
Sections 3.3.2 and 3.3.3 respectively.  Neutrophil Apoptosis was represented as the 
percentage of neutrophils in the different stages of apoptosis (alive, early apoptosis, late 
apoptosis and necrosis).  Neutrophil phagocytotic function was represented by the 
Phagocytosis Index which provided a quantitative measure of neutrophil phagocytotic 
function.  It was calculated as follows: 
Phagocytosis Index = (Percentage of pHrodo ‘bright’ cells  100) x Median Fluorescent Intensity 
6.4.6 In-vitro Investigation with HMG-CoA Reductase Inhibitors 
The HMG-CoA reductase inhibitor used in the in-vitro experiments was simvastatin (Sigma-
Aldrich).  The dose used to investigate the in-vitro effects of simvastatin was 1μM.  The 
rationale for the dose selection is outlined in Section 3.1.1.  The solvent Dimethyl Sulfoxide 
(DMSO; Sigma-Aldrich) is the vehicle control for simvastatin. The rationale for its selection is 
outlined in Section 3.1.2. 
Quantification of Neutrophil Extracellular Trap Formation (3.3.1) and  Neutrophil Apoptosis 
(3.3.2) assays were repeated after isolated neutrophils, suspended in RPMI-1640 (Sigma-
Aldrich) at a concentration of 1x106/ml, were incubated with 1μM simvastatin (Sigma-




6.4.7 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism Version 6 (La Jolla, California, USA). 
Categorical data was analysed using Fisher’s Exact tests for two variables or χ2 tests for 
greater than two variables.  Continuous data was analysed using non-parametric statistical 
models.  Mann-Whitney U tests were used for independent samples and Wilcoxon Signed 
Rank tests for related samples for two groups.    All statistical tests performed were two-
















6.5.1  Population Characteristics According to Statin Use 
55 patients were identified at the MDT meeting and approached for inclusion into the study.  
45/55 patients (81.8%) were successfully recruited into the study and were followed up for a 
median of 21.3 months (IQR 16.7-23.5 months).   Consent was refused from the remaining 
10/55 patients (18.2%).  44/45 patients (97.8%) underwent surgical resection.  1/45 patient 
(2.2%) was deemed unfit for surgery on the day of surgery and never progressed to surgical 
resection.  The baseline population characteristics, operative characteristics and patient 
outcomes are displayed in Table 4.1, Table 4.2 and Table 4.3 respectively. 
The patients were analysed according to statin use; patients receiving peri-operative statin 
(statin users) and patients not receiving peri-operative statin (non-statin users).  Statin users 
were defined as, ‘patients who were prescribed and had taken a statin ≤ 5 days before the 
index procedure and who were prescribed and received a statin ≤ 5 days after the index 
procedure’.  All statins currently available for use in the UK were included (atorvastatin, 
fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin). 
20/45 patients (44.4%) were statin users as determined by the criteria above.   The majority 
of statin users were on simvastatin (70.0% [14/20]) and the remainder were on atorvastatin 
(25.0% [5/20]) and pravastatin (5.0% [1/20]).  The majority of patients were on moderate-
dose statin (80.0% [16/20]) and the remainder were on low-dose (20.0% [4/20]).  No Statin 
Users were prescribed high-dose statins. The median number of statin doses omitted during 





Statin Users and Non-statin Users were similar in their population characteristics, but as 
expected Statin Users were significantly more co-morbid. 
The population characteristics according to statin use are summarised in Table 6.1. 
 
Table 6.1 Population Characteristics According to Statin Use 





Age, median (IQR) 
Gender, n (%), M/F 
BMI, median (IQR), kg/m
2
 
Smoking Status, n (%), 1/2/3
a 
 
ASA, n (%), 1/2/3/4 
 




CR-POSSUM, %, median (IQR) 
mGPS, n (%), 0/1/2 
 
NLR, median (IQR) 
SRS (Pre-operative [%]), median (IQR) 
68.0 (62.5-73.0) 
14 / 7 (70.0 / 30.0) 
24.1 (22.2-27.7) 
7 / 4 / 9 
(35.0 / 20.0 / 45.0) 
1 / 12 / 6 / 1 
(5.0 / 60.0 / 30.0 / 5.0) 
0 / 11 / 8 / 1 
(0.0 / 55.0 / 40.0 / 5.0) 
9 / 4 /8 / 4 
2.14 (1.33-4.78) 
16 / 1 / 3  
(80.0 / 5.0 / 15.0) 
3.52 (2.78-5.72) 
72.6 (71.2 – 83.6) 
71.0 (63.5–76.0) 
12 / 13 (48.0 / 52.0) 
27.7 (23.1-30.2) 
2 / 5 / 18 
(8.0 / 20.0 / 72.0) 
3 / 13 / 8 / 1 
(12.0 / 52.0 / 32.0 / 4.0) 
10 / 10 / 2 / 3 
(40.0 / 40.0 / 8.0 / 12.0) 
12 / 5 / 3 / 3 
2.58 (1.80-3.58) 
18 / 2 / 5 
(72.0 / 8.0 / 20.0) 
3.38 (2.68-3.96) 
















Presentation Statin User  
(N=20) 
Non-statin User  
(N=25) 
P-value 
Presentation, n (%), 1/2
c 
 
Cancer Location, n (%), 1/2
d
 
18 / 2 
(90.0 / 10.0) 
11 / 9 
(55.0 / 45.0) 
21 / 4  
(84.0 / 16.0) 
16 / 9 





y = yes,  1/2/3
a
 = active / former / never,  1/2/3/4
b
 = antihypertensive / β-antagonist / anti-platelet / oral 
hypoglycaemic ,  1/2
c
 = symptomatic / screened ,  1/2
d





Statin Users and Non-statin Users were well matched in their tumour and operative 
characteristic and no significant differences were identified. 
The tumour and operative characteristics according to statin use are displayed in Table 6.2. 
 
Table 6.2 Tumour and Operative Characteristics According to Statin Use 
Tumour Characteristics Statin User 
 (N=20) 
Non-statin User  
(N=24) 
P-Value 
Neo-adjuvant Therapy, n (%), y 
T-Stage, n (%), 0/1/2/3/4 
 
N-Stage, n (%), 0/1/2 
 
M-Stage, n (%), 0/1 
 
Dukes’ Stage, n(%), A/B/C/D 
 
Differentiation, n (%), 1/2
a 
 
EMVI, n(%), y 
5 (25.0) 
1 / 0 / 4 / 12 / 3 
(5.0 / 0.0 / 20.0 / 60.0 / 15.0) 
14 / 3 / 3 
(70.0 / 15.0 / 15.0) 
19 / 1 
(95.0 / 5.0) 
3 / 11 / 5 / 1 
(15.0 / 55.0 / 25.0 / 5.0) 
18 / 2 
(90.0 / 10.0) 
9 (45.0) 
6 (25.0) 
1  / 2 / 5 / 10 / 6 
(4.2 / 8.3 / 20.8 / 41.7 / 25.0) 
18 / 5 / 1 
(75.0 / 20.8 / 4.2) 
23 / 1 
(95.8 / 4.2) 
7 / 10 / 6 / 1 
(29.2 / 41.7 / 25.0 / 4.2) 
21 / 3 














Operative Characteristics Statin User 
 (N=20) 
Non-statin User  
(N=24) 
P-value 
Operation Type, n (%), 1/2
b 
 
Operation technique, n (%), 1/2
c 
 
Stoma Formation, n (%), y 
Length of Operation (minutes), 
median (IQR) 




10 / 10 
(50.0 / 50.0) 
13 / 7 




13 / 7 
(65.0 / 35.0) 
15 / 9 
(62.5 / 37.5) 
14 / 10 




14 / 10 










y = yes,  1/2
a
 = well and moderately differentiated / poorly differentiated,  1/2
b
 = segmental / rectal,  1/2
c
 = 
laparoscopic / open and laparoscopic converted to open,  1/2
d




Despite being a more co-morbid patient group, Statin Users were identified to have 
equivalent patient outcomes as outlined in Table 6.3. 
 
Table 6.3 Patient Outcomes According to Statin Use 





Complication, n (%), y 
Clavien-Dindo Classification, n (%), 
I/II/III/IV/V 
Re-operation, n (%) 
Critical Care Admission, n (%), y 
Total LOS, median (range, IQR) 
SRS (Post-operative [%]), median (IQR) 
Readmission, n (%), y 
Disease Recurrence, n (%) 







9 / 1 / 1 / 1 / 1 













3 / 3 / 1 / 1 / 1 




































6.5.2  Neutrophil Extracellular Trap Formation 
6.5.2.1  Neutrophil Extracellular Traps In-vivo 
Quantification of NET formation was conducted on Day-0 (n=45), Day-1 (n=44) and Day-3 
(n=22).   The population was stratified and analysed according to statin use in an attempt to 
identify differences in NET production between Satin Users and Non-statin Users in-vivo.  To 
account for the variation in number of circulating neutrophils between individuals the ANPP 
was also determined.    
NET production and ANPP, according to statin use, on Day-0, Day-1 and Day-3 are displayed 



















Table 6.4 NET Production, Absolute NET Production Potential and Absolute 



















11380 (10230 – 15340) 
42790 (31040 – 48100) 
13770 (8632 – 15750) 
13540 (11890 – 17590) 




10400 (7759 – 14780) 
35110 (28790 – 47170) 
11820 (9534 – 14190) 
11280 (8881 – 16100) 


























5.40 (4.16 – 9.01) 
19.33 (11.98 – 24.91) 
5.68 (4.01 – 9.11) 
6.06 (4.13 – 9.65) 






4.87 (2.62 – 8.13) 
15.62 (8.92 – 26.37) 
5.07 (2.86 – 9.14) 
5.36 (2.94 – 9.33) 












































Figure 6.1 NET Production (A) and Absolute NET Production Potential (B) in Statin 
Users and Non-statin Users on Day-0 
Box and Whisker Plots (10-90 percentile) of NET Production (A) and Absolute NET Production Potential (B) in 
Statin Users and Non-statin Users on Day-0 in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  



















Table 6.5 NET Production and Absolute NET Production Potential in Statin Users and 



















8883 (7167 – 10370) 
42250 (33760 – 54510) 
10120 (8000 – 11720) 
10420 (8154 – 13040) 




8622 (6236 – 10840) 
31880 (26300 – 41620) 
8236 (7391 – 10700) 
7622 (6507 – 12790) 


























7.88 (5.74 – 10.73) 
40.39 (28.09 – 56.69) 
9.77 (6.31 – 13.23) 
10.48 (6.43 – 12.51) 






6.83 (5.34 – 9.85) 
29.35 (19.32 – 40.95) 
7.29 (6.01 – 9.63) 
7.41 (6.03 – 10.17) 












































Figure 6.2 NET Production (A) and Absolute NET Production Potential (B) in Statin 
Users and Non-statin Users on Day-1 
Box and Whisker Plots (10-90 percentile) of NET Production (A) and Absolute NET Production Potential (B) in 
Statin Users and Non-statin Users on Day-1 in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  



















Table 6.6 NET Production and Absolute NET Production Potential in Statin Users and 
Non-statin Users on Day-3 
 



























9882 (7816 – 10570) 
33170 (27950 – 36750) 
10410 (9109 – 14140) 
10410 (9436 – 12810) 




10270 (7503 – 15850) 
34550 (30860 – 42540) 
10860 (8780 – 15380) 



























6.16 (5.21 – 8.33) 
24.52 (18.13 – 28.20) 
7.13 (5.43 – 1.75) 
8.11 (4.84 – 8.79) 






7.16 (4.02 – 9.47) 
21.24 (15.86 – 33.38) 
7.37 (4.48 – 10.12) 
6.18 (4.54 – 8.79) 































Figure 6.3 NET Production (A) and Absolute NET Production Potential (B) in Statin 
Users and Non-statin Users on Day-3 
Box and Whisker Plots (10-90 percentile) of NET Production (A) and Absolute NET Production Potential (B) in 
Statin Users and Non-statin Users on Day-3 in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  
Statistical significance, measured by Mann Whitney U test, is denoted by * (p<0.05), ** (p<0.01) and *** 
(p<0.001). 
 
No significant differences in NET production or ANPP were demonstrated between Statin 
Users and Non-statin Users on Day-0 or Day-3. 
On Day-1 significant increases in NET production and ANPP were identified in response to 
stimulation with PMA and fMLP in Statin Users when compared to Non-statin Users. 
No statistically significant differences were identified in absolute neutrophil counts on Day-








6.5.2.2  Neutrophil Extracellular Traps In-vitro 
Quantification of NET formation was performed with in-vitro statin treatment (1μM 
Simvastatin) or vehicle control (DMSO) on Day-0 (n=15) and Day-1 (n=14).  The population 
characteristics of the patients who underwent in-vitro experiments are summarised in Table 
6.7. 
Table 6.7 Population Characteristics of Patients who Underwent In-vitro Experiments 
with Statin Treatment 
Patient Demographics N=15 
Age, median (IQR) 72.0 (59.0-80.0) 
Gender, n (%), M/F 11 / 4 (73.3 / 26.7) 
BMI, median (IQR), kg/m
2
 24.5 (21.6-27.8) 
Smoking Status, n (%), 1/2/3
a 
3 / 3 / 9 (20.0 / 20.0 /60.0) 
ASA, n (%), 1/2/3/4 
Co-morbidity, n (%), 0/1/2/≥3 
Medications, n, 1/2/3/4
b 
Statin User, n (%), y 
CR-POSSUM, (%), median (IQR)  
Dukes’ Stage, n (%), A/B/C/D 
Operation Type, n (%), 1/2
c 
Operation technique, n (%), 1/2
d 
Clavien-Dindo Classification, n (%), I/II/III/IV/V 
Total LOS, median (range, IQR) 
Disease Recurrence, n (%) 




1 / 6 / 6 / 2  (6.7 / 40.0 / 40.0 / 13.3) 
4 / 5 / 3 / 3 (26.7 / 33.3 / 20.0 / 20.0) 
7 / 7 / 6 / 1 
5 (33.3) 
3.1 (1.3-4.95) 
4 / 7 / 7 / 0 (26.7 / 46.7 / 46.7 / 0.0 
9 / 6 (60.0 / 40.0) 
10 / 5 (66.6 / 33.3) 







y = yes,  1/2/3
a
 = active / former / never,  1/2/3/4
b
 = antihypertensive / β-antagonist / anti-platelet / oral 
hypoglycaemic,  1/2
c
 = segmental / rectal,  1/2
d





NET production in patents who underwent in-vitro treatment with statin treatment on Day-
0 and Day-1 are displayed in Table 6.8 and Figure 6.4 and Table 6.9 and Figure 6.5 
respectively. 
Table 6.8 NET Production with in-vitro treatment with Statin Treatment (1μM 
Simvastatin) or Vehicle Control (DMSO) on Day-0 
 


























12730 (8986 – 14680) 
35730 (29930 – 44080) 
14350 (11740 – 17210) 
12190 (10390 – 14110) 




14560 (10040 – 15910) 
41930 (36030 – 50640) 
15190 (9438 – 17620) 
15280 (11210 – 18640) 













Figure 6.4 NET Production with in-vitro Statin Treatment (1μM Simvastatin) vs. 
Vehicle Control (DMSO) on Day-0 
Box and Whisker Plot (10-90 percentile) of NET Production with in-vitro Statin Treatment (1μM Simvastatin) vs. 
Vehicle Control (DMSO) on Day-0 in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical 












Table 6.9 NET Production with in-vitro treatment with Statin Treatment (1μM 
Simvastatin) or Vehicle Control (DMSO) on Day-1 
 
Statistical significance, measured by Wilcoxon Signed Rank test. 
 
 
Figure 6.5 NET Production with in-vitro Statin Treatment (1μM Simvastatin) vs. 
Vehicle Control (DMSO) on Day-1 
Box and Whisker Plot (10-90 percentile) of NET Production with in-vitro Statin Treatment (1μM Simvastatin) vs. 
Vehicle Control (DMSO) on Day-1 in response to No stimulant (Unstim), PMA, IL-8, LPS and fMLP.  Statistical 




















8147 (6720 – 10300) 
36280 (30780 – 51210) 
8891 (6943 – 12330) 
9479 (7185 – 11360) 




10240 (8793 – 12010) 
48280 (39680 – 58840) 
11690 (10220 – 14580) 
12850 (9626 – 13660) 












The experiments revealed a reduction in NET production in patients treated with 1μM 
Simvastatin in-vitro at all time points.  This NET reduction was significant to No stimulant, 
PMA, LPS and fMLP on Day-0 and to all stimulants on Day-1. 
As outlined in Chapter 4, when neutrophils from a colorectal cancer population were primed 
with TNF-α, NET production was significantly increased in response to No stimulant 
(p=0.0021), IL-8 (p=0.0007), LPS (p=0.0233) and fMLP (p=0.0002) (Table 4.1). 
When neutrophils from a colorectal cancer population were treated with 1μM Simvastatin 
the converse is true with a significant reduction in NET production in response to No 
stimulant (p=0.0256), PMA (p=0.0015), LPS (p=0.0302) and fMLP (p=0.0029) (Table 6.8).  
This finding is also maintained in the post-operative period where a significant reduction in 
NET production was identified in response to all stimulants on Day-1 (Table 6.9). 
Figure 6.6 demonstrates a comparison of unprimed versus primed NET production and 
vehicle control versus statin treatment NET production in a colorectal cancer population on 








Figure 6.6 Unprimed vs. Primed NET Production and Vehicle Control vs. Statin 
Treatment NET Production on Day-0 in response to stimulation with fMLP 
Box and Whisker Plot (10-90 percentile) of Unprimed versus Primed (TNF-α) NET Production and in-vitro Statin 
Treatment (1μM Simvastatin) vs. Vehicle Control (DMSO) NET Production in a colorectal cancer population on 
Day-0 in response to stimulation with fMLP.  Statistical significance, measured by Wilcoxon Signed Rank test, is 















6.5.3  Neutrophil Apoptosis 
6.5.3.1  Neutrophil Apoptosis In-vivo 
Neutrophil apoptosis was performed at 4-hours incubation on Day-0 (n=43), Day-1 (n=40) 
and Day-3 (n=22) and at 24-hours incubation on Day-0 (n=36), Day-1 (n=33) and Day-3 
(n=12).  The population was stratified and analysed according to statin use in an attempt to 
identify differences in neutrophil apoptosis between Satin Users and Non-statin Users.  
Neutrophil apoptosis, according to statin use, on Day-0, Day-1 and Day-3 is displayed in 




















Table 6.10 Stage of Apoptosis at 4-hours and 24-hours in Statin Users and Non-statin 
Users on Day-0 
 








Figure 6.7 Stage of Apoptosis at 4-hours (A) and 24-hours (B) in Statin Users and Non-
statin Users on Day-0 
Bar graph depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 4-hours (A) and 24-hours (B) incubation in Statin Users and Non-
statin Users on Day-0.  Statistical significance, measured by Mann Whitney U test, is denoted by * (p<0.05), ** 
















76.90 (72.10 – 84.80) 
15.90 (8.10 – 25.10) 
3.40 (1.20 – 4.50) 
2.20 (0.90 – 2.70) 
 
 
77.0 (69.43 – 83.18) 
17.17 (12.30 – 27.68) 
3.10 (1.85 – 4.68) 






















13.50 (9.55 – 19.78) 
73.05 (54.93 – 83.45) 
9.90 (5.68 – 26.68) 
0.35 (0.18 – 0.55) 
 
 
15.30 (11.05 – 23.98) 
71.85 (57.00 – 78.40) 
8.80 (3.95 – 16.58) 































Table 6.11 Stage of Apoptosis at 4-hours and 24-hours in Statin Users and Non-statin 
Users on Day-1 
 








Figure 6.8 Stage of Apoptosis at 4-hours (A) and 24-hours (B) in Statin Users and Non-
statin Users on Day-1 
Bar graph depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 4-hours (A) and 24-hours (B) incubation in Statin Users and Non-
statin Users on Day-1.  Statistical significance, measured by Mann Whitney U test, is denoted by * (p<0.05), ** 
















80.20 (73.02 – 85.45) 
14.30 (5.80 – 19.83) 
3.25 (1.98 – 6.15) 
1.35 (1.03 – 2.80) 
 
 
78.70 (68.79 – 82.98) 
16.25 (11.80 – 23.02) 
3.00 (2.08 – 5.05) 






















35.40 (23.90 – 55.35) 
47.58 (37.31 – 69.32) 
4.20 (1.86 – 13.43) 




38.0 (21.65 – 42.19) 
54.60 (37.68 – 69.88) 
5.61 (2.73 – 17.69) 
































Table 6.12 Stage of Apoptosis at 4-hours and 24-hours in Statin Users and Non-statin 
Users on Day-3 
 








Figure 6.9 Stage of Apoptosis at 4-hours (A) and 24-hours (B) in Statin Users and Non-
statin Users on Day-3 
Bar graph depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 4-hours (A) and 24-hours (B) incubation in Statin Users and Non-
statin Users on Day-3.  Statistical significance, measured by Mann Whitney U test, is denoted by * (p<0.05), ** 

















74.70 (65.53 – 82.58) 
18.80 (13.40 – 25.73) 
2.60 (1.60 – 4.53) 
2.70 (0.60 – 4.70) 
 
 
74.80 (62.33 – 81.83) 
16.50 (10.60 – 29.95) 
5.40 (4.63 – 6.85) 





















17.60 (15.80 – 22.25) 
79.78 (68.30 – 82.10) 
2.60 (1.35 – 6.21) 
0.50 (0.15 – 0.90) 
 
 
21.64 (14.10 – 48.10) 
71.86 (46.80 – 82.10) 
3.70 (3.50 – 6.32) 































It was not possible to demonstrate differences in the stages of apoptosis between Statin 
Users and Non-statin Users at 4-hours and 24-hours incubation on Day-0 and Day-1. 
A significant result was attained on Day-3 with a demonstrable reduction in late apoptotic 
neutrophils at 4-hours incubation in Statin Users. 
6.5.3.2  Neutrophil Apoptosis In-vitro 
Neutrophil Apoptosis was performed with in-vitro treatment with 1μM Simvastatin (Statin 
Treatment) or DMSO (Vehicle Control) on Day-0 (n=13) and  Day-1 (n=12) at 4-hour and 24-
hour time points. 
Neutrophil apoptosis in patents who underwent in-vitro treatment with 1μM Simvastatin on 

















Table 6.13 Stages of Apoptosis with in-vitro treatment with Statin Treatment (1μM 
Simvastatin) or Vehicle Control (DMSO) on Day-0 
 
Statistical significance, measured by Wilcoxon Signed Rank test. 
 
 
Figure 6.10 Stages of Apoptosis at 24-hours incubation with in-vitro treatment with 
Statin Treatment (1μM Simvastatin) or Vehicle Control (DMSO) on Day-0 
Bar graph depicting the Stage of Apoptosis (Alive, Early Apoptosis [Early Apop], Late Apoptosis [Late Apop], 
Necrosis) of Neutrophils (Mean [%] + SEM) at 24-hours incubation with in-vitro Statin Treatment (1μM 
Simvastatin) vs. Vehicle Control (DMSO) on Day-0.  Statistical significance, measured by Wilcoxon Signed Rank 
















76.60 (71.40 – 83.55) 
18.50 (13.35 – 27.00) 
1.40 (1.15 – 3.10) 
0.80 (0.45 – 1.15) 
 
 
76.50 (72.45 – 82.30) 
18.50 (14.15 – 23.40) 
1.70 (1.15 – 3.80) 















14.70 (8.20 – 24.00) 
71.00 (65.30 – 85.20) 
6.50 (5.60 – 15.20) 
0.20 (0.05 – 0.30) 
 
 
12.20 (9.40 – 17.50) 
79.60 (72.10 – 84.85) 
6.10 (4.70 – 9.40) 



















Table 6.14 Stages of Apoptosis with in-vitro treatment with Statin Treatment (1μM 
Simvastatin) or Vehicle Control (DMSO) on Day-1 
 
Statistical significance, measured by Wilcoxon Signed Rank test. 
 
The experiments revealed a significant reduction in Early Apoptotic neutrophils and a 
significant increase in Late Apoptotic neutrophils in response to in-vitro treatment with 1μM 
Simvastatin at 24-hours incubation on Day-0.  This finding is consistent with changes of 
favoured apoptosis and a restoration of impaired apoptosis in patients with colorectal 
cancer.  No significant differences were demonstrated in response to in-vitro treatment with 






















82.10 (77.28 – 85.65) 
15.50 (12.15 – 17.68) 
1.75 (1.40 – 3.25) 
0.90 (0.60 – 1.08) 
 
 
80.15 (77.88 – 86.58) 
15.10 (11.28 – 19.35) 
1.85 (1.18 – 3.45) 















30.28 (23.85 – 51.63) 
66.75 (45.08 – 71.00) 
2.29 (1.53 – 4.62) 
0.43 (0.30 – 0.61) 
 
 
27.45 (21.15 – 49.75) 
67.95 (46.83 – 74.58) 
2.80 (1.76 – 4.82) 










6.5.4   Neutrophil Phagocytosis 
Neutrophil phagocytosis was performed on Day-0 (n=27), Day-1 (n=25) and Day-3 (n=9), in 
response to E.Coli and S.Aureus.   
The assay was performed at three time points (30 minutes, 45 minutes and 60 minutes) and 
the Phogocytosis Index was calculated for each time point.  The Phagocytosis Index was also 
represented as AUC which enabled comparisons to be made considering all time points. 
The population was stratified and analysed according to statin use in an attempt to identify 
differences in neutrophil apoptosis between Satin Users and Non-statin Users. 
Neutrophil phagocytosis, according to statin use, on Day-0, Day-1 and Day-3 is displayed in 
















Table 6.15 Neutrophil Phagocytosis Index in response to E.Coli and S.Aureus in Statin 













3446 (2349 – 7174) 
6615 (4396 – 11670) 
9915 (6463 – 14870) 
 
3378 (2244 – 8050) 
6773 (4703 – 9960) 





E.Coli (Area Under Curve) 
 
5861 (3588 – 10240) 
 








5463 (2122 – 8605) 
8240 (6253 – 13760) 
14760 (10330 – 18540) 
 
4607 (2701 – 9730) 
8198 (6048 – 12650) 





S.Aureus (Area Under Curve) 
 













Figure 6.11 Neutrophil Phagocytosis Index in response to E.Coli (A) and S.Aureus (B) in 
Statin Users and Non-statin Users on Day-0 depicted by Area Under the 
Curve (AUC) 
Box and Whisker Plot (10-90 percentile) of Phagocytosis Index represented by Area Under Curve (AU) in 
response to E.Coli (A) and S.Aureus (B) in Statin Users and  Non-statin Users on Day-0.  Statistical significance, 






































Table 6.16 Neutrophil Phagocytosis in response to E.Coli and S.Aureus in Statin Users 













3812 (1796 – 9949) 
7166 (4292 – 16200) 
9276 (4866-15460) 
 
7417 (3589 – 13750) 
8094 (6979 – 17430) 





E.Coli (Area Under Curve) 3483 (2252 – 7685) 4152 (3664 – 8713) 0.3048 






10260 (8366 – 18780) 
15080 (12970 – 22410) 
 
6300 (3729 – 9054) 
10420 (7171 – 14430) 





S.Aureus (Area Under Curve) 5119 (4282 – 7825) 5069 (3470 – 7220) 0.5982 
 
Statistical significance, measured by Mann Whitney U test. 
 
Table 6.17 Neutrophil Phagocytosis Index in response to E.Coli and S.Aureus in Statin 













3581 (3402 – 9630) 
6683 (4845 – 14410) 
9811 (7182 – 21390) 
 
13550 (9980 – 14420) 
23270 (17760– 23330) 





E.Coli (Area Under Curve) 
 










10070 (6155 – 12830) 
17140 (10020 – 19300) 
22150 (14910 – 25750) 
 
5116 (1593 – 9468) 
6860 (4027 – 11410) 





S.Aureus (Area Under Curve) 
 
8369 (5138 – 10120) 
 










A significant increase in the Phagocytosis Index, when represented as AUC, was identified on 
Day-0 in Statin Users in response to E.Coli when compared to Non-statin Users.  No 
differences in the Phagocytosis Index were identified in response to S.Aureus on Day-0. 
It was not possible to demonstrate differences in the Phagocytosis Index between Statin 

















The experiments undertaken in this chapter reveal the potential for neutrophil immune-
modulation with statin therapy. 
Firstly, Statin Users and Non-statin Users were similar in their population, tumour and 
operative characteristics.  As anticipated, Statin Users had significantly more co-morbidities 
than Non-Statin Users.  Despite being a more co-morbid patient group, Statin Users were 
identified to have equivalent patient outcomes.  This replicates the findings of the larger 
retrospective cohort study which was undertaken and presented in Chapter 2. 
Secondly, the evaluation of neutrophil function in Statin Users compared to Non-statin Users 
in-vivo revealed; a significant increase in NET production in response to stimulation with 
PMA and fMLP on Day-1, a significant reduction in late apoptosis at 4-hours incubation on 
Day-3, and a significant increases in the Phagocytosis Index, when represented as AUC, in 
response to E.Coli on Day-0. This was a small, heterogeneous study population with many 
potential confounding variables and as a result firm conclusions cannot be drawn from the 
in-vivo analysis.  It must also be acknowledged that 5/20 (25%) patients taking statins in the 
study population were also taking aspirin, which has been associated with positive survival 
outcome in patients undergoing surgery for colorectal cancer, thought to be as a 
consequence of its anti-inflammatory effects. 
Thirdly, neutrophil functional changes were observed when neutrophils were stimulated 
with simvastatin in-vitro under controlled experimental conditions.  On Day-0 it was 
demonstrated that NET production was reduced and apoptosis was promoted when 




in NET production was revealed with statin treatment on Day-1.  No differences were 
observed in stages of apoptosis on Day-1 with statin treatment.  This is contrary to the 
experimental hypothesis which theorised that the neutrophil functional changes observed 
following surgery would be attenuated by in-vitro treatment with simvastatin.  In fact this 
finding contradicts evidence which suggests that neutrophil immune paralysis seen in the 
development and progression of sepsis is amenable to correction with statin therapy [297-
299].  The observed reduction in NET production on Day-1 with in-vitro treatment with 
simvastatin may, however, explain why statins are advantageous in the setting of cancer 
surgery.  The reduction in NETs following surgery theoretically reduces the tumour-
neutrophil interaction and the potential for disease dissemination and progression.   
Neutrophils are appreciated to have an important role in cancer progression and 
dissemination.  The high-grade, non-specific SIR associated with cancer surgery may be 
amenable to modulation with statin therapy.  This might explain why patients taking peri-
operative statins appear to have a greater baseline peri-operative risk compared to non-
statin users but achieve equivalent outcomes [248, 250] and why there is a reduced risk of a 
variety of cancer types [233-235] and a reduced all cause and cancer specific mortality [237] 
associated with statin use. 
As outlined in Chapter 4, when neutrophils from a colorectal cancer population were primed 
with TNF-α, NET production was significantly increased in response to No stimulant 
(p=0.0021), IL-8 (p=0.0007), LPS (p=0.0233) and fMLP (p=0.0002).  When neutrophils from a 
colorectal cancer population were treated with 1μM Simvastatin the converse is true with a 
significant reduction in NET production in response to No stimulant (p=0.0256), PMA 




treatment opposes the effect of priming with TNF-α.  This adds to the evidence supporting 
the anti-inflammatory effect of statins.  A reduction in NET production was also identified on 
Day-1, which supports an anti-inflammatory action in the post-operative period.  
This experimental study has a number of limitations.  Firstly, the population evaluated was 
small and heterogeneous with regard to patient demographics, patient co-morbidities, 
tumour characteristics and operative characteristics making interpretation of the results 
difficult and limiting the generalisability of the study findings.  Secondly, in-vitro 
experiments performed to assess neutrophil function were conducted outside of the 
biological context and consequently there are challenges in extrapolating the results and it 
must be acknowledged that they cannot be readily transposed to, and predict the reaction 
of, the entire organism in-vivo.  Thirdly, neutrophils were treated with simvastatin in 
experimental conditions in-vitro and this may not replicate the effect on systemic 
neutrophils in-vivo, also the 1μM concentration of simvastatin used was a predicted 
concentration corresponding to a plasma concentration following ingestion of 40mg 
simvastatin.  The benefit of in-vitro experimental methods in this context is that each 
patient acted as its own control and the true impact of simvastatin treatment was detected.  
This was supported further by the use of the vehicle control for simvastatin in the non-









As surgical resection remains the mainstay of treatment for the majority of solid tumours it 
is appreciated that an uncontrolled inflammatory response should be avoided in an attempt 
to minimise damage to the host.  The evidence suggests that it is conceivable to implement 
a therapeutic strategy in the peri-operative period to reduce the systemic inflammation 
associated with surgery and improve oncological outcomes.  The interaction between 
tumour immunity and systemic immunity is likely to be complex, but the administration of 
immune-modulatory therapies in an attempt to modify the peri-operative inflammatory 
response could be utilised to enhance the anti-tumour immune competency of the host and 
merits further investigation in the context of cancer surgery.  A therapeutic strategy aimed 
at modifying tumour-neutrophil interactions may maximise the therapeutic benefit of 
surgery.  Statins are promising immune-modulatory agents in the context of cancer surgery.  
Further basic science research should be performed to ascertain which cancer types and 
patient populations are more likely to benefit from immune-modulatory therapies, such as 












HISTONE DEACETYLASE ACTIVITY IN NEUTROPHILS 















Histone acetylation regulates inflammatory gene expression and is responsible for a number 
of diverse functions including DNA repair, cell proliferation and apoptosis [251, 252].  In the 
resting cell, DNA is tightly compacted around a core of histones.  Specific residues in the N-
terminal tails of histones can be post-translationally modified by acetylation leading to the 
release of the tightly wound DNA.  Conversely, histone deacetylation is thought to re-
establish the tight nucleosomal structure [251, 252]. Histone acetylation is regulated by a 
dynamic balance between HAT, which is associated with an open chromatin state and 
transcriptional activation, and HDAC, which is associated with a closed chromatin state and 
transcriptional repression [253]. 
Changes in histone acetylation patterns have been described in the context of cancer.  It has 
been demonstrated that HDACs regulate the expression of a large number of genes by 
directly interacting with transcription factors [254].  HDACs have also been implicated in the 
deacetylation of chromatin proteins, leading to altered gene transcription regulation and 
the deacetylation of non-histone proteins that regulate cellular homeostasis (cell-cycle 
progression and differentiation) [255].  HDAC inhibitors have subsequently been 
investigated for a potential anti-tumour effect.   
Recent evidence from animal models has suggested that HDAC inhibitors may have the 
potential to act as anti-inflammatory agents.  Although it was initially believed that HDAC 
inhibitors did not induce apoptosis in non-malignant cells [257, 258] this has been 
subsequently disproven where HDAC inhibitors have been found to enhance apoptosis in 




cytokines [253].  This suggests that HDAC inhibitors could potentially resolve neutrophilic 
and eosinophilic inflammation by inducing apoptosis. 
Eighteen HDAC enzymes have been identified and they can be subdivided into four different 
classes (Class I, Class II, Class III and Class IV) as outlined in Table 1.9. 
HDACs can induce aberrant transcription of key genes in the context of cancer and 
inflammation causing dysregulation of cellular functions.  Consequently, HDACs are 
promising therapeutic targets for cancer treatment and perhaps, for the resolution of 
inflammation.   
It has been demonstrated that statins target epigenetic mechanisms including histone 
deacetylation and epigenetic studies have shown simvastatin to be a direct inhibitor of 
HDAC-1 and HDAC-2 and it has therefore been proposed that statins may act by this 
mechanism and inhibit epigenetically influenced diseases such as cancer [264]. 
From the existing published evidence it is speculated that changes in HDAC activity may be 
apparent; in those patients with cancer compared to healthy individuals, in patients 
undergoing surgery and in those patients taking statins.  This investigation may help to 
explain the neutrophil phenotypic change that has been outlined in this thesis and could 
possibly assist in the generation of a mechanistic hypothesis for the observed pleiotropic 








In a hypothesis generation exercise, it was theorised that there would be a reduction in 
HDAC activity in neutrophils following the surgical insult, which would allow a disruption in 
the closed chromatin state within the nucleus of the neutrophil and a subsequent reduction 
in transcriptional repression and ensuing transcriptional activation. 
It is proposed that HMG-CoA Reductase Inhibitors may inhibit HDAC activity as outlined in 















The objectives of this chapter were: 
1. To investigate Histone Deacetylase activity and expression in the neutrophil of 
patients with Colorectal Cancer pre-operatively (Day-0_ and post-operatively (Day-1). 
3. To evaluate whether HMG-CoA Reductase Inhibitors influence Histone Deacetylase 


















Dr. Vijay D’Souza (Post-Doctoral Research Scientist of the Institute of Inflammation and 
Ageing at the University of Birmingham, UK) provided expert advice and assistance when 
conducting the Histone Deacetylase Activity Assay and Quantitative Real-time PCR.  The 
experimental techniques utilised in this Chapter are challenging even to the experts in 
laboratory science.  Utilising the skills of an expert Post-Doctoral Research Scientist with a 
vast experience in the experimental techniques was vital in achieving reliable results, 
particularly when using neutrophils which are notoriously experimentally intractable.  
7.4.2 Recruitment of Patients 
Patients undergoing an elective colorectal resection for cancer, within an established 
enhanced recovery programme, who satisfied the specific inclusion and exclusion criteria, 
were recruited to the study as outlined in Section 3.1.1. 
Patient Demographics, Patient Co-morbidities, Pre-operative Risk Prediction, Tumour 
Characteristics and Operative Characteristics were recorded from study participants as 
outlined in Table 3.1.  
Patient outcomes were collected prospectively and included: 
1. Post-operative complications up to 30 days after surgery using pre-defined criteria 
and graded by the Clavien-Dindo classification system (Appendix 3). 
2. Return to theatre within 28 days of the index procedure. 




4. Total hospital length of stay. 
5. Readmissions to hospital within 30 days of the index procedure requiring a hospital 
stay ≥ 24 hours. 
6. 30 day and 90 day mortality. 
7.4.3 Sample Collection 
Patients underwent peripheral blood tests.  Blood tests were performed by an experienced 
medical practitioner by peripheral venepuncture or from a peripheral arterial cannula.  A 
total of 24mls of blood was taken from each patient and deposited into 4x6ml lithium-
heparin vacutainers (Becton-Dickinson, Oxford, UK).  The samples were then placed on ice 
and transported to the laboratory for processing. 
7.4.4 Neutrophil Isolation 
Processing began with 45 minutes of obtaining the blood sample.  Neutrophils were isolated 
by following the method outlined in Section 3.2.  A purity of ≥95% and a viability of ≥97% 
were routinely achieved. 
7.4.5 Histone Deacetylase Activity Assay 
HDAC activity of neutrophils was evaluated using an HDAC Fluorometric Activity Assay Kit 
(Cayman Chemical) as per manufacturer’s instructions, as outlined in Section 3.5.1.  The 
assay provides a fluorescent-based method of measuring HDAC activity.  Firstly a lysine 
substrate is incubated with samples containing HDAC activity.  Deacetylation sensitises the 
substrate such that treatment with the HDAC developer releases a fluorescent product that 




The average fluorescence of each standard, positive control, positive control + Trichostatin 
A, sample, and sample + Trichostatin A was calculated. 
The average fluorescence of Standard A was subtracted from itself and all other standards 
and plotted as a function of the deactylated standard (Table 3.2) as shown in Figure 3.10. 
The average fluorescence of the Trichostatin A treated samples was subtracted from the 
fuorescence of its corresponding samples to give the corrected sample fluorescence (CSF). 
The deacetylated concentration was then calculated as follows: 
Deacetylated Compound (µM) = [(CSF – y-intercept)/slope] 
The HDAC activity was calculated as follows: 
HDAC Activity (nmol/min/ml) = [µM/30 minutes] x sample dilution 
7.4.6 Quantitative Real-time PCR 
Firstly, total RNA was extracted from neutrophils using NucleoSpin® RNA isolation kit 
(Macherney-Nagal) according to the manufacturer's protocol. Complementary DNAs 
(cDNAs) were then generated by reverse transcription using High Capacity RNA-to-cDNA Kit 
(Life Technologies).  Finally, quantitative real-time PCR was performed under the expert 
guidance of Dr. Vijay D’Souza (Post-doctoral Research Scientist, School of Clinical and 
Experimental Medicine, University of Birmingham, UK) using a Roche Light Cycler 480 
(Roche; Life Science), as outlined in Section 3.5.2. 
Quantitative real-time PCR was performed on the cDNA samples using the TaqMan® Gene 




instructions.  SYBR-green dye is a double-stranded DNA binding dye that detects double-
stranded DNA generated during PCR which negates the need to target specific probes.   
GAPDH was used as the reference gene and the Class I (HDAC-1, HDAC-2, HADC-3) and Class 
II (HDAC-4, HDAC-7, HDAC-9) HDAC genes were the genes of interest. 
Relative transcript abundance values of the genes of interest are expressed as ΔCt values 
(ΔCt = Ctreference – Cttarget) and they were used to calculate the statistical significance 
between groups.   
The reciprocal values of the relative transcript abundance are expressed as 1/ΔCt and they 
were used to depict the data in graphical form.  
7.4.7 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism Version 6 (La Jolla, California, USA). 
Categorical data was analysed using Fisher’s Exact tests for two variables or χ2 tests for 
greater than two variables.  Continuous data was analysed using non-parametric statistical 
models.  Mann-Whitney U tests were used for independent samples and Wilcoxon Signed 
Rank tests for related samples for two groups.  All statistical tests performed were two-









7.5.1 Population Characteristics 
A total of 10 patients undergoing elective colorectal cancer resection, within an established 
enhanced recovery programme, underwent HDAC activity analysis and quantitative real-
time PCR.   The baseline population characteristics are presented in Table 7.1 and they are 
representative of all patients recruited to the study. 
Patient outcomes were collected prospectively and included: 
1. Post-operative complications up to 30 days after surgery using pre-defined criteria 
and graded by the Clavien-Dindo classification system (Appendix 3). 
2. Return to theatre within 28 days of the index procedure. 
3. Admission to and length of stay on the Intensive Care Unit. 
4. Total hospital length of stay. 
5. Readmissions to hospital within 30 days of the index procedure requiring a hospital 
stay ≥ 24 hours. 









Table 7.1 Population Characteristics of Patients who Underwent HDAC Activity and 
Quantitative Real-time PCR Experiments 
Patient Demographics N=10 
Age, median (IQR) 69.5 (59.8 – 75.3) 
Gender, n (%), M/F 6 / 4 (60.0 / 40.0) 
BMI, median (IQR), kg/m
2
 26.8 (24.9 – 29.8) 
Smoking Status, n (%), 1/2/3
a 
2 / 4 / 4 (20.0 / 40.0 / 40.0) 
ASA, n (%), 1/2/3/4 
Co-morbidity, n (%), 0/1/2/≥3 
Medications, n, 1/2/3/4
b 
Statin User, n (%), y 
CR-POSSUM, (%), median (IQR)  
Dukes’ Stage, n (%), A/B/C/D 
Operation Type, n (%), 1/2
c 
Operation technique, n (%), 1/2
d 
Complication, n (%) 
Clavien-Dindo Classification, n (%), I/II/III/IV/V 
Total LOS, median (range, IQR) 
Disease Recurrence, n (%) 




0 / 9 / 1 / 0 (0.0 / 90.0 / 10.0 / 0.0) 
2 / 4 / 3 / 1 (20.0 / 40.0 / 30.0 / 10.0) 
6 / 3 / 2 / 1 
5 / 5 (50.0 / 50.0) 
2.2 (1.7 – 3.7) 
3 / 2 / 4 / 1 (30.0 / 20.0 / 40.0 / 10.0) 
8 / 2 (80.0 / 20.0) 
7 / 3 (70.0 / 30.0) 
4 (40.0) 
3 / 0 / 1 / 0 / 0 (30.0 /0.0 / 10.0 /0.0 / 0.0) 






y = yes,  1/2/3
a
 = active / former / never,  1/2/3/4
b
 = antihypertensive / β-antagonist / anti-platelet / oral 
hypoglycaemic ,  1/2
c
 = segmental / rectal,  1/2
d
 = laparoscopic / open and laparoscopic converted to open 
 
50% (5/10) of patients were receiving peri-operative statin, defined as, ‘patients were 
prescribed and had taken a statin ≤ 5 days before the index procedure and who were 
prescribed and received a statin ≤ 5 days after the index procedure’.  All statins currently 
available for use in the UK were included (atorvastatin, fluvastatin, lovastatin, pravastatin, 





7.5.2 Histone Deacetylase Activity Assay 
The HDAC activity assay was performed in patients with colorectal cancer (n=10).  The 
baseline population characteristics and HDAC activity is summarised in Table 7.2. 





Age, median (IQR) 69.5 (59.8 – 75.3) 
Gender, n (%),  M/F 6 / 4 (60.0 /40.0) 
HDAC activity (nmol/min/ml), 
median (IQR) 
0.341 (0.200 – 0.449) 
 
 
All patients with colorectal cancer underwent surgical resection.  The HDAC activity was 
analysed pre-operatively (Day-0) and postoperatively (Day-1) and the results were 























Figure 7.1 HDAC Activity in patients with Colorectal Cancer on Day-0 and Day-1  
Box and Whisker Plot (10-90 percentile) of HDAC Activity in patients with Colorectal Cancer on Day-0 and Day-
1. Statistical significance, measured by Wilcoxon Signed Rank test, is denoted by * (p<0.05), ** (p<0.01) and 
*** (p<0.001). 
 
A significant reduction in HDAC activity was observed, in neutrophils of patients with 
colorectal cancer, from the pre-operative to the immediate post-operative period. 
The HDAC activity was then analysed, stratifying patients into Statin Users and Non-statin 
Users, on both pre-operative (Day-0) and post-operative (Day-1) days.  The results are 
summarised in Table 7.3 and represented graphically in Figure 7.2.  The fold change from 














Table 7.3 HDAC Activity on Day-0 and Day-1 in Statin Users and Non-statin Users 
 
Statistical significance is measured by Mann Whitney U test. 
 
 
Figure 7.2 HDAC Activity on Day-0 and Day-1 in Statin Users and Non-statin Users 
Box and Whisker Plot (10-90 percentile) of HDAC Activity in patients with Colorectal Cancer on Day-0 and Day-
1 in Statin Users vs. Non-statin Users. Statistical significance, measured by Mann Whitney U test, is denoted by 












Day-0 HDAC activity (nmol/min/ml), 
median (IQR) 
0.396 (0.239 – 0.545) 
 





Day-1 HDAC activity (nmol/min/ml), 
median (IQR) 
 
-0.019 (-0.133 - -0.006) 
 
 























Figure 7.3 Fold Change in HDAC Activity from Day-0 to Day-1 in Statin Users and Non-
statin Users 
Box and Whisker Plot (10-90 percentile) of Fold Change (AU) in HDAC Activity from Day-0 to Day-1 in Statin 
Users vs. Non-statin Users. Statistical significance, measured by Mann Whitney U test, is denoted by * 
(p<0.05), ** (p<0.01) and *** (p<0.001). 
 
On Day-0 no significant differences were identified between Statin and Non-statin Users, 


















-0.060 (-0.332 - -0.014) 





7.5.3 Quantitative Real-time PCR 
Quantitative real-time PCR was performed in patients with colorectal cancer (n=10).  The 
genes of interest analysed in Quantitative Real-time PCR analysis are outlined in Table 7.4.  
The relative transcript abundance of the HDAC genes of interest are summarised in Table 
7.5. 
 
Table 7.4 HDAC Genes of Interest for Quantitative Real-time PC 
Class I HDAC-1, HDAC-2, HDAC-3 
Class IIa HDAC-4, HDAC-7, HDAC-9 
 
Table 7.5 Relative Transcript Abundance (ΔCt = Ctreference – Cttarget) of HDAC 






Age, median (IQR) 69.5 (59.8 – 75.3) 
Gender, n (%),  M/F 6 / 4 (60.0 / 40.0) 








3.733 (3.470 – 3.941) 
6.555 (6.096 – 7.008) 
5.255 (4.832 – 5.494) 
3.275 (3.231 – 3.539) 
2.365 (1.898 – 2.964) 






A comparison of the relative transcript abundance of the HDAC genes of interest are 
summarised on Day-0 and Day-1 are displayed in Table 7.6 and displayed graphically in 
Figure 7.4. 
Table 7.6 Relative Transcript Abundance (ΔCt = Ctreference – Cttarget) of HDAC 
















3.733 (3.470 – 3.941) 
6.555 (6.016 – 7.008) 
5.255 (4.831 – 5.494) 
3.275 (3.231 – 3.539) 
2.365 (1.898 – 2.964) 
8.763 (8.261 – 9.878) 
 
4.210 (3.813 – 4.398) 
6.595 (6.163 – 6.925) 
5.645 (5.354 – 5.904) 
3.498 (3.108 – 4.108) 
2.475 (2.031 – 3.060) 


















Figure 7.4 Relative Transcript Abundance (ΔCt = Ctreference – Cttarget) of HDAC 
Genes of Interest on Day-0 and Day-1    
Box and Whisker Plot (10-90 percentile) of Relative Transcript Abundance (AU) (ΔCt = Ctreference – Cttarget) 
of HDAC Genes of Interest on Day-0 and Day-1.  ΔCt values were used to calculate the statistical significance 
between groups.  Statistical significance, measured by Wilcoxon Signed Rank test, is denoted by * (p<0.05), ** 
(p<0.01) and *** (p<0.001). The reciprocal values of the relative transcript abundance (1/ΔCt) are used to 
depict the data in graphical form. 
 
A significant difference in the relative transcript abundance of HDAC-9 was identified 
between in neutrophils of patients with colorectal cancer from Day-0 (pre-operative) and 
Day-1 (post-operative).  A reduction in relative transcript abundance of all HDAC genes of 
interest was observed, but a statistically significant result was only identified for HDAC-9.  
Plotting reciprocal values of the transcript abundance demonstrates a visual reduction in 
HDAC expression in patients with colorectal cancer post-operatively (Day-1) compared to 



























The results obtained from the Quantitative real-time PCR were then analysed, stratifying 
patients into Statin Users and Non-statin Users, on both pre-operative (Day-0) and post-
operative (Day-1) days.  The results are summarised in Table 7.7 and represented graphically 
in Figure 7.5.   
 
Table 7.7 Relative Transcript Abundance (ΔCt = Ctreference – Cttarget) of HDAC 
























































































Figure 7.5 Relative Transcript Abundance (ΔCt = Ctreference – Cttarget) of HDAC 
Genes of Interest on Day-0 and Day-1 in Statin Users and Non-statin Users 
Floating Bar Plot (Min / Max / Median) of Relative Transcript Abundance (AU) (ΔCt = Ctreference – Cttarget) of 
HDAC Genes of Interest on Day-0 and Day-1 in Statin Users and Non-statin Users.  Statistical significance, 
measured by Mann Whitney U test, is denoted by * (p<0.05), ** (p<0.01) and *** (p<0.001).  The reciprocal 
values of the relative transcript abundance (1/ΔCt) are used to depict the data in graphical form. 
 
When HDAC expression was analysed according to statin use over the peri-operative period, 
a significant reduction in HDAC-9 expression was observed in Statin Users compared to Non-
statin Users (p=0.0357).  This result corresponds to the reduction in HDAC activity witnessed 






























The experiments in this chapter were undertaken to provide a greater understanding of the 
epigenetic changes in HDAC within the neutrophil of patients with colorectal cancer 
undergoing resectional surgery.  The epigenetic changes in HDAC within the neutrophil were 
also explored to identify any differences in Statin Users compared to Non-statin Users in-
vivo. 
Firstly, it must be recognised that the experiments performed in this chapter were 
conducted in a small, heterogeneous study population with potentially confounding 
variables and therefore firm conclusions cannot be drawn from the analysis.  The 
experiments, however, provide interesting results which may assist in the explanation of the 
distinct neutrophil phenotype described in this thesis and generate a possible hypothesis for 
the observed neutrophil phenotype changes as a consequence of the surgical insult. 
A reduction in HDAC expression was observed in patients with colorectal cancer from the 
pre-operative to the immediate post-operative period for all genes of interest and this 
reached statistical significance when evaluating the HDAC-9 gene.  In this experiment, the 
reduction in HDAC expression was supported by the demonstration of a significant 
reduction in HDAC activity in neutrophils of patients with colorectal cancer from Day-0 to 
Day-1.  Epigenetic changes in HDAC expression in the neutrophil from pre-operative to the 
immediate post-operative period may help to explain the distinct pro-inflammatory 
neutrophil phenotype described in patients undergoing resectional surgery for colorectal 





When HDAC expression was analysed according to statin use over the peri-operative period, 
a significant reduction in HDAC-9 expression was observed in Statin Users compared to Non-
statin Users on Day-1.  This result corresponds to the reduction in HDAC activity witnessed 
in Statin Users compared to Non-statin Users when using the fluorometric HDAC activity 
assay on Day-1.  Reductions were appreciated on Day-0, but they did not achieve statistical 
significance.  The reduction in HDAC expression and HDAC activity on Day-1 in Statin Users 
corresponds to the observed reduction in NET production and a restoration of apoptosis 
identified in the neutrophil functional assays performed in this thesis  These findings 
support the published evidence which describe a promotion of neutrophil apoptosis with 
the inhibition of HDAC [253].  
It was hypothesised that HDAC activity would decrease in patients with colorectal cancer 
following the surgical insult, which would allow a disruption in the closed chromatin state 
and ensuing transcriptional activation.  The experiments performed in this chapter suggest 
that, in the nucleus of the neutrophil, reduced HDAC expression and subsequent 
transcriptional activation may contribute to the distinct neutrophil phenotype observed as a 
consequence of surgery.   
The novel results reported in this chapter suggest that epigenetic changes in neutrophils 
may predispose neutrophils to specific phenotypes.  These epigenetic changes may arise as 
a consequence of the chemokine landscape of the tumour micro-environment, the systemic 
inflammatory response associated with cancer or as a consequence of the surgical insult.  
Hypothetically, statins may cause alterations in HDAC activity / expression within the 




specific neutrophil phenotype, which consequently may impact upon patient outcomes and 



















HDACs can induce aberrant transcription of key genes in the context of cancer and 
inflammation causing dysregulation of cellular functions.  Consequently, HDACs are 
promising therapeutic target for cancer treatment and the resolution of inflammation. 
As described in this thesis, the neutrophil has an important role in cancer progression and 
dissemination and it has been suggested that the chemokine landscape in the tumour 
microenvironment and the cancer-associated systemic inflammation may polarise 
neutrophils towards a pro-tumour neutrophil phenotype. It is also recognised that 
neutrophils may facilitate metastatic progression in the context of systemic inflammation 
and the inflammation associated with surgery.   
The evidence presented in this chapter suggests that changes in HDAC activity / expression 
may contribute mechanistically to the the phenotypic changes seen in neutrophils in 




























8.1 General Discussion 
Neutrophils are key mediators in the SIR and in the resolution of inflammation.  It is 
appreciated that an uncontrolled inflammatory response should be avoided in an attempt to 
minimise damage to the host.  In the context of cancer surgery, an overwhelming SIR may 
suppress the anti-tumour immunity and promote tumour progression and dissemination.  It 
is also recognised that post-operative infective complications result in further compromise 
of the anti-tumour immune response to residual disease and are associated with a poor 
oncological outcome and increased mortality secondary to metastatic disease.   
The interaction between tumour immunity and systemic immunity has been complex and 
the delivery of appropriate immune-modulatory therapies to modify the peri-operative 
inflammatory response could be utilised to preserve anti-tumour immune competency in 
the host.  It has been proposed that the pleiotropic effects of statins could be utilised in the 
peri-operative period in an attempt to modulate the SIR and prevent infective 
complications.  The use of statins in the context of cancer surgery may therefore influence 
oncological outcomes. 
In the context of cancer, it is suggested that neutrophils have two distinct phenotypes, anti-
tumour and pro-tumour, suggesting that neutrophils differ in their contribution to the 
progression and dissemination of cancer and are capable of phenotypic plasticity.  This 
opens up the possibility of therapeutic intervention to enhance anti-tumour and suppress 
pro-tumour functional properties.  Modifications in neutrophil function and phenotype have 
been demonstrated with simvastatin treatment in-vitro and in-vivo, but not in the context 





This study was conducted to: 
1. Characterise neutrophil function in patients with colorectal cancer undergoing 
resectional surgery over the peri-operative period. 
2. Investigate whether NET formation is associated with patient characteristics, 
operative characteristics, patient outcomes and existing validated prognostic scores. 
3. Evaluate the effect of statins on neutrophil function in-vivo and in-vitro over the peri-
operative period. 
4. Explore the role of Histone Deacetylase as a potential epigenetic marker of 
neutrophil phenotype change. 
 
Analysis performed in this thesis suggests that that adverse patient outcomes (post-
operative complications, prolonged hospital recovery and mortality) are associated with 
increased pre-operative NET production when evaluating NET production in patients with 
colorectal cancer on Day-0 (pre-operatively).  This indicates increased neutrophil activation 
which may, conceivably, occur as a consequence of cancer associated inflammation.  
Significant increases in NET production in response to stimulation with fMLP were 
demonstrated in patients who developed significant post-operative complications or who 
had a prolonged hospital stay.  fMLP stimulation of neutrophils activates a wide variety of 
intra-cellular signalling pathways which causes superoxide generation and degranulation of 
neutrophils [292] and this may explain the experimental findings observed in this analysis.   
It is proposed that NET production, particularly in response to stimulation with fMLP, 
therefore has potential prognostic significance and further investigation into their predictive 
value is justified.  Indeed, ROC curve analyses of NET production in response to stimulation 




complications and had a prolonged hospital stay with significance.  Despite the 
accumulating evidence that suggests an association between NETs and tumour progression, 
the experimental evidence revealed no significant differences in NET production in patients 
with more advanced disease when patients with early stage and late stage colorectal cancer 
were compared. 
An attempt to characterise serial changes in neutrophil function over the peri-operative 
period in patients undergoing major resectional surgery for colorectal cancer was then 
conducted.  The findings suggest that a novel neutrophil phenotype may exist in patients 
undergoing colorectal resection for cancer as a result of the surgical insult which 
demonstrates reduced NET formation, impaired apoptosis and increased phagocytosis. 
A significant reduction in NET formation from Day-0 to Day-1 was detected.  This observed 
NET reduction, as a consequence of the surgical insult, appears to replicate and support the 
findings outlined in in-vitro experiments which studied the neutrophil functional changes in 
patients with sepsis and severe sepsis [294].  Significant changes indicating delayed 
apoptosis were detected from Day-0 to Day-1 and significant changes favouring apoptosis 
were identified from Day-1 to Day-3 at 24-hours incubation.  Evidence supports reduced 
apoptosis of neutrophils in inflammation and this is associated with poor patient outcomes 
[295, 296].  Therefore, delayed apoptosis from Day-0 to Day-1 is indicative of pro-
inflammation and favoured apoptosis from Day-1 to Day-3 is suggestive of anti-
inflammation (resolution of inflammation).  In this study it was not possible to identify any 
statistically significant results when analysing the stages of neutrophil apoptosis with 
adverse patient outcomes, however, it is hypothesised that neutrophils that exhibit a 




outcomes as it is essential that neutrophils are ‘switched off’, undergo apoptosis and are 
successfully cleared to minimise host damage. 
Demonstrable increases in neutrophil phagocytotic activity were revealed on sequential 
peri-operative days, over the peri-operative period.  Significant increases in phagocytotic 
index from Day-1 to Day-3 were observed to E.Coli which suggests an increase in 
phagocytotic activity up to the third post-operative day in response to stimulation with 
E.Coli.   
The experimental findings suggest that neutrophils adopt a distinctive phenotype, 
characterised by a reduction in NET formation, inhibition of the apoptosis and increase in 
phagocytosis in response to E.Coli, as a consequence of the surgical insult.  The resultant 
accumulation of activated neutrophils in the circulation following surgery may cause more 
extensive collateral tissue damage and potential organ dysfunction.  The increase in NET 
formation and the restoration of apoptosis in the late post-operative phase coincides with 
apparent surgical recovery and therefore an early phenotypic switch (from dysregulated to 
normal neutrophil function) may be desirable.   
Peri-operative NET production was evaluated when classifed by operative technique and 
operation type and when classified by post-operative complication, total length of hosital 
stay and mortality.  No significant differences in peri-operative NET production were 
identified in the analysis of operative technique or operation type.  Significant increases in 
NET production were, however, associated with an increased hospital stay and prolonged 
hospital recovery in response to PMA.  No differences were identified in patients who 
experienced significant post-operative complications or died during the study follow-up.   




reduction in the change in NET production was observed in patients who died in response to 
fMLP.  This might imply that a reduced fold change in NET production as a consequence of 
surgery may have a role in prognostication and mortality prediction.  The evidence indicates 
that further investigation into the prognostic value of NET production is justified and the 
change in NET production over the peri-operative may be a promising area to study in 
relation to patient outcomes. 
The work undertaken in this thesis supports the pleiotropic effects of statin therapy in the 
context of colorectal cancer resection and strengthens the evidence to suggest that 
neutrophil immune-modulation with statin therapy is possible 
It was investigated whether statin use is associated with reduced post-operative 
complications and improved clinical outcomes in patients undergoing elective colorectal 
cancer resection and whether a dose dependent effect on clinical outcomes could be 
demonstrated.  A retrospective review of prospectively collected data was conducted for all 
elective colorectal cancer resections within an established enhanced recovery programme 
over a 5 year period.  It was observed that statin users had equivalent outcomes in 
frequency of post-operative complications, post-operative antibiotic use, re-operations, re-
admissions and there was no statistically significant difference in mortality after appropriate 
age and gender adjustments despite having a higher peri-operative risk.  No statistically 
significant dose related differences were identified in patient outcomes although an overall 
risk reduction in mortality with increasing dose of statin was suggested. The results of a 
multi-variate analysis of a large retrospective data set provided evidence to further explore 
the potential benefit of the pleiotropic effects of statin therapy in the context of colorectal 




recently been investigated in a prospective, double-blind, placebo-controlled RCT in the 
context of major colorectal surgery, including both malignant and benign resectional 
surgery.  Although numbers were relatively small (65 simvastatin vs. 67 placebo) it was 
identified that peri-operative statin therapy attenuates the early pro-inflammatory response 
to surgery with significant reductions in plasma concentrations of IL-6, IL-8 and TNF-α and 
peritoneal concentrations in Il-6 and IL-8 on Day-1, but no differences in post-operative 
complications were identified (OR 0.71, 95% CI 0.33-1.52, p = 0.444) [300]. 
The evaluation of neutrophil function in Statin Users compared to Non-statin Users was 
performed in patients and experimental evidence revealed; a significant increase in NET 
production in response to stimulation with PMA and fMLP on Day-1, a significant reduction 
in late apoptosis at 4-hours incubation on Day-3, and a significant increase in the 
Phagocytosis Index, when represented as AUC, in response to E.Coli on Day-0. This was a 
small, heterogeneous study population with many potential confounding variables and as a 
result firm conclusions cannot be drawn from the in-vivo analysis.  
Controlled, in-vitro experiments were then undertaken to assess neutrophil functional 
changes when neutrophils were directly stimulated with simvastatin.  In patients with 
colorectal cancer a reduced NET production and favoured apoptosis (pro-apoptosis) was 
identified in response to treatment with simvastatin.  Following surgery a further reduction 
in NET production was revealed with statin treatment on Day-1.  This finding may help to 
explain why statins are advantageous in the setting of cancer surgery as a reduction in NETs 
following surgery theoretically reduces the tumour-neutrophil interaction and the potential 





Furthermore, when neutrophils from a colorectal cancer population were primed with TNF-
α, a known pro-inflammatory cytokine, NET production was significantly increased when 
compared to a significant reduction in NET production when neutrophils from a colorectal 
cancer population were treated with simvastatin.  A reduction in NET production with statin 
treatment opposes the effect of priming with TNF-α.  This finding adds to the evidence to 
support the anti-inflammatory effect of statins (and improved patient outcomes in patients 
taking statins) in the context of colorectal cancer. 
During analysis a novel calculation was undertaken (Absolute Neutrophil Production 
Potential) in an attempt to account for the variation in the number of circulating neutrophils 
and to predict the number of circulating NETs in-vivo.  Although this is an unvalidated 
calculation it enables an assessment of the ‘potential’ NET production in an individual.   
ANPP is an interesting concept and merits further review. When taking into account the 
number of absolute circulating neutrophils, despite an observed reduction in NET formation 
from Day-0 to Day-1, a significant increase in the ANPP was identified from Day-0 to Day-1.  
This might imply that the number of circulating neutrophils are also important when 
determining patient outcomes and this may also explain why the NLR has been used 
successfully to predict overall and cancer specific survival in numerous solid organ 
malignancies [99].   
Experiments were then conducted to provide a greater understanding of the epigenetic 
changes in HDAC within the neutrophil of patients with colorectal cancer undergoing 
resectional surgery.  The epigenetic changes in HDAC within the neutrophil were also 




A reduction in HDAC expression was observed in patients with colorectal cancer from the 
pre-operative to the immediate post-operative period for all genes of interest and this 
reached statistical significance when evaluating the HDAC-9 gene.  In this experiment, the 
reduction in HDAC expression was supported by the demonstration of a significant 
reduction in HDAC activity in neutrophils of patients with colorectal cancer from Day-0 to 
Day-1.  Again, epigenetic changes in HDAC expression in the neutrophil from pre-operative 
to the immediate post-operative period may help to explain the distinct pro-inflammatory 
neutrophil phenotype described in patients undergoing resectional surgery for colorectal 
cancer which demonstrates; reduced NET formation, reduced apoptosis and increased 
phagocytotic activity. 
When HDAC expression was analysed according to statin use over the peri-operative period, 
a significant reduction in HDAC-9 expression was observed in Statin Users compared to Non-
statin Users on Day-1.  This result corresponds to the reduction in HDAC activity witnessed 
in Statin Users compared to Non-statin Users when using the fluorometric HDAC activity 
assay on Day-1.  The reduction in HDAC expression and HDAC activity on Day-1 in Statin 
Users corresponds to a reduction in NET production and a restoration of apoptosis.  These 
findings support the published evidence which indicates a promotion of neutrophil 
apoptosis with the inhibition of HDAC [253].  
The novel results reported in this thesis suggest that epigenetic changes in neutrophils may 
predispose neutrophils to specific phenotypes.  These epigenetic changes may arise as a 
consequence of the chemokine landscape of the tumour micro-environment, the systemic 
inflammatory response associated with cancer or as a consequence of the surgical insult.  

























8.2 Study Limitations  
Limitations to the study are recognised and include: 
1. The population evaluated was small and heterogeneous with regard to patient 
demographics, patient co-morbidities, tumour characteristics and operative 
characteristics.  This makes interpretation of the results difficult and limits the 
generalisability of the study findings.   
2. Comparative analyses stratifying patients according to cancer location, cancer stage 
and patient outcomes is subject to misinterpretation as potential confounding 
variables were not accounted for.  The number of adverse patient outcomes in the 
study population was low which makes interpretation of adverse patient outcomes 
challenging.   
3. Comparative analyses which stratified patients according to statin use is also 
impeded by the influence of confounding variables.  Although the groups appeared 
well matched, many factors could potentially impact on the results in a small cohort 
study, particularly the role of aspirin which has been implicated in the modulation of 
peri-operative inflammation and patient outcomes in colorectal cancer. 
4. In-vitro experiments performed to assess neutrophil function were conducted 
outside of the biological context and consequently there are challenges in 
extrapolating the results and it must be acknowledged that they cannot be readily 
transposed to, and predict the reaction of, the entire organism in-vivo. 
5. For all neutrophil functional assays blood was collected in lithium-heparin 
vacutainers.  There is active debate about the anti-coagulant of choice for isolating 




conclusions regarding the most appropriate anticoagulant.   It is proposed that 
lithium-heparin may induce cell activation; however, this claim is not substantiated.  
All blood samples in this thesis were collected in lithium-heparin vacutainers and 
therefore the inter-sample variability is minimised.  It is also acknowledged that 
neutrophils can be isolated in either lithium-heparin or ethylenediaminetetraacetic 
acid (EDTA) and subsequently be utilised effectively for neutrophil functional analysis 
[301]. 
6. Any protocol used to isolate neutrophils will result in a degree of neutrophil 
activation, although this can be minimised by isolating neutrophils with Percoll, 
which has been demonstrated to induce minimal neutrophil activation [285], as 
utilised when isolating neutrophils in the experiments conducted in this thesis. 
7. The neutrophil functional assays were performed without blinding the experimenter 
to the use of statin therapy in-vivo or to the treatment with simvastatin in-vitro.  This 
introduces the potential for experimenter and observer bias which could influence 
the results obtained.  Inter-experimenter bias was minimised as all experiments 
were performed under the same experimental conditions and by the same individual 
(s) which maximised the validity and reliability of the experiments performed in this 
thesis.  The results of some of the neutrophil functional experiments were validated 
by another trained individual who repeated the experiments and compared the 
results to ensure consistent results were obtained. 
8. When neutrophils were treated with simvastatin in experimental conditions in-vitro 
a 1μM concentration of simvastatin used.  This was only a predicted concentration 




Importantly, all experiments were performed using the same experimental 
conditions which utilised a consistent 1μM concentration of simvastatin. 
It should be noted that the benefit of studying a surgical population, compared to patients 
with other inflammatory conditions, for example in patients with sepsis, is that the true 
impact of a provoked SIR can be identified as pre-operative and post-operative evaluation is 
undertaken.  It is also appreciated that the surgical insult is relatively consistent between 
individuals, particularly with the universal implementation of a standardised enhanced 
recovery peri-operative care pathway.  The benefit of in-vitro experimental methods which 
utilised statin treatment is that each patient acted as its own control and the true impact of 
simvastatin treatment was detected.  This was supported further by the use of the vehicle 
control for simvastatin in the non-treatment group which assisted in determining the true 












8.3 Future Work 
This thesis has characterised the serial changes in neutrophil function over the peri-
operative period in patients undergoing resectional surgery for colorectal cancer and 
determined the effect of statins on neutrophil function in-vivo and in-vitro over the peri-
operative period.  The activity and expression of HDAC was also investigated which proposes 
a possible epigenetic change which may be, in part, responsible for distinct neutrophil 
phenotype described which may be a potential target for the immune-modulatory effects of 
statins. 
This investigation has opened up many potential research opportunities and it is proposed 
that future work be conducted as follows: 
1. An assessment of serum neutrophil elastase in patients with colorectal cancer and an 
evaluation of changes in serum neutrophil elastase over the peri-operative period is 
suggested to provide an assessment of the degree of neutrophil activation in both 
circumstances.  Neutrophil elastase is abundantly secreted into the extracellular 
environment upon neutrophil activation at inflammatory sites and could be used to 
explain the neutrophil functional changes, in terms of neutrophil activation, 
identified in this thesis. 
2. An evaluation of the ROS production in neutrophils in patients with colorectal cancer 
and over the peri-operative period by undertaking ROS production assays would 
clarify whether NETs are produced by an oxidant dependent (ROS dependent) 
pathway or oxidant independent pathway.  It would be anticipated that ROS 
production would replicate the findings of NET production as the pathway of NET 




3. An evaluation of the migratory capacity of neutrophils in patients with colorectal 
cancer and following surgery could be conducted by undertaking neutrophil 
chemotaxis assays.  The migratory capacity may be of paramount importance in 
determining whether neutrophils in cancer, or following cancer surgery, have 
migratory and therefore metastatic potential.  
4. Following surgery, where possible, the function of neutrophils should be assessed 
from the peritoneal cavity (i.e. in those patients with an intra-peritoneal drain).  This 
would characterise the neutrophil function of the transmigrated neutrophils at the 
site of tissue trauma and this could be compared to circulating neutrophils.   
5. HDAC activity and expression assays should be performed in greater numbers to 
substantiate the findings in this thesis.  Additionally, controlled experiments should 
be conducted to assess the direct impact of statin therapy on HDAC activity and 
expression by exposing neutrophils to statin treatment in-vitro prior to evaluation. 
6. An evaluation of plasma cell-free DNA, a product of cell death and immune system 
activation, in patients with colorectal cancer and following surgery by undertaking a 
cell-free DNA quantification assay.  This may assist our understanding of the 
‘quantity’ of systemic inflammation associated with cancer and provide an insight 
into the changes following surgery.  It is anticipated that the post-operative, pro-
inflammatory response would reveal elevated plasma cell-free DNA.  It may be 
possible to correlate this with the ANPP and attempt to validate its use in 
prognostication of outcomes following cancer surgery. 
7. An assessment of local tumour inflammatory response, utilising the validated 
klintrup-Makinen scoring method, a 4 point grade which determines the 




complex immunohistochemical techniques looking specifically for NETs could be 
used to determine whether the tumour inflammatory response is modified in 
patients taking statins.  It is invisaged that large numbers of tumours would be 
required to be analysed to identify if patients on established statin therapy 
demonstrated differences in tumour inlammation when compared to non-statin 
users. 
8. An evaluation of the effect of in-vivo statin therapy, in the peri-operative period of 
patients undergoing elective colorectal resection for cancer within an etablished 
enhanced recovery programme, on neutrophil function and on short-term and long-
term outcomes, by conducting a double-blind, placebo controlled, randomised 
control trail.  The trial could include a laboratory based analysis of neutrophil 
function (both circulating and trans-migrated neutrophils [peritoneal cavity]) and if 












8.4 Thesis Conclusion 
This study was conducted to investigate the neutrophil function in patients with colorectal 
cancer, to serially characterise the neutrophil function in patients undergoing colorectal 
cancer resection over the peri-operative period and to explore the impact of statin therapy 
on neutrophil function. 
The experiments conducted in this thesis demonstrate a distinc neutrophil phenotype which 
exhibits reduced NET formation, reduced apoptosis and increased phagocytotic activity 
following resectional surgery in patients with colorectal cancer. 
Epigenetic changes in HDAC activity and expression were identified from Day-0 to Day-1 
which may contribute to the distinct neutrophil phenotype described. 
The immune-modulatory capacity of statins was investigated over the peri-operative period. 
Following surgery, a reduction in NET production was identified with in-vitro treatment with 
simvastatin which is considered advantageous as NETs are strongly implicated in cancer 
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A1 Patient Information Sheet for STARS-CRC 
STAtins in Reduction of Septic complications after ColoRectal Cancer resection 
REC: 13/WM/0485 
PATIENT INFORMATION SHEET 
 
You are being invited to take part in a research study. Before you decide to take part it is extremely important 
you understand why the research is being conducted and exactly what it involves. You should understand the 
potential risks and benefits prior to making any decision. This process is known as informed consent. Please 
take time to read the following information sheet and if something is not clear or you do not fully understand, 
please do not hesitate to ask. Please take your time to decide if you would like to take part and thank you for 
taking the time to read this information sheet. 
 
What is the purpose of the study? 
 
This study aims to investigate how the function of the body’s white blood cells are affected by surgery and why 
some patients develop infections and complications after surgery. White blood cells are the first line of 
defence against micro-organisms (like bacteria) which are responsible for infections in humans.  It has been 
proposed that the function of these cells is altered following surgery and it has been suggested that this is why 
some patients develop infections and complications after surgery.  Furthermore, it is recognised that surgery 
may compromise the body’s defences against cancer and the defences may be weakened further in the 
presence of an infection.  It is therefore important to minimise infections and complications following surgery. 
 
Statins (cholesterol lowering medications) may be used for the treatment and prevention of infection and it 
has been suggested that they may reduce infections and complications after surgery. Statins may change the 
function of the body’s white blood cells and this is why they may be beneficial. 
 
This study will look at the white blood cells from samples of blood in patients undergoing bowel resection.  
This research aims to improve our understanding of what happens to these cells that leads to infections and 
complications after surgery. 
 
This research area requires further investigation due to the lack evidence to support using statins routinely 
around the time of surgery. By increasing our understanding of these processes it may be possible to identify 
potential treatments that could improve outcomes in patients undergoing surgery. 
 
What does this involve? 
 
The study involves collecting a sample of your blood on up to three separate occasions, one before your 
operation and two afterwards.  The blood will be taken from a vein, as for any blood test, and samples will be 
analysed and then stored in a freezer.   
 






You will be given no additional medication within this research study other than the medications given to you 
by the doctors looking after you and no additional body tissue will be removed from you for the purposes of 
research. 
Would my taking part in this study be kept confidential? 
The information collected from this study will be stored in anonymous form on a password protected hospital 
computer and combined with the results from other study participants. In the future, the findings of this study 
may be discussed at a scientific meeting of doctors and published in a medical journal in order to share our 
research with the wider medical community.  It will not be possible to identify you as an individual from any 
reports.  
What is required from me? 
We wish to seek your permission to allow us to take a blood sample on up to three separate occasions, one 
before your operation and two afterwards, and retain these samples to perform laboratory tests related to this 
study.  Some of the samples will be stored for up to 20 years in a secure location at the University of 
Birmingham and may be used in future similar research studies.   
We also request that you complete a questionnaire before and after your surgery to assess your recovery after 
your operation.  
You are under no obligation to give your consent to this request and your future medical care will not be 
affected by your decision. In the unlikely event that you lose capacity (the ability to consent) during the study 
then you will be withdrawn from the study and no further research data or blood samples will be collected 
from you.  The research team will retain data and blood samples already collected and continue to use it 
confidentially. 
What happens if I have any questions about the study? 
 
If you have any questions regarding the study, please ask the person presenting this form to you, or contact 
the Principal Investigator, Mr. Jonathan Richardson on (****) *** ****. 
 
What if things go wrong? 
 
If you have any comments, concerns or complaints about any aspect of the way you have been approached or 
treated during the course of this study, you should write to Mr. J. Richardson, Academic Department of 
Anaesthesia, Critical Care, Pain and Resuscitation, Heart of England NHS Foundation Trust, Birmingham, B9 
5SS. 
 
Alternatively you may wish to contact the Patient Advice and Liaison Service (PALS) on (****) *** **** who 
will act independently to help you. If you wish to make a complaint via the NHS complaints mechanism the 







A2 Patient Consent Form for STARS-CRC 
STAtins in Reduction of Septic complications after ColoRectal Cancer resection 
REC: 13/WM/0485 
PATIENT CONSENT FORM - CONFIDENTIAL 
 
1. I confirm that I have read, understood and received a personal copy of the information sheet, dated 
30th December 2013, for the above study and have had the opportunity to ask questions and discuss 
the study. 
YES / NO      Initials: 
 
2. I confirm that I have had sufficient time to consider whether or not to be included in this study 
requiring sample collection. 
YES / NO      Initials: 
 
3. I consent to the retention and subsequent testing of my blood and cells for this project. 
YES / NO      Initials: 
 
4. I understand that sections of my medical notes may be inspected by responsible individuals of research 
institutions or from regulatory authorities, where it is relevant to my taking part in research.  I give 
permission for these individuals to have access to my records. 
YES / NO       Initials: 
 
5. I give permission that anonymous data may be made available to other groups for the purposes of 
improving clinical diagnosis and treatment of related conditions. 
YES/ NO      Initials: 
 
6. I give permission for any residual samples (blood and cells) to be stored following this research project, 
for use in future research projects aiming to improve understanding of related conditions. 
YES/ NO       Initials: 
 
7. I understand how the samples will be collected, that giving a sample for this research is voluntary and 
that I am free to withdraw my approval for use of the sample at any time, without giving any reason, 
without my medical care or legal rights being affected. 
YES / NO      Initials: 
 
8. I understand that in the unlikely event that I lose capacity (the ability to consent) during the study then I 
will be withdrawn from the study and no further research data or blood samples will be collected from 
me.  The research team will retain data and blood samples already collected and continue to use it 
confidentially. 




_______________________    ___________            _______________________ 




________________________   ___________             _______________________  





A3  Clavien-Dindo Classification of Surgical Complications (Clavien, 2009) 
The Clavien-Dindo Classification of Surgical Complications is a validated classification used to rank surgical 
complications in an objective and reproducible manner.  It consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V).  
Complications that have the potential for long-lasting disability are highlighted in the present classification by a 
suffix (“d” for disability).  This suffix indicates that a follow-up is required to comprehensively evaluate the 
outcome related to long-term quality of life.  
 
Grades  Definition 
Grade  I Any deviation from the normal post-operative course without the 
need for pharmacological treatment or surgical, endoscopic and 
radiological interventions  
Allowed therapeutic regimens are drugs such as anti-emetics, anti-
pyretics, analgesics, diuretics, electrolytes and physiotherapy 
This grade also includes wound infections opened at the bedside 
Grade  II 
 
 
Requiring pharmacological treatment with drugs other than those 
allowed for Grade I complications 
Blood transfusions and total parenteral nutrition are also included 
Grade  III 
 
Requiring surgical, endoscopic or radiological intervention 
III-a Intervention not under general anaesthesia 
III-b Intervention under general anaesthesia 
Grade IV Life-threatening complication (including CNS complications ‡) 
requiring ICU management 




Multi organ dysfunction 
Grade V 
 
Death of a patient 
 





A4 Surgical Recovery Scale Questionnaire (Paddison, 2011) 
The Surgical Recovery Scale questionnaire is a validated, comprehensive multi-dimensional recovery scale 
consisting of 13 items adapted from the previously validated Identity-Consequence Fatigue Scale 
questionnaire which was designed specifically to assess post-operative fatigue and correlates with peritoneal 
inflammation and cytokine release following colorectal surgery.  Higher scores indicate improved functional 
recovery. 
 













I have been feeling energetic       
I have been feeling worn out       
I have been feeling vigorous       
I have done very little with the 
day 
      
I have been feeling fatigued       
Physically, I have felt tired       
I have had to restrict how 
much I try and do in a day 
      
I have been feeling lively       
During the last two days 














Read a newspaper / book or 
watch TV 
      
Dress       
Visit or socialize with family 
and friends 
      
Engage in leisure or 
recreational activities 
      




A5 Colorectal Physiological and Operative Severity Score (Tekkis, 2004) 
POSSUM is a tool used to compare morbidity and mortality in a wide range of general surgical procedures in 
order to facilitate surgical audit and the comparison of performance, adjusting for the  risk of a surgical 
procedure based on the patients physiological condition. 
Colorectal-POSSUM takes into account the following physiological and operative parameters and is calculated 
using the formula: 
Ln R/1-R = -9.065 + (0.1692 x physiological score) + (0.1550 x operative severity score)  






Cardiac Failure No / Mild 
Moderate 
Severe 
Systolic Blood Pressure  
(mmHg) 
100-170 
>71 or 90-99 
<89 








10.0-12.9 or 16.1-18.0 











Peritoneal Contamination None / Serous 
Local pus 
Free bowel content / pus / blood 










A6 Neutrophil Function Assay Results on Sequential Peri-operative Days 
Neutrophil Extracellular Trap Production, Absolute Neutrophil Extracellular Trap Production, Stage of 
Neutrophil Apoptosis (4-hour and 24-hour incubation) and Neutrophil Phagocytosis Index (E.Coli and S.Aureus) 




Day-1 Day-3 P-value 
* 
Day-0 - Day-1 
P-value 
* 
Day-1 - Day-3 
P-value 
$ 
Day-0 - Day-3 
























































































































































AUC 3255 4077 4756 0.0673 0.0078 0.1828 






















AUC 4507 5119 6061 0.2260 0.2031 0.2313 
 
* = p-value as determined by Wilcoxon Signed Rank test  
$ = p-value as determined by Freidmann’s test 
AUC = Area Under Curve 
 
 
